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Background:  Long-term mechanical ventilation (LTMV) is a treatment option for 
patients with severe chronic respiratory failure. The treatment is carried out in 
patients’ home or in a nursing home, and can completely or partially compensate for 
their breathing failure. The majority of patients receive ventilation through a mask 
covering the nose or both mouth and nose (non-invasive), while a small percentage 
receive ventilation through a tracheostomy, which is an opening in the neck leading 
directly to the trachea (invasive). The main goal with LTMV is to maintain or increase 
quality of life and to prolong survival. Previous research examining quality of life and 
health-related quality of life (HRQoL) in this group have used a large number of 
different questionnaires, none of which has been sensitive to the specific challenges of 
living with LTMV. There is limited knowledge about the long-term outcome of 
LTMV on quality of life, factors associated with changes in HRQoL and the 
association with mortality.  
 
Aims: The overall aim of this thesis was to provide new knowledge about HRQoL in 
patients treated with LTMV in a six-year follow-up study. To achieve the overall aim, 
we had to provide a validated Norwegian version of a specific questionnaire to 
measure HRQoL in patients treated with LTMV. The main aims were to examine 
changes in HRQoL in patients receiving LTMV, to examine factors associated with 
changes in HRQoL in relation to socio-demographic background variables, treatment 
variables and respiratory variables, and to examine mortality in LTMV patients and 
the associations between HRQoL and mortality.  
 
Materials and methods: This thesis was based on data from the Norwegian LTMV 
Register in West Norway, the Norwegian Patient Register, the Cause of Death 
Register, and data on patient-reported outcome measures.  
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In 2008, all the potential eligible adult patients on the LTMV Register in three 
counties in West Norway were requested to participate in the study. Data from this 
register and the Short Form-36 (SF-36) generic questionnaire were used to examine 
the psychometric properties of the Norwegian version of the Severe Respiratory 
Insufficiency (SRI) questionnaire, a specific HRQoL instrument developed together 
with patients treated with LTMV. All the patients were followed up from 2008 to 
2014. Changes in HRQoL in the patients still treated with LTMV were measured by 
the SRI questionnaire, in relation to socio-demographic background variables, 
treatment variables and respiratory variables.  
Mortality and the ability of the SRI questionnaire to predict mortality were measured 
by adjusting for socio-demographic variables, including age and education level, 
clinical variables including main disease group, and treatment variables including 
hours per day on LTMV, time since initiation of LTMV and comorbidity. Data 
concerning comorbidity was collected from the Norwegian Patient Register and data 
on mortality was confirmed by the Cause of Death Register.  
 
Results: Out of 193 potential patients on the Norwegian LTMV Register, 127 people 
(66%) agreed to participate in the study in 2008. The patients were categorized into 
groups according to neuromuscular diseases, chronic obstructive pulmonary diseases, 
obesity hypoventilation syndrome and chest wall diseases. The mean age was 61.5 
years (SD 15.6) and 68 (53.5%) of the patients were male. The most patients received 
LTMV via a nasal or mouth mask (92%) and 8% received LTMV via a tracheostomy. 
The Norwegian version of the SRI questionnaire had good reliability and validity. The 
reliability of was confirmed by Cronbach Alpha between 0.68 and 0.88 for the 
subscales and 0.94 for the SRI sum score. The validity was confirmed by high 
correlations between subscales on the SF-36 and SRI questionnaires. In addition, the 
validity was supported by that the SRI questionnaire was able to confirm known a 
priori differences among patients receiving LTMV (Paper I).  
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After six years, 60 patients were still receiving LTMV and confirmed their 
participation in the follow-up study. HRQoL improved significantly in the majority of 
the patients according to the total SRI sum score and in four subdomains of the SRI 
questionnaire. Patients reported satisfaction with training, while follow-up from 
healthcare professionals was associated with changes in HRQoL. Side effects of the 
treatment such as facial soreness were associated with lower SRI scores and thus 
changes in HRQoL. Older age was associated with lower HRQoL on SRI physical 
functioning subscales. Lung function, as measured by high forced vital capacity, was 
associated with improved HRQoL on the SRI social functioning subscale (Paper Ⅱ). 
During the 80-month follow-up period, 52 participants died. The highest mortality rate 
was among patients with chronic obstructive pulmonary disease (75%), followed by 
patients with neuromuscular disease (46%), obesity hypoventilation syndrome (31%) 
and chest wall disease (25%). Lower SRI sum scores in 2008 were associated with a 
higher mortality risk after adjustment for age, education level, time since initiation of 
LTMV, hours per day on LTMV, comorbidity and disease category. In addition, 
according to the SRI questionnaire, physical functioning, psychological well-being and 
social functioning remained significant risk factors for mortality after covariate 
adjustment (Paper Ⅲ).  
 
Conclusions: Based on quality of life as a conceptual framework, this thesis has 
provided new important knowledge on HRQoL in patients receiving LTMV from a 
six-year perspective. Improved HRQoL in the majority of the patients also provides 
new insights for patients and healthcare professionals. Improvements in the subscale 
related to overall satisfaction with life, reduced anxiety related to breathing, greater 
capacity among patients to cope with their condition, and contact and relationship with 
other people are clinically important. There was also an absence of deterioration in the 
SRI subscales related to physical functioning, respiratory complaints and attendant 
symptoms, and sleep during six years of ongoing LTMV. From a healthcare 
perspective, it important that professionals have the potential to influence their 
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patients’ HRQoL by helping to reduce side effects and improve training and follow-
up. A greater awareness of the strong association between HRQoL measured by SRI 
and mortality provides important new knowledge to healthcare professionals and 
political decision makers responsible for the treatment and care of people treated with 
LTMV. These results highlight the need to identify patients with low HRQoL and 
initiate interventions to improve HRQoL. Future research should focus on developing 
effective interventions to assist patients in living with LTMV as well as improving 
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The main purpose of long-term mechanical ventilation (LTMV) is to improve quality 
of life and extend life expectancy (1-3). The indication for treatment is hypoventilation 
and chronic hypercapnic respiratory failure (CHRF), while LTMV implies that 
patients are dependent on mechanical ventilation for at least four hours a day for more 
than six weeks (4). LTMV is initiated for a variety of disorders and is performed in 
patients’ home or nursing facilities. Previous research has shown that patients with 
hypoventilation who are not treated with LTMV have a very low quality of life (5) and 
high mortality (6-8). Patients’ underlying conditions are most often incurable and side 
effects are reported in the case of both invasive and non-invasive LTMV (4, 9, 10). 
Therefore, it is crucial to gain knowledge about quality of life among patients 
receiving LTMV. Quality of life is fundamental to the human health experience and a 
frequently used outcome of health workers’ research and practice, aiming to maintain 
and restore a person’s overall experience of well-being (11) and a good life (12, 13). 
However, the definition of quality of life lacks accuracy, and there is no common 
universal definition or measurement of the concept (12, 13). The Severe Respiratory 
Insufficiency (SRI) questionnaire, which specifically aims to measure health-related 
quality of life (HRQoL) in patients receiving LTMV (14), was originally developed in 
close collaboration with LTMV patients. The SRI questionnaire has good 
psychometric properties (10, 14-17) and is based on a definition of HRQoL including 
functional capacities, psychological well-being and social relations (10). This thesis 
has used the framework and understanding of HRQoL as reflected in the SRI 
questionnaire. 
LTMV is most commonly a lifelong treatment. However, a few studies have examined 
the long-term changes in HRQoL during ongoing LTMV, while no studies have 
examined it using a specific questionnaire for this patient group. Follow-up studies 
have examined HRQoL before treatment compared to one year after initiating LTMV 
by using the SRI questionnaire (10, 18-20), and two years after initiating LTMV using 
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a generic questionnaire (21). To the best of our knowledge, the only previous cohort 
study covering a period of more than five years among patients receiving LTMV 
found improvements in symptoms such as anxiety, depression, poor sleep quality and 
nocturnal dyspnoea (22).  
Results from previous studies with different measures of health and quality of life have 
shown that these measures were prognostic factors for mortality. These findings were 
obtained from patients with cancer measured by a cancer-specific scale (23), COPD 
patients with measures of health status such as St George’s Respiratory Questionnaire 
(SGRQ) and the Maugeri Foundation Respiratory Failure (MFR-28) questionnaire 
(24), and among patients with idiopathic pulmonary fibrosis measured by SGRQ (25). 
Thus, the rationale for this thesis was to gain new knowledge of the impact of long-
term treatment on HRQoL and the predictors for change in HRQoL using the specific 
SRI questionnaire, as well as to provide new insights into the capacity of HRQoL to 
predict mortality in people treated with LTMV. 
 
1.2 LTMV treatment 
Definitions, indications and prevalence of LTMV 
In the US and Canada, “ventilator-assisted individual” (VAI) or “vent user,” rather 
than “patient”, is often used to describe a person who is chronically dependent on a 
mechanical ventilator (26). “Home mechanical ventilation” is also a frequently used 
term for LTMV. The term LTMV is used in the Norwegian guidelines for LTMV and 
may be more in line with international practice (4). We also use LTMV in the current 
thesis, as well as “patient”, “ventilator user” and “ventilator-assisted individual”. 
Hypoventilation causing CHRF often develops gradually, depending on the underlying 
disease, comorbidity and other factors. As ventilatory control in all humans is reduced 
during sleep, the earliest signs of hypoventilation occur in sleep. The symptoms of 
sleep-disordered breathing are, however, most evident during daytime, consisting of 
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extensive sleepiness, poor concentration, impaired cognitive functioning and, in some 
patients, headache, particularly in the morning (27). As the disorder progresses to 
daytime hypercapnia, symptoms related to mechanical imbalance develop, such as 
breathlessness and tachypnoea.  
CHRF patients treated with LTMV were categorized into neuromuscular disease 
(NMD), chronic obstructive pulmonary disease (COPD), obesity hypoventilation 
syndrome (OHS) and chest wall disease (CWD) (10, 28, 29). Initially, LTMV was a 
treatment for patients with NMD (30, 31), a heterogeneous category concerning 
pathogenesis, disease progression, degree of muscle weakness and ventilator 
dependency.  
The worldwide prevalence of LTMV has increased rapidly in the last decade due to the 
more comfortable use of non-invasive ventilation via a mask or a mouthpiece (31, 32). 
The most recent prevalence estimate of non-invasive LTMV in Europe was 
6.6/100,000 inhabitants (28); however, the estimate varies widely between European 
countries, partly due to an extensive lack of high-quality registries for this treatment 
(28). The prevalence was 12.9/100,000 in Canada (33), 9.9 and 12.0/100,000 in 
Australia and New Zealand, respectively (34), and 63/100,000 in Lombardy, a major 
region of Italy (35). In 2012, around 11,000 patients were treated with LTMV in the 
US (26), with a shift towards non-invasive LTMV and wider indications for treatment 
in recent years (32). In Norway, the prevalence was 19.9/100,000 as of 31 December 
2007 (36) and 46/100,000 in 2017 (37), with similar incidences to those on the 
Swedish register (38).  
In 2018 congenital muscular dystrophies constituted 8% of new patients treated with 
LTMV, while patients with acquired NMD including amyotrophic lateral sclerosis 
(ALS), post-polio syndrome and spinal cord injury comprised 20% of the new LTMV 
patients (39). People with COPD accounted for one third of LTMV users in Europe in 
2005 (28), while an almost identical percentage of patients was diagnosed with COPD 
among European countries in 2016, albeit with a wide range of variance between the 
countries (40). In Norway, from 2002 to 2018, approximately 25% of the patients 
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treated with non-invasive LTMV had lung disease, mainly COPD (39). OHS refers to 
the fastest-growing group of LTMV users worldwide (31) and the largest group of new 
patients in Norway in 2017 (37). 
 
Basic principles and outcomes of LTMV treatment 
Mechanically assisted ventilation refers to the use of a mechanical device to provide 
ventilator support for patients in order to fully or partially compensate for failure in 
ventilation and normalization of blood gases (41). The most commonly used objective 
measure for impaired ventilation is increased arterial carbon dioxide tension (PaCO2) 
and decreased arterial oxygen tension (PaO2) (42). LTMV provides assistance with 
inspiration and decreases the work of breathing by unloading the respiratory muscles, 
leading to increased tidal and minute ventilation and improved gas exchange (43).  
Symptoms of hypoventilation improve considerably by LTMV, with a relapse in 
symptoms occurs upon discontinuation of treatment. Better one-year survival and 
improvement in some subscales in generic HRQoL have been found in ALS patients 
treated with non-invasive LTMV (6). However, the outcome of LTMV will depend on 
the basic underlying disease, the course of disease, and the extent of treatment 
requirements, as well as on a number of factors related to patients’ overall situation 
(4). Individuals receiving LTMV are also heterogeneous in terms of pathophysiology, 




The origins of modern LTMV can be traced back about five centuries (44). In the late 
19th century, ventilators based on negative pressure ventilation (NPV) appeared, using 
sub-atmospheric pressure which was delivered around the body of the patient to 
replace or augment the work performed by the respiratory muscles. The “iron lung” 
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was developed and used extensively during the polio epidemics of the 1930s and 
1950s. Negative pressure ventilation, in the form of “body ventilators” or “shield 
ventilators”, is still available, but rarely used today. Originally, positive pressure 
ventilators (PPVs) were developed for use during anaesthesia (41). Early PPV 
ventilators delivered breaths according to a pre-set volume in addition to a pre-set 
back-up respiratory rate and inspiratory time. These ventilators worked regardless of 
any inspiratory effort from the patient and were therefore often uncomfortable and 
poorly endured by the patient (43). In the 1980s, pressure support and pressure-
controlled ventilation were introduced. Bi-level positive airway pressure (BiPAP) 
ventilators provided non-invasive positive pressure ventilation in a wide variety of 
settings (41). In this mode, which is the most frequently used ventilation in LTMV 
today, the practitioner selects an inspiratory positive airway pressure (IPAP) and an 
expiratory positive airway pressure (EPAP) to be delivered by the ventilator. The 
patient triggers an inspiration from the ventilator, or the ventilator delivers an 
inspiration if the patient’s spontaneous breathing rate falls below a pre-set back-up 
rate. The ventilator’s ability to respond automatically to their breathing was reported 
as important or very important to 91% of LTMV patients (29). Newer modes of 
ventilation are able to combine aspects of both volume and pressure modes (43).  
Non-invasive and invasive LTMV modes 
LTMV can be applied invasively via a tracheostomy (an opening in the neck with 
access to the trachea) and non-invasively via a mask or a mouthpiece. In 2017, 98% of 
Norwegian LTMV users started the treatment in the non-invasive mode (37), while, in 
2008, at the baseline of this thesis, about 92% of the patients received LTMV in the 
non-invasive mode(4, 36). The interfaces (i.e., the connection between the patient and 
the ventilator) used in non-invasive ventilation are nasal masks, nasal pillows, oral 
masks or mouthpieces, or masks covering both mouth and nose. When selecting an 
interface, it is important to evaluate the fit and air leaks as well as the patient comfort 
because these influence patient compliance with LTMV. Other aspects to consider 
include the volume of dead space (volume not included in the ventilation), the position 
of the interface exhalation port, and finally the type of ventilator to be used (45).   
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A problem in LTMV might be treatment-related inconvenience or side effects (4, 9, 
17, 46). Most side effects are the result of a mismatch between the natural human 
airway and the artificial airway, but can also occur from the ventilator as a 
synchronization problem between the patient’s own breath and the ventilator-given 
breath. Mask discomfort is reported by up to 50% of patients receiving non-invasive 
LTMV (9, 10, 27), such as facial and/or nasal erythema, skin soreness or ulcerations 
(27). Intentional air leaks are incorporated into the ventilator circuits and necessary for 
CO2 removal. Unintentional leaks around the edge of the interface or through the 
mouth can cause problems of various levels of concern, ranging from eye irritation and 
dry mouth to an inability to trigger inspiration (27). Other side effects might be 
dryness of nose, throat or the bronchial tree, epistaxis, ear or sinus pain, gastric 
insufflation or distension, belching or flatulence, and nausea/vomiting. Sleep-related 
problems such as late sleep onset and/or sleep disruption (i.e., insomnia) can also 
occur, sometimes caused by noise from the ventilator (27).  
Invasive ventilation is an option when a person has a high degree of ventilator 
dependency and/or problem with secretion (4, 43). The non-invasive mode is however 
physiologically more favourable and preferred whenever possible (4, 9). The patients 
then avoids risks and complications that are associated with a tracheostomy (4).   
 
Organization of the initiating, training and follow-up in LTMV 
Major treatment advancements and quality improvements in care from specialist and 
primary healthcare services have influenced the lives for patients with hypoventilation 
and CHRF in recent decades in Norway. One example is that of a patient with 
hypoventilation successfully discharged from the hospital Ullevål, where he had lived 
his life continuously for 26 years (47). The Norwegian Centre of Excellence in Home 
Mechanical Ventilation was established in 2003, later renamed the National Advisory 
Unit for Long Term Mechanical Ventilation (48). The main goal for the centre was to 
increase or maintain quality of life in LTMV patients (3, 4). Since its beginning, the 
centre’s work has been organized as a decentralized national multi- and 
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interdisciplinary network, in line with recommendations for the organization of the 
treatment and care for patients receiving LTMV (49). Dissemination and sharing of 
knowledge in the field of LTMV are the focus areas for the national network, initially 
organized by part-time employers from different parts of Norway all having in 
common the fact that their main employment is within the specialist healthcare 
service. The unit was reorganized in 2011 into the model that exists today. It includes 
a central cohort of staff in Bergen and four regional resource groups. The network also 
includes LTMV user representatives, whose presence is legally anchored in the law on 
patient and user rights (§3-1), referring to patients’ or users’ right to participation (50).  
A description of the usual routines in Norway for the start and follow-up of LTMV 
treatment in line with the national guidelines is as follows: 
Adaptation and training in the use of the ventilator takes place in the hospital ward, 
outpatient clinic and, in some cases, patients’ home. Lung function (forced expiratory 
volume in one second (FEV1), forced vital capacity (FVC)) and arterial blood gases 
are routinely tested and measured, respectively. In selected cases, the clinicians apply 
advanced recordings such as transcutaneous CO2 monitoring, and even more seldom in 
combination with polysomnography. Downloading the compliance data retrieved from 
the ventilator’s software allows for the ventilator settings to be evaluated and 
confirmed; furthermore, nurses with specialist expertise perform controls of masks and 
equipment. A few patients need life-sustaining LTMV 24/7 and about 10% of LTMV 
patients need an assistant continuously (4). The care needs of patients with LTMV 
vary greatly with the underlying disease, comorbid conditions and ventilator 
dependency (4). In 2017, about 62% of the specialized healthcare services in Norway 
offered home visits to adult LTMV users requiring life-sustaining treatment (37). The 
municipalities are responsible, both economically and practically, for the daily care of 
LTMV patients. Healthcare professionals, paraprofessionals and family caregivers 
perform the care (4).  
Respira is an association for LTMV users, connected to the Norwegian National 
Association for Heart and Lung Diseases. The goal of Respira is to spread knowledge 
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about LTMV and establish a network of LTMV users to share experiences, as well as 
to protect the interests of LTMV users and share information about new research in the 
field of LTMV (51).  
 
1.3 Quality of life  
Quality of life is becoming an increasingly used concept in daily life and in research 
(13). The concept was introduced in the 1950s, as part of the social and cultural 
criticism of materialism (52). Disciplines such as the social sciences often address 
objective measures including welfare, life conditions, living arrangements and 
economic status in their understanding of quality of life (13, 53, 54). Quality of life has 
been and remains one of the core concepts in nursing (55, 56).  
Most commonly, quality of life has been considered as a multidimensional concept, 
including satisfaction with life and well-being, physical, psychological and social sub 
dimensions (57-61). A common way to understand overall quality of life is by 
satisfaction with life, an approach  used by the Organization for Economic 
Cooperation and Development (OECD) (62, 63) and the European Union (EU) (64) 
and recommended by the Norwegian Health Directorate (65) to derive knowledge of 
the general population’s subjective life satisfaction. This understanding of quality of 
life has also been present in research on quality of life in patients receiving LTMV (22, 
66, 67). Satisfaction with life includes a wide range of a people’s experiences and 
emotions and has been perceived as an overall quality of life term (68). It has also 
been seen as a degree to which a person positively evaluates her/his overall quality of 
life (69).  
The World Health Organization (WHO) (1995) defines quality of life in terms of 
individuals’ perception of their position in life, in the context of the culture and value 
systems in which they live, and in relation to their goals, expectations, standards and 
concerns (70). It is a broad concept, which includes people’s physical health, 
psychological state, level of independence, social relationships, personal beliefs and 
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relationships with the environment (70). This definition includes both positive and 
negative facets of life, is multidimensional and recognizes that quality of life is 
subjective; further, it concerns people’s global evaluations of behaviours, states and 
capacities, as well as satisfaction versus dissatisfaction, all of which inform quality of 
life (70). 
According to Moons and colleagues (2010), there are some important requirements for 
quality of life studies. The first criterion is to define the quality of life term used in the 
study (71). Secondly, researchers are required to state the domains of quality of life 
that they have assessed. Thirdly, researchers are required to justify the reason(s) for 
choosing the questionnaire they use. Fourthly, researchers are required to state whether 
they measure overall quality of life or HRQoL. Therefore, a distinction between 
overall quality of life and HRQoL should be made clear. The last requirement is that 
researchers explicitly state the indicators and determinants of quality of life that they 
have assessed in their research. Researchers have to describe how they have measured 
quality of life itself , and how they have measured influencing factors (71). Despite 
many years of research within quality of life a resent systematic review (2019) 
concluded that researchers still have to pay closer attention to methodological and 
conceptual clarity of quality of life (72).  
 
Health-related quality of life 
To distinguish between quality of life and the requirements of clinical practice and 
research, the term HRQoL is frequently used (13). The term is used when the purpose 
is to gain knowledge of issues that are most relevant in a clinical setting, but excludes 
aspects of quality of life that are not directly related to health, such as politics, religion 
and culture. The term includes components of the physical state, functional capacities, 
social relations and psychological well-being (73). However, due to the absence of any 
agreed definition of HRQoL, most researchers describe what they incorporate in the 
concept by their choice of instrument. The concept has been developed in order to 
focus on aspects of a person’s subjective experience which relate directly and 
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indirectly to health, disease, disability and impairment (74), as well as the 
effectiveness of treatment (54).  
HRQoL can address both generic problems and condition- or disease-specific 
problems (75) and be categorized into generic HRQoL and specific HRQoL (76).  
Generic HRQoL is not specific to any disease or health condition; rather, it is used to 
measure HRQoL in the general healthy population. The advantages of the generic 
HRQoL approach is that the non-specific character of the concept allows for a broad 
application and usefulness in terms of comparing HRQoL a different groups of 
patients and the general population (73, 76). However, this broad understanding of 
HRQoL can also be a disadvantage because it does not include the specific and 
important aspects of life among those with CHRF and severe respiratory insufficiency 
who are receiving LTMV.   
Condition-specific HRQoL addresses the specific elements that affect the lives of 
people with a given condition and is often used to focus on the effect or outcome of a 
specific condition, disease or treatment (75). The advantages of this approach is it 
provides more detailed information on how the condition influences HRQoL (76). 
Thus, this approach is useful when the aim is to examine changes in HRQoL over time 
(73). Condition-specific HRQoL can provide a measure for evaluating the benefits and 
the burden of modern medical treatment, while reflecting the most relevant problems 
associated with a disease or treatment (13). Patients with CHRF usually have 
breathlessness and symptoms of severe respiratory insufficiency, which affect their 
daily lives. Therefore, it is important to choose questionnaires for addressing these 
symptoms (73).  
 
1.4 Questionnaires for patients receiving LTMV 
A large number of instruments exists; therefore, researchers need to explain the 
reasons for choosing to use a particular questionnaire.  
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Overall quality of life questionnaires 
Overall quality of life measures offer advantages due to their ability to capture core 
aspects of quality of life. However, in our opinion, they are not sufficiently sensitive 
and responsive to identify specific aspects of the lives of people who are dependent on 
LTMV.  
One example of such a questionnaires is the Satisfaction with Life Scale (SWLS), 
which was developed to measure global life satisfaction (77). This scale has been used 
to measure life satisfaction in individuals with Duchene muscular dystrophy (DMD) 
who are treated with LTMV (66, 78). 
Satisfaction with life may also be measured by one single item such as, “How would 
you rate your overall quality of life?”, which has shown to be a valid and reliable 
measure compared to scores from multidimensional questionnaires (13, 79), for 
example, the Cantril Ladder. Another kind of measure of quality of life is based on the 
WHO’s definition (80) and has been used to measure the impact of mechanical 
ventilation on quality of life after discharge from the intensive care unit (ICU) (81) and 
in COPD patients (82), as well as the effects of lung function reduction on quality of 
life (83). We were not able to identify whether this has been used with people 
receiving LTMV.  
 
HRQoL questionnaires 
HRQoL questionnaires mainly consist of two categories of questionnaire, the generic 
questionnaire and the condition-specific questionnaire.  
Generic HRQoL questionnaires 
The advantage of generic questionnaires is that they focus on wide aspects of HRQoL; 
thus, they are suitable to compare HRQoL between disease groups and the general 
population (13). Some of the generic HRQoL questionnaires reference values 
appropriate to the general population (13, 73). This applies to SF-36, which was 
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developed from the medical outcome study, based on the WHO’s definition of health 
(84, 85). The concept of health was defined by the WHO (1947) as not only absence of 
disease and infirmity, but also one state of complete physical, mental and social well-
being (86). This concept of health is similar albeit narrower than the definition of 
quality of life from the WHO, as it lacks the specific aspects of culture and value 
systems included in it. This is a multidimensional questionnaire which has been 
referred to as a health measure, a quality of life measure and a generic HRQoL 
measure (87). By adding the subjective personal judgement of health, it is common to 
use the SF-36 as a measure of HRQoL. It has been widely used among patients 
receiving LTMV (6, 21, 46, 87-92) and shown to differentiate between the underlying 
diseases leading to CHRF (93). However, the non-specific nature of the generic 
HRQoL questionnaire might lead to insufficient sensitivity and responsiveness in 
relation to the specific problems and symptoms among patients with CHRF who are 
receiving LTMV (10).  
Condition- and disease-specific HRQoL questionnaires 
Condition- and disease-specific questionnaires have been developed for a large 
number of different conditions and diagnoses (76). The main advantages of using 
condition- or disease-specific HRQoL instruments is that they are more likely to be 
responsive to the detection of sometimes small, but clinically significant, changes in 
specific HRQoL.  
The SRI questionnaire is a condition-specific HRQoL instrument developed by 
Windisch and colleagues (2003) in the German language. The development process is 
well documented and involved pulmonologists specialized in LTMV, psychologists 
specialized in quality of life and open interviews with patients receiving LTMV about 
subjective descriptions of their daily lives (14). The SRI, which was initially 
developed to assess HRQoL in patients with chronic respiratory failure, due to various 
underlying diseases, who are receiving LTMV, was validated by a survey including 
patients with NMD, COPD, OHS and CWD, such as idiopathic kyphoscoliosis and 
post-tuberculosis sequelae. Patients’ view on those aspects that are important to their 
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HRQoL determined a significant part of the content of the SRI questionnaire; thus, it 
was derived directly by involving the target group for the questionnaire. The items 
were then incorporated into physical, social and psychological health domains. 
Physical health included impairments in terms of physical functioning and capability 
due to breathlessness and severe respiratory problems. Items asking about well-being 
and anxieties covered the psychological domain of HRQoL. Items related to “anxiety” 
were specifically related to respiratory problems such as “fear of breathlessness”. 
Items concerning limitations in social relationships and activities due to respiratory 
symptoms reflected social aspects of HRQoL. The first version of the SRI 
questionnaire included 80 items. Thereafter, items were excluded if they were similar 
to remaining items or did not meet the criterion of a minimal item-scale correlation of 
0.30. After this item evaluation, 49 items passed the selection process (14). The 
minimal clinically important difference of the SRI questionnaire ranged from five and 
seven points in patients with severe but stable COPD (94). The use of the SRI 
questionnaire has expanded widely since 2008 and, according to the European 
Respiratory Society’s handbook for non-invasive ventilation (2015), both this and the 
MRF-28 questionnaires provide the backbone for research on HRQoL in patients 
treated with LTMV (17).  
 
Other questionnaires used for patients receiving LTMV 
The MRF-28 was primarily developed for use in patients with respiratory failure 
secondary to pulmonary disease or CWD. The conception included 152 identified 
items from several different questionnaires, 28 of which items correlated with patients’ 
perceptions of overall health. Three specific factors were identified: daily activities, 
cognitive function and invalidity. Despite the fact that MRF-28 has been used in some 
studies to measure quality of life in patients treated with LTMV (95, 96), this 
questionnaire does not apply a multidimensional approach which ought to be included 
in a specific HRQoL questionnaire. 
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The Chronic Respiratory Disease (CRQ) questionnaire has been used in several studies 
among patients treated with LTMV (95, 97, 98). It contains four aspects of patients’ 
lives: dyspnoea, fatigue, emotional function, and mastery, however, as it does not 
include physical function, it does not apply a multidimensional approach to the 
measurement of quality of life. 
The SGRQ, which was developed to measure health status among those with chronic 
airflow limitation (99), has been used in studies involving COPD patients treated with 
LTMV (89, 100). It is mainly a measure of symptoms caused by the disease and 
includes questions concerning to what degree these symptoms affect the daily 
activities of patients.  
Thus, as these questionnaires (MFR28, CRQ and SGRQ) lack important aspects of 
quality of life measures, we consider the SRI questionnaire to be the most appropriate 
instrument for studying specific HRQoL in patients receiving LTMV. 
 
Psychometric testing of a questionnaire 
The psychometric testing of a questionnaire includes examining evidence for 
reliability, validity, sensitivity and responsiveness (101). It consists of a number of 
stages, where the tester is trying to gather evidence that the instrument produces useful 
measurements according to the intended purpose of the questionnaire (13). The 
selected test group should be as representative as possible in relation to the target 
population. 
The reliability refers to the accuracy of information obtained in a study and to what 
extent the measurement is free from measurement error (101). The internal consistency 
of a questionnaire is a statistical expression of the degree to which the different 
questions measure parts of the same. The most common statistical method for 
measuring internal consistency is Cronbach’s alpha. The range of values is from 0 to 1, 
with coefficients above 0.70 generally regarded as acceptable (102). Internal 
consistency uses item correlation to assess the homogeneity of multi-item scales.  
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Validation of an instrument is a process for determining whether it measures what is 
intended (102). Validity includes three main aspects: content validity, criterion validity 
and construct validity (13). Construct validity is the most important condition that 
must be fulfilled in the validation process. It firstly involves creating a hypothetical 
model before describing the constructs being assessed and postulating their 
relationship.  
Sensitivity is the ability to identify differences between groups, which is one of the 
most important characteristics of a condition- and disease-specific questionnaire (13); 
for example, the SRI questionnaire discriminates between the different underlying 
diagnoses among LTMV patients (14). Responsiveness is related to sensitivity and 
refers to the ability of a measurement to detect changes as well as to the validity of a 
changed score (101); for example, the responsiveness of the SRI questionnaire in the 
detection of changes in HRQoL after commencement of  non-invasive LTMV was 
better than that of the generic questionnaire, SF-36 (10). 
Translations, cultural adaptations and validations of the SRI questionnaire have been 
produced in the most commonly used languages worldwide, including Chinese (103), 
Spanish (104), English (105), Portuguese (106) and Japanese (107). The SRI 
questionnaire has also been translated and transculturally adapted into French (108) 
and Turkish (109), but there have been no validation studies in these languages. The 
psychometric quality of the specific SRI questionnaire has been well documented in 
several studies (10, 14-17, 73, 110). A validation study re-examined the internal 
structure of SRI specifically for COPD patients (111). According to the study, the 
psychometric condition was better in the case of SRI, compared to the MRF-28 and 
Clinical COPD questionnaires, as well as the CRQ, in a study of patients with severe 
COPD who were being treated with non-invasive LTMV (15). The SRI questionnaire 
addresses some of the shortcomings in the generic and other questionnaires and seems 
to be a more sensitive HRQoL questionnaire for people treated with LTMV (110). 
Further, SRI shows the best performance in terms of predicting mortality among 




1.5 Previous research  
For the present review, we mainly included studies measuring HRQoL using the SRI 
questionnaire. However, as only a few follow-up studies using the questionnaire have 
been performed, we also included studies on HRQoL using other questionnaires in the 
literature review. Survival and mortality have been the primary outcome in some 
randomized controlled trials (RCTs) (6, 19, 20, 89, 96, 112). We carried out a 
literature search for this thesis prior to the study in 2008 and several systematic 
literature searches were subsequently performed with the assistance of library staff 
from the University of Bergen. The latest literature search was performed in May 
2019.  
 
HRQoL among patients receiving LTMV 
HRQoL among patients receiving LTMV measured by RCT  
The results from RCTs involving patients with COPD and CHRF receiving non-
invasive LTMV have shown a trend of improved HRQoL (19) as well as improved 
HRQoL (18, 20). Importantly, the patients in these RCTs also received LTMV in the 
ventilator mode, which includes a higher ventilator inspiratory pressure also known as 
a “high-intensity mode” (18, 20). Another RCT compared rehabilitation alone versus 
non-invasive LTMV in addition to rehabilitation among patients with COPD (95). In 
this study, the SRI questionnaire identified improved HRQoL in COPD patients who 
were receiving non-invasive LTMV in addition to rehabilitation (95).   
McEvoy and colleagues (2009) found differences in HRQOL, as measured by SF-36, 
in patients receiving LTMV and a control group, with the patients in the intervention 
group reporting impaired HRQoL (106). In the RCT by Kohnlein and colleagues 
(2014), the SRI summary scale score improved significantly after one year in favour of 
the intervention group, which was receiving highly intensive LTMV. Changes in SF-
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36 scores did not differ significantly between the intervention group and the control 
group, apart from the general health subscale of SF-36. The RCT by Murphy and 
colleagues (2017) measured HRQoL using the SRI questionnaire. After six weeks, the 
patients receiving both LTMV and long-term oxygen treatment (LTOT) reported 
significantly better HRQoL when measured by SRI, compared to those receiving 
LTOT only.  
Burke and colleagues (2006) performed one of the few RCTs which has compared 
non-invasive LTMV with no LTMV treatment among patients with NMD. After one 
year, the patients with good bulbar function (swallow and speech function) reported 
significant improvements in HRQoL, as measured by the SF-36 subscales, mental 
health, energy vitality and general health. The ALS subgroup with severe bulbar 
function reported no significant HRQoL, as measured by SF-36.  
Masa and colleagues (2015) compared the efficacy of different treatment alternatives 
for patients with OHS without obstructive sleep apnoea (OSA). After two months, 
there was significant improvement in the SF-36 mental health sum scale in the group 
that received non-invasive LTMV in addition to lifestyle modification compared to the 
group comprising patients who received lifestyle modification (113).  
Follow-up studies  
A one-year follow-up study of HRQoL, as measured by SRI, showed significant 
improvement across all SRI subscales, except for physical functioning, among patients 
with NMD and OHS who were receiving non-invasive LTMV. Significant 
improvements were found across all the SRI subscales except for the social 
relationship subscale (10). The highest improvement was in the attendant symptoms 
and sleep subscales in patients with NMD and OHS. The patients with NMD reported 
being less susceptible to sleep disturbances after starting with LTMV, as the attendant 
symptoms and sleep domain increased from 46 out of 100 prior to the initiation of 
non-invasive LTMV to 70 out of 100 one year after receiving LTMV. The patients 
with OHS reported that the attendant symptoms and sleep domain increased from 36 
prior to the initiation of non-invasive LTMV to 67 one year after initiating LTMV. 
32 
 
NMD patients reported significant less anxiety after starting non-invasive LTMV, as 
the SRI anxiety subscale increased from 44 to 57 after one year of receiving non-
invasive LTMV. Patients with COPD reported significant improvements in their 
respiratory complaints subscale from 38 to 56 one year after initiating LTMV (10). 
Patients with restrictive thoracic diseases reported significant improvement in physical 
functioning as this domain increased from 38 to 51 one year after initiating non-
invasive LTMV (10).  
A two-years follow-up study using the SF-36 questionnaire identified improved 
HRQoL among patients with COPD, OHS and RTD, but not in patients with NMD, 
where 10 of 11 patients had ALS (21). The deterioration in HRQoL is possible 
explained by the progressive nature of the ALS course. 
 
Potential predictors of change in HRQoL among patients receiving LTMV 
Disease-dependent differences in SRI subscales have been identified (114), and 
disease-dependent improvements in HRQoL were found in single subscales of the SRI 
questionnaire (10). In studies among patients treated with LTMV, older age has been 
associated with impaired HRQoL, when measured by the SF 36 (108) and SRI (147) 
questionnaires. The total hours per day of receiving LTMV was a significant 
independent predictor of the improvement in HRQoL, when measured by the SF-36, in 
patients with OHS, COPD and RTD (21).  
A cohort measured HRQoL in difficult-to-wean patients, with and without a ventilator, 
after discharge from the ICU (115). SRI showed lower HRQoL in ventilator-dependent 
versus weaned patients, with lower SRI scores for physical functioning and feelings of 
fear, but with similar scores in social functioning, relations and mental health. 
Conversely, SF-36 scores in the physical domains and mental health showed no 
different between patients with a ventilator or who were weaned at discharge from the 
ICU (115).  
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Concerning synchrony between the patient and the ventilator, patients ranked highest 
the “smoothness” or “natural feeling” of breathing, being able to fall asleep and the 
comfort of the mask (29). The SRI questionnaire was used to evaluate the impact of 
ventilator modality, such as by comparing average volume assured pressure support 
(AVAPS) versus pressure support (PS). No influence on HRQoL was found in patients 
with OHS (116, 117); nor did patients report differences in HRQoL, when measured 
by SRI, after adding a high back-up rate in addition to high ventilator pressure in 
COPD patients receiving LTMV (118). Ventilator modality did not influence HRQoL 
when measured by SRI (118). A recent systematic review concluded that different 
positive airway pressure modalities appear to be equally effective in improving 
HRQoL outcomes in patients with OHS (119). 
Lower lung function measures, including an obstructive pattern from the FEV1/FVC 
ratio (114), are independently predicting lower SRI scores in patients receiving LTMV 
(120). Whether nasal or face masks were used or additional long-term oxygen therapy 
was applied, no influence was found in the SRI sum scores in patients treated non-
invasively (121).  
 
Mortality in patients treated with LTMV 
In the work on Norwegian guidelines for LTMV, the Norwegian Institute of Public 
Health ordered three systematic reviews of the effect of LTMV (122-124). The 
primary outcomes in these reviews were life prolongation, quality of life, 
hospitalization and sleep. 
The conclusion from these systematic reviews is that LTMV may be associated with 
improved survival in CWD and DMD patients, as well as in ALS patients with good 
bulbar function (122, 125). Mortality did not seem to differ between DMD patients 
who were invasively and non-invasively ventilated (124). The Norwegian systematic 
reviews did not find any benefit in terms of the survival of COPD patients treated with 
non-invasive LTMV (123). A systematic review and meta analyses involving stable 
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and recently hospitalized COPD patients could not prove any reduction in mortality in 
the case of domiciliary non-invasive LTMV, compared to usual care alone (126). 
However, there is too little evidence to draw any conclusions on the potential survival 
benefits of high-pressure non-invasive LTMV settings (126) Among patients with 
OHS, no controlled studies of the effect of LTMV on mortality were identified (122).  
In a RCT performed by Bourke and colleagues (2006), 13 out of 22 patients (59%) 
with ALS died in the group that received non-invasive LTMV, compared to 16 out of 
19 patients (84%) in the group receiving standard care without LTMV during one year 
of follow-up or until death (6). For the total study sample, the median survival for the 
LTMV group participants was 48 days longer than the standard care group participants 
(219 days versus 171 days) (127). In patients with normal or moderately impaired 
bulbar function, there was a significant improvement: 205 days’ longer survival 
compared to the standard care group (127). In ALS participants with poor bulbar 
function, LTMV did not confer survival advantage (6, 127). An Australian cohort 
study reported significantly increased survival among ALS patients with bulbar onset 
disease who were treated with non-invasive LTMV, compared to ALS patients with 
bulbar onset who were not receiving LTMV (128). Among Norwegian ALS patients 
treated with invasive LTMV, the median survival was 74.8 months and, in patients 
treated with non-invasive LTMV, it was 15.4 months (129).  
Without LTMV, the survival among young patients with DMD is very poor: patients 
with FVC<1 l had a five-year mortality rate at 92% (130). In a retrospective cohort, an 
analysis of 835 patients with DMD found that the mean age for respiratory deaths 
among those without LTMV was 17.7 years, while the mean age for those treated with 
LTMV increased to 27.9 years (131).  
Several RCTs have examined non-invasive LTMV as an intervention to address 
mortality in COPD patients (19, 20, 89, 96, 112, 132). LTMV provided no survival 
benefit compared to standard care in patients with prolonged hypercapnia after acute 
respiratory failure (96, 132). Conversely, McEvoy and colleagues (2009) found 
significantly improved one-year mortality in COPD patients who received both LTMV 
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and LTOT, compared to those receiving LTOT only. Importantly, the surviving 
patients reported impaired HRQoL (89). In a group of COPD patients with 
hypercapnia in their habitual phase, 12 out of 102 (12%) died among those randomized 
to high-intensity LTMV after one year, compared to 31 out of 93 (33%) in the ordinary 
care group (112). In COPD patients with hypercapnia which persisted two weeks or 
more after treatment for acute respiratory failure, 16 out of 36 patient (44%) died in 
the high-intensity-plus-LTOT group, compared to 19 out of 28 (68%) in those treated 
with LTOT only (20). Based on these RCTs, Duiverman (2018) stated that non-
invasive LTMV is a cost-effective treatment for COPD patients, as only five COPD 
patients with CHRF need to be treated with non-invasive LTMV to avoid one death 
(133). 
An uncontrolled four-year follow-up study in patients with OHS, found that three out 
of 54 patients (5.5%) died in the group treated with non-invasive LTMV, while seven 
out of 15 patients (46%) died among those who did not want to continue LTMV 
treatment (7). No significant differences in age, body mass index (BMI) and baseline 
blood gases were found between the two groups, but more women and higher rates of 
psychiatric problems were found in those who refused LTMV (7). Survival in the 
CWD category has been reported two cohort studies (134, 135), based on the Swedish 
LTMV Register. Among patients with kyphoscoliosis, 32% died in the group treated 
with LTMV, compared to 76% in the group treated with LTOT (134). In a 10-year 
cohort of patients with CWD caused by tuberculosis sequelae, 60% died in the LTMV 
group compared to 87% in the LTOT-only group (135).  
 
Potential predictors for mortality in LTMV patients 
A variety of factors has been examined as predictors of death in LTMV patients other 
than the underlying cause of disease (31, 67, 121, 136-138), such as socio-
demographic variables, comorbidities (including body weight and nutrition), lung 
function and blood gases, ventilator treatment settings and interface strategies, 
treatment commencement in an elective or acute setting, and ways of organizing the 
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follow-up. Finally, a few studies have reported on the association between HRQoL and 
mortality in LTMV patients.  
Older age (24, 128, 137, 139) is associated with mortality. Sex might have an 
influence on mortality among LTMV patients as men with ALS had a 46% greater 
mortality rate than women (140) and DMD affect almost exclusively men (141). Even 
if women had a more severe condition when OHS was diagnosed; no gender 
difference in survival rates was found in OHS treated with LTMV (142). Socio-
economic status such as the level of education has been shown to be associated with 
mortality in patients with chronic disease (143). Married patients experienced longer 
survival after initiation of non-invasive LTMV than non-married patients (144).  
Comorbidity has been identified as a predicting factor for mortality in LTMV patients 
with NMD (136), COPD (145) and CWD (146), while cardiovascular comorbidities 
remained the only factor independently associated with a higher risk of death in 
patients with OHS (136, 147).  
Higher BMI has been associated with mortality in LTMV patients (121, 148). 
However, no association between baseline BMI and mortality in patients with OHS 
treated with LTMV was identified (149). In addition, obesity was a good prognostic 
factor for COPD patients using non-invasive LTMV (150). Good enteral nutrition was 
associated with longer survival in the case of ALS patients (151) and of DMD patients 
treated with LTMV (131).  
Low FVC has been associated with mortality in LTMV patients with OHS (152) and 
in a population with mixed diagnoses treated with LTMV or LTOT (138). However, 
another study found no difference in baseline spirometry values between survivors and 
deceased (67). PaCO2 assessed by arterial blood gases is the most important 
monitoring parameter for patients treated with LTMV (17), with a decreasing level of 
PaCO2 having been suggested as an explanation of improved survival in COPD 
patients (20, 112). However, improvement in PaCO2 did not seem to be associated 
with an improved survival in COPD patients treated with non-invasive LTMV (153). 
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The ventilation strategy, “high-intensity” LTMV, which is a combination of higher 
IPAP and back-up rate, with the aim of decreasing PaCO2, can explain the reduced 
mortality in COPD patients with CHRF who are treated with non-invasive LTMV (20, 
112, 149). However, a marked reduction in cardiac output in “high-intensity” 
ventilation mode has been reported (154). However, this study used very high IPAP 
(mean IPAP of 28 cmH2O), while cardiac output was measured over a short period but 
clinical relevance was not investigated (154). Another study where the patients 
received non-invasive LTMV for a longer period found no change in cardiac output or 
clinical cardiac outcomes. However, both of these two studies had a small sample 
(133). New studies to better understand the pathophysiological changes occurring in 
patients using “high-intensity” LTMV are needed (155). 
The influence of invasive versus non-invasive LTMV has revealed some contradictory 
results. Longer survival was reported in cohort studies involving patients with DMD 
using non-invasive LTMV and mechanically assisted coughing, compared to DMD 
patients receiving LTMV via a tracheostomy (156, 157). Conversely, the risk of death 
among patients with DMD was not associated with the use of invasive versus non-
invasive LTMV in a 12-year prospective cohort study (158). 
Follow-up by a multidisciplinary ALS team was associated with mortality (144), while 
the size of the treatment centre or regional treatment prevalence did not influence 
mortality in LTMV patients (137). Starting LTMV in an acute setting was also found 
to be a negative predictor of survival (137). The proportion of elective commencement 
of LTMV in Norway has increased in recent last years (it was 77% in NMD patients in 
2017) (37). 
Another aspect is that life expectancy at birth in Norway has improved by two years 
since 2005 (it  was 82.4 years in 2015), and has remained two years higher compared 
to the average in other OECD countries (63). 
HRQoL measured by SRI has been associated with mortality in LTMV patients (121, 
148). In the study by Budweiser and colleagues (2007), the SRI scores was associated 
with mortality in all patients except for those with COPD (121). The study from Oga 
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and colleagues (2017) found that SRI scores was associated with mortality in LTMV 
patients with COPD or pulmonary tuberculosis sequelae (148). The associations 
between HRQoL measured by SRI and mortality were investigated for up to three 
years (121, 148). Other health measures have also shown to predict mortality in 
LTMV patients with COPD (24) and with NMD and CWD (67). However, the SRI 
scores showed the most significant predicting ability for mortality in patients receiving 
LTMV in comparison to other health status measures (16).  
 
1.6 Gaps in knowledge: a summary 
As described above, there is highly limited knowledge on the relation between HRQoL 
and living with LTMV from a lifelong perspective. The treatment is both time- and 
cost-consuming and can causes side effects. Therefore, it is important to address 
whether or not acceptable condition-specific HRQoL follows the prolongation of life 
gained by LTMV. If LTMV increases burdens without maintaining or increasing 
HRQoL, this would be an ethical concern (73). Quality of life and survival have shown 
consistent trends in terms of improvement after initiating LTMV in studies covering a 
period of up to one or two years, but an essential question is for how long does this 
trend continue?  
Previously, there has been no specific HRQoL questionnaire sensitive enough for 
patients with severe respiratory insufficiency validated for use in Norwegian LTMV 
patients. In earlier research, a huge number of different questionnaires was used, but 
they were not sufficiently sensitive and responsive to address the specific challenges of 
living with LTMV, influence on HRQoL. The SRI questionnaire is a specific HRQoL 
instrument developed by and for patients treated with LTMV and has shown good 
psychometric qualities. No study worldwide has examined long-term HRQoL in 
people receiving LTMV by using an instrument that is specific to such a population. 
Knowledge is also lacking on factors associated with changes in HRQoL among these 
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patients, especially the importance of factors that healthcare professionals can 
influence directly. 
The SRI questionnaire predicts mortality in LTMV patients; however, these studies 
have only lasted up to three years and reported contradictory results concerning in 




2. AIMS OF THE THESIS 
With quality of life as a conceptual framework, this thesis aimed to provide new 
knowledge about the SRI questionnaire as a HRQoL instrument in patients receiving 
LTMV. 
We addressed all research questions in three papers using data from self-administered 
questionnaires and register-based data from Western Norway.  
Paper Ⅰ addressed the following research questions: 
(i) Is the reliability and the validity of the Norwegian version of the SRI 
questionnaire sufficient for use in HRQoL research and clinical practice among 
Norwegian patients receiving LTMV? 
(ii) Does the Norwegian version of the SRI questionnaire differentiate between 
generally accepted differences between patients receiving LTMV? 
Paper Ⅱ addressed the following research questions: 
(i) Does HRQoL change for people receiving LTMV from baseline in 2008 to 
2014 according to the SRI subscales and sum score?  
(ii) Do socio-demographic, clinical or patient-reported variables explain changes in 
HRQoL in people receiving LTMV? 
Paper Ⅲ addressed the following research questions: 
(i) How is the association between HRQoL measured by the SRI questionnaire at 
baseline and all-cause mortality in people receiving LTMV over 80 months of 
follow-up? 
(ii) How was mortality in patients treated with LTMV from 2008 to 2014? 
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3. MATERIAL AND METHODS 
3.1 Study populations (Papers I to Ⅲ)  
In this section, I will describe the main study population and how we recruited patients 
with regard to the papers in this thesis. 
 
LTMV Register 
The Norwegian LTMV Register was the basis for patient recruitment to this study. The 
register was established in 2002 and is currently funded and managed by the Western 
Norway Regional Health Authority. The register is based on information from all 31 
Norwegian hospitals which initiate LTMV treatment (39). In 2012, the register was 
approved by the Ministry of Health and Care Services as a national medical quality 
register (39).  
One of the main purposes of the register is to provide new knowledge on LTMV 
treatment through research. Additionally, it collects healthcare activity data to 
document the need for resources and measure changes in the specialist and municipal 
health service. Finally, the register provides information on geographical equalities 
and differences in the national healthcare of LTMV patients (39).  
In 2013, the register received approval from the Data Inspectorate for linkage to the 
following national registers in Norway: the Norwegian Patient Register (NPR), the 
Cause of Death Register, the Prescription Register, the Medical Birth Register of 
Norway, the Cancer Register, and tax information from Statistics Norway (SSB). 
Further, patient-reported outcomes measurement (PROM) data were included from 
2014 onwards in connection with the established electronic register version. All 
patients must sign a consent form before registration (39). 
The LTMV Register includes patients with CHRF with a wide variety of causes who 
are permanently dependent on LTMV for more than four hours a day. Ventilation 
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modes include BiPAP with a back-up respiratory rate or pressure and/or volume-
controlled ventilators. Ventilator connections between patient and ventilator are non-
invasive, including masks, nozzles or mouthpieces, or invasive via a tracheostomy 
(39).  
Exclusion criteria in the LTMV Register includes obstructive sleep apnoea syndrome 
(OSAS) and complex sleep disturbance among patients with CPAP,  BiPAP or an 
adaptive servo ventilator (39) , but includes patients with OSAS as part of OHS treated 
with BiPaP. At the baseline period for this thesis, 1149 adults was enrolled on the 
register from all over the country, and 30 different diagnoses were reported as the 
underlying condition for LTMV (4, 36).  
 
Recruitment and inclusion criteria 
We contacted patients on the register from the counties of Rogaland, Hordaland and 
Sogn og Fjordane by post in March 2008 with study information and an invitation to 
participate, as well as indicating that data would be stored for 10 years for a possible 
follow-up study. Due to practical feasibility, we did not include patients from other 
parts of Norway. The study inclusion criteria were: patients with well-adapted LTMV 
treatment for at least three months, in a clinically stable state, above 18 years, and 
cognitively able to answer study questions themselves or with help from family 
members. Of the initial 211 patients on the LTMV Register in Rogaland, Hordaland 
and Sogn og Fjordane, 18 patients did not meet the inclusion criteria (Figure 1). Of the 
remaining 193 eligible patients, 127 (66%) attended the study by returning the 
completed questionnaire by mail.  
Prior to the follow-up after six years in 2014, the Cause of Death Register was 
contacted to collect information on those who were diseased in the study sample from 
2008. We contacted the surviving patients by post and requested them to participate in 
a new data collection round for the follow-up study. The patients provided written 




3.2 Health-related quality of life (Papers I to Ⅲ) 
We used specific HRQoL, both as exposure and as outcome, in this thesis (see Table 
1). SRI measured specific HRQoL while SF-36 measured generic HRQoL by using 
self-administered questionnaires. The SF-36 questionnaire was included in Paper I for 
the validation of the Norwegian version of the SRI questionnaire. We sent 
questionnaires to participants by post in March 2008. Patients still alive were asked to 
fill in the same questionnaires once more in 2014 during their regular contact with the 
Outpatient Clinic at either Haukeland University Hospital or Stavanger University 
Hospital.  
Papers Ⅰ and Ⅱ used the SRI data as the outcome, whereas Paper Ⅲ used SRI data as 
the exposure.  
 
SRI (Papers I to Ⅲ) 
The SRI questionnaire is a specific HRQoL instrument for people receiving LTMV 
(14). It includes 49 items and seven subscales. Each item belongs to only one of seven 
subscales; respiratory complaints (eight items), physical functioning (six items), 
attendant symptoms and sleep (seven items), social relationships (six items), social 
functioning (eight items), anxiety (five items) and psychological well-being (nine 
items). The order of the items is not categorized in the seven divided subscales; but is 
in arbitrary order. The items refer to patients’ HRQoL in the previous week. The 
answer options are graded using a five point Likert scale from "strongly agree" to 
"strongly disagree". The items are recoded and transformed, such that high values refer 
to high HRQL on the SRI subscales and in the sum score (14). The scale from 0 to 100 
is similar to the scale of SF-36 and the mean values of each of the seven subscales are 
calculated if at least half of the items are answered. The order of the items is 
randomized, which also strengthens the internal validity. The SRI summary scale is the 
mean value of each subscale, which is not calculated if one of the subscales is missing 
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(159, 160). The SRI questionnaire has one summary scale in contrast to SF-36, which 
contains both physical and mental health component scales. One explanation for this is 
that all items on the SRI questionnaire have the same attribution concerning the cause 
of the limitation in social, psychological and physical health (14).  
We contacted the author of the SRI questionnaire in order to obtain approval to use the 
questionnaire and to acquire access to procedures for recoding and calculating the SRI 
scores.  
 
SF-36 (Paper Ⅰ) 
SF-36 is one of the most-used generic HRQoL questionnaire. It includes 36 items, 
measuring physical functioning (10 items), physical roles (four items), emotional role 
limitations (four items), bodily pain (two items), mental health (five items), social 
functioning (two items), general health (five items) and vitality (four items). The 
scores in each domain are transformed into a scale from 0 to 100 where higher scores 
indicate better HRQoL (161). SF-36 has been translated into many language including 
Norwegian (162). Without increasing the number of items, SF-36 version 2 has been 
evaluated, with the new version offering better reliability and validity (85). The new 
version also has identical items to those of the original SF-36, but the response scales 
have been extended with a wider range of response options which increase score 
precision and maintain comparability with the original version of SF-36 (161). SF-36 
was used as a validation questionnaire for the criterion validity in the validation study 
of the SRI questionnaire in the German language (14). As part of the psychometric 
testing of the Norwegian version of the SRI questionnaire, SF-36 version 2 was 
included in this study. The use of SF-36 version 2 requires a licence, which this study 






Table 1 An overview of the studies 
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Abbreviations: LTMV, long-term mechanical ventilation; SRI, severe respiratory insufficiency; SF-36, Short 
Form-36; ANOVA, Analysis of variance; HR, hazard ratio. 
 
3.3 Mortality (Paper Ⅲ) 
The Norwegian Cause of Death Register contains data on all deaths among Norwegian 
residents in Norway and abroad (163), and the purpose of the register is to monitor 
causes of death and elucidate changes in these causes over time, as well as provide a 
basis for preparation of statistics, research, planning and quality assurance (164). A 
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standardized death certificate for each individual death is required, provided by 
medical doctors (163). The structure of the death certificate is based on principles 
established by the WHO, and the Cause of Death Register has used the (International 
Classification of Diseases and Related Health Problems (ICD) (163) coding system 
since 1951. The register uses the IRIS software (165) with the Automated 
Classification of Medical Entities (ACME) module for coding (166), while input to 
this module is the ICD-10 for identifying the underlying cause of death (167). The 
Norwegian Cause of Death Register provided information on mortality in the cohort 
study. Information on mortality and cause of death was collected between 2008 until 
31 August 2014 (up to 80 months).  
 
3.4 Study design and sample selection criteria 
Paper Ⅰ:  This was a cross-sectional study including 127 patients, defined by the 
number of patients on the LTMV Register from three counties of Western Norway in 
2008. As the diagnosis, obstructive sleep apnoea, was an exclusion criterion on the 
LTMV Register, four patients with this diagnosis should not have been included on it 
and were thus removed from the register after the invitation to participate in the study 
was sent (n=4). Nine people had stopped LTMV treatment (n=9). According to their 
family, two of the patients were unable to answer the questionnaires (n=2). Further 
two people moved from the region and we were not able to locate them (n=2). In 
addition, one patient died during the week that the postal invitation to participate was 
sent (n=1). Thus, the number of potential patients receiving LTMV who could respond 
was 193. Out of these, 127 patients (66%) consented to participate and returned the 
questionnaires. 
Paper Ⅱ: This was a longitudinal study including 60 of patients at baseline (2008) and 
who were still alive at end of follow-up (2014), still treated with LTMV and able to 
answer the questionnaire after six years of ongoing LTMV. Of the 127 patients treated 
with LTMV in 2008, 75 patients were alive in 2014. However, 15 patients were not 
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included because they stopped using LTMV (n=8); dementia or unable to answer the 
questionnaire according to relatives or nurses (n=3); unable to make contact (n=1) or 
they did not want to participate in the follow-up study (n=3). Among the reasons given 
to stop LTMV treatment were problems with adapting to LTMV, problems with 
falling asleep, side effects, and no need for LTMV due to weight reduction surgery. 
These excluded patients were related to the NMD (n=6), COPD (n=2), OHS (n=6) and 
CWD (n=1) disease groups, leaving a final study sample of 60 patients.  
Paper Ⅲ: This was a prospective cohort study including 112 patients. During the 
follow-up from 2008 to 2014 (80 months), 52 patients died. We obtained written 
consent from the patients to perform individual data linkage between the study sample 
and the NPR. The Regional Committee for Medical and Health Research Ethics gave 
exemptions from the consent requirement for patients who died during the follow-up 
period. The sample size reflects the number of patients who gave written consent to 
data linkage with the NPR. Initially, for this paper, we wanted to include the same 127 
patients from Paper I. We, however, did not obtain written consent from 15 of the 
patients because they had stopped using LTMV (n=8); had dementia or unable to 





Figure 1 Flow chart: study population (Papers Ⅰ-Ⅲ) 
  2008: Potential patients on the 
Norwegian LTMV Register 
(n=211) 
Excluded patients because they 
did not meet the inclusion 
criteria (n=18) 
Potential LTMV responders 
(n=193) 
2008: Responders (n=127) 
Non-responders  
(n=66) 
Not able to contact (n=1) 
Died (n=52) 
Follow-up study-sample (n=60) 
   2014: Six years of follow-up 
 
Stopped LTMV (n=8) 
Non-responders (n=3) 
Not able to respond (n=3) 
Potential responders (n=63) 
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3.5 Other variables (Papers Ⅰ to Ⅲ)  
We also collected data on marital status, education level, hours per day on LTMV, 
dependency on daily assistance with LTMV treatment, side effects of LTMV 
treatment, satisfaction with training in the use of ventilators and BIPAP, satisfaction 
with follow-up from healthcare professionals, and need for assistance to fill out the 
questionnaires. The variables were used in each paper for various purposes. 
In Paper Ⅰ, the above-mentioned variables were used for description purposes and to 
investigate whether the study population was similar to non-attendants. In Paper Ⅱ, the 
variables were studied as risk factors for changes in SRI. In Paper Ⅲ, we evaluated 
these variables as potential confounding factors in the relation between SRI and 
mortality. The variables were selected based on previous literature, as well as advice 
from experienced clinicians and members from the LTMV user organization Respira. 
Data collected from the LMTV register concerned the following: age, sex, main 
diagnosis, date of starting LTMV, main ventilator mode and interface, additional 
treatment (LTOT and humidification), respiratory variables before treatment 
commencement and at baseline (FVC, FEV1, PO2, pCO2), and BMI.  
Comorbidity data were collected from the NPR (168). This register contains health 
information about all people who have received treatment or who are waiting for 
treatment in the specialist health service in Norway (168). We measured comorbidity 
by the total number of somatic ICD-10 diagnoses registered during hospital stays or 
outpatient visits for all patients during the recruitment period in 2008, when these 
patients answered the baseline specific HRQoL questionnaire.   
 
3.6 Statistical analyses 
In this section, I will provide a brief description of how we derived the SRI sum score 
and the corresponding subscale scores. I will also summarize the statistical methods 
used in each paper of the thesis. All statistical analyses were carried out using 
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Statistical Package for the Social Sciences version 18 and 20 (SPSS Inc., Chicago, IL, 
USA) or Stata SE version 14 (StataCorp LP, College Station, TX, USA) for Windows.  
The items in the SRI questionnaire were analysed according to the guidelines(14, 160) 
including recoding of the following items: 1, 2, 4, 5, 6, 8, 11, 12, 13, 14, 15, 16, 17, 
19, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 34, 35, 38, 39, 40, 42, 43, 45, 46, 47 and 48.  
The mean values of the SRI subscales were calculated if at least 50% of the items were 
answered. The process of transformation produces a score between 0 and 100 with 
higher values indicating a better HRQoL according to the content of the scale. The 
sum score was calculated by the mean of the values for the subscales (SRI-RC, SRI-
PF, SRI-AS, SRI-SR, SRI-AX, SRI-WB, SRI-SF). The SRI sum score for an 
individual was not calculated if one of the subscales was missing. 
SF-36 version 2 was scored according the User’s Manual for the SF-36v2® Health 
Survey and Scoring Software 2.0 (161, 169). Missing item responses were handled 
according to the Half-scale Rule, which implies that the score of the scale is 
considered missing in cases where the respondent did not answer at least 50% of the 
items. Recoding item response values was performed for 10 items, with the 
transformation of subscale raw scores to a 0-100 metric with higher values indicating 
better HRQoL.   
Paper I: Internal consistency for each subscale and the SRI sum score for the SRI 
questionnaire were calculated using Cronbach’s alpha. Spearman’s correlation 
coefficient was used to examine the associations between the subscales in the 
Norwegian version of the SRI and the SF-36 version 2 questionnaires. We used the chi 
squared test to test for difference in percentages and the two-sample t-test was used to 
test for difference in means. To examine the SRI questionnaire ability to discriminate 
between clinical differences among categories 
of patients receiving LTMV, we used analysis of variance (ANOVA) to measure 




Paper Ⅱ: We used linear mixed-effects models to investigate changes and risk factors 
associated with changes in SRI from 2008 to 2014. In the analysis of changes in SRI, 
the regression model included a random intercept term for the individual to account for 
correlated observations of the same individual and a fixed-effect term for the time to 
obtain estimates for SRI changes. To investigate risk factors associated with changes 
in SRI, we extended the first model to include the relevant factor and the product 
between the factor and time (i.e., factor-by-time interaction) as model terms. Estimated 
mean changes in the SRI subscales and sum score were reported using regression 
coefficients (β) with 95% confidence intervals (CIs). To obtain p values for factors 
associated with SRI changes, we used the likelihood ratio test, i.e., we compared the 
log-likelihood between models with and without the factor-by-time interaction term. 
We adjusted a priori for the following background variables: age, sex, education level, 
and marital status and disease groups. 
Paper Ⅲ: We used the Kaplan-Meier survivor function with the log-rank test to 
estimate and test the difference in the percentage of survivors across disease groups 
from study inclusion in 2008 to the end of follow-up 31 August 2014. To estimate the 
association between SRI and mortality, we used Cox regression models. We reported 
associations as hazard ratios (HRs) with 95% CIs. The association between SRI and 
mortality was estimated both by crude and by adjusted Cox regression models to 
control for factors that may potentially confound the true association between SRI and 
mortality. We adjusted a priori for the following background variables: age, education 
level, disease category, number of years treated with LTMV, hours per day on LTMV, 
and comorbidity. We also performed analyses for the specific disease groups NMD, 
COPD, and OHS, but not for CWD due to low numbers. 
 
3.7 Ethical considerations and approval 
The Western Norway Regional Committee for Medical and Health Research Ethics 
approved the project, reference 273.06-/4647 and reference 2012/1090-11. The 
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Norwegian Centre for Research Data (NSD) approved the project, number 16001. The 
Norwegian LTMV Register approved the project prior to the study. All studies were 
performed in accordance with the ethical principles stated in the Declaration of 
Helsinki 
Common to all three studies was the mailed information letter about the study which 
was sent to potential eligible patients on the LTMV Register in Rogaland, Hordaland 
and Sogn og Fjordane, along with a request to participate in the study. This letter also 
informed that the data would be stored for 10 years for a possible follow-up study. An 
information letter about the follow-up study with a request to participate was sent by 
post to the surviving patients prior the longitudinal study.  
The Regional Committee for Medical and Health Research Ethics required written 
consent from the participants to link data between the LTMV Register, the NPR and 
the Cause of Death Register. For cohort patients who had died, exemption from the 
written consent requirement for linking data between these registers was granted. This 
study also required approval from the Cause of Death Register and the NPR to collect 
and link data from these registers.  
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4. SUMMARY OF RESULTS 
4.1 Study I 
Norwegian version of the SRI questionnaire 
Translation and validation of the SRI questionnaire from German into Norwegian were 
carried out according to generally accepted procedures. A pilot study including LTMV 
users and healthcare professionals evaluated the feasibility and face validity of the SRI 
questionnaire. Thereafter, the Norwegian version of the SRI questionnaire was 
psychometrically tested in the full survey. Of the 193 potential patients recruited from 
the Norwegian LTMV Register, 127 responded to the SRI questionnaire, giving a 
response rate of 66%. The patient groups included categories of NMD, COPD, OHS 
and CWD (Table 1, Paper Ⅰ). Blood gases (PaCO2 and PaO2) taken before 
commencement of LTMV showed that all patients had CHRF with PaCO2>6 kPa 
before starting up LTMV (Table 1, Paper Ⅰ). There were no significant differences 
between responders and non-responders in age, gender, diseases, years treated with 
LTMV, BMI and PaCO2. However, we found that no-responders had slightly lower 
FVC and FEV1, compared with the LTMV patients who responded (Table 2, Paper Ⅰ). 
Reliability and internal consistency, as measured by Cronbach’s alpha, varied between 
0.68 and 0.88 for the subscales and 0.94 for the SRI sum score (Table 3, Paper Ⅰ).  
Correlations between the SRI subscales and the SF-36 subscales were found as one of 
the criteria for validating the Norwegian version of the SRI questionnaire. The highest 
correlations were found between SRI ‘physical functioning’ and SF-36 ‘physical 
function’ (r=0.73; p<0.001) and between SRI ‘psychological well-being’ and SF-36 
‘vitality’ (r=0.72; p<0.001), and between SRI ‘psychological well-being’ and SF-36 




The ability to detect some known differences between patient groups receiving LTMV 
was the criterion for the construct validity of the Norwegian version of the SRI 
questionnaire. This was confirmed by identifying that COPD patients had the lowest 
score on the SRI ‘respiratory complaint’ subscale at 40.3 (18.7), while CWD patients 
had the highest score at 65.0 (22.1) (Table 5, Paper Ⅰ). Patients with COPD also had 
the poorest HRQoL indicator related to ‘anxiety’ at 41.2 (26.3), while patients with 
NMD had the highest score at 67.4 (24.6). In addition, COPD patients had a low SRI 
‘social functioning’ score at 34.0 (22), compared to NMD patients who reported a 
score of 55.1 (22.6). Patients with NMD had the highest SRI sum score at 61.0 (14.7), 
while patients with COPD had the lowest SRI sum score at 43.3 (19.0) (Table 5, Paper 
Ⅰ). 
Ventilator hours per day were inversely correlated with the SRI sum score (r=-0.20; 
p=0.03), the SRI ‘physical function’ score (r=-0.36; p<0.001) and the SRI ‘social 
function’ score (r=-0.20; p=0.03), which also confirmed known a priori knowledge 
concerning LTMV treatment. 
 
4.2 Study II     
Factors associated with changes in HRQoL among individuals treated with LTMV: 
a six-year follow-up study 
Non-invasive LTMV was still used by 58 of the 60 patients (97%) still alive after six 
years of follow-up. Two patients in the follow-up study were receiving LTMV via a 
tracheostomy. None of the patients surviving during the follow-up study had ALS. 
Baseline characteristics including background, treatment and respiratory variables are 
shown in Table 1, Paper Ⅱ. Half of these individuals reported side effects (n=29) 
(50%), with air leakage between the face and the mask (n=21) (36%) and pressure 
soreness caused by mask pressure (n=10) (17%) being the most common.  
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We found that the SRI sum score increased by 4.74 (95% CI: 1.49-8.00) from 2008 to 
2014 (Table 2, Paper Ⅱ). Significant improvements in HRQoL were also found in four 
of the seven SRI subscales: ‘social relationship’ by 8.47 (95% CI: 3.48-13.5), ‘anxiety’ 
by 7.94 (95% CI: 2.42-13.5), ‘psychological well-being’ by 7.66 (95% CI: 3.28-12.0), 
and ‘social functioning’ by 5.89 (95% CI: 0.91-10.9) (Table 2, Paper Ⅱ). There were 
no significant changes in the SRI subscales for ‘respiratory complaints’, ‘physical 
functioning’ or ‘attendant symptoms and sleep’ (Table 2, Paper Ⅱ).  
Among potential risk factors of changes in SRI, we selected the background variables 
of age, sex, educational level, marital status, disease group, and years treated with 
LTMV. The treatment variables chosen were LTMV hours a day, dependency of daily 
assistance related to LTMV treatment, side effects of LTMV, satisfaction with 
training, and satisfaction with follow-up from healthcare professionals. In addition, we 
chose the respiratory variables FVC and PaCO2.  
We identified age, FVC, patient-reported side effects of non-invasive LTMV, 
satisfaction with training on LTMV, and follow-up from healthcare professionals as 
important risk factors for changes in SRI scores from 2008 to 2014.  
The treatment variable, side effects of masks or ventilator, was positively associated 
with changes in the SRI sum score (Table 3, Paper Ⅱ) and the SRI ‘physical function’ 
subscale (Table S1, Paper Ⅱ).  People reporting side effects at baseline in 2008 
increased their SRI sum score from 56.2 (16.1) in 2008 to 65.1 (15.4) in 2014 (p for 
change<0.001), while those not reporting side effects remained at the same high level 
of 63.9 (20.1) in 2008 and 64.7 (18.4) in 2014 (p for interaction=0.02) (Table 3, Paper 
Ⅱ). 
Patients reporting some satisfaction in training in the use of the ventilator or BIPAP 
equipment had the highest improvement in the SRI ‘psychological well-being’ score 
from 61.0 (16.0) at baseline to 74.4 (11.8) in 2014 (p for change=0.01) and from 58.5 
(21.1) to 72.4 (16.2) (p for change<0.001). Those reporting very high satisfaction with 
training in 2008 also reported very high ‘psychological well-being’ both in 2008 and 
in 2014 (p for interaction=0.01)(Table 4, Paper Ⅱ).  
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Patients reporting some satisfaction with follow-up by healthcare professionals at 
baseline in 2008 also reported the highest change in the SRI ‘anxiety’ subscale, from 
49.5 (37.1) in 2008 to 75.0 (23.3) in 2014 (p for change<0.001) indicating less anxiety 
after six years of receiving LTMV. Patients reporting very high satisfaction with 
follow-up at baseline also reported the least anxiety in 2008 and in 2014 (p for 
interaction=0.009) (Table 5, Paper Ⅱ). 
Age was associated with changes in HRQoL, as younger patients (≤60 years) 
increased their SRI score from 46.1 (19.6) in 2008 to 52.4 (22.1) in 2014, while those 
older than 60 years had decreased their SRI ‘physical functioning’ score from 45.8 
(25.7) in 2008 to 41.6 (23.6) in 2014 (p for interaction=0.04) (Table S1, Paper Ⅱ).  
The respiratory variable, FVC, appeared to be a significant risk factor for changes in 
the SRI ‘social function’ score, which increased by 7.87 per one unit in FVC (Table 
S2, Paper Ⅱ).  
 
4.3 Study Ⅲ 
HRQoL as a predictor of mortality in patients treated with LTMV  
During the 80 months of follow-up from 1 January 2008 to 31 August 2014 as the final 
follow-up date, 52 (46%) patients died. One of the inclusion criteria for the study was 
that the treatment should have been established for at least three months; therefore, we 
counted 80 months of follow-up from 1 January 2008, and not from 1 March 2008. 
Baseline sum score of the SRI questionnaire by background characteristics of the 
LTMV patients are shown in Table 1, Paper Ⅲ. Patients with COPD had the highest 
overall mortality rate (75%), followed by patients with NMD (46%), OHS (31%) and 
CWD (25%) (Table 2, Paper Ⅲ). The mortality rates differed between age groups, 
education levels, LTMV hours per day, years on LTMV, disease categories, and the 
burden of comorbidity (Table 2, Paper Ⅲ). The mean SRI sum at baseline was 
substantially higher in survivors than in those who died during the 80-month follow-up 
(Table 3, Paper Ⅲ). The score in six of the SRI subscales was also significant higher in 
the survivors compared with the deceased (Table 3, Paper Ⅲ).  
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We repeated the analyses of SRI and mortality using Cox regression analyses to 
appropriately take into account the fact that people died at different time points and 
also to account for potential confounding factors regarding the associations. 
Unadjusted Cox regression analysis showed a significant association between the SRI 
sum score and mortality (Table 4, Paper Ⅲ). The association also remained significant 
after adjusting for age, education level, time since initiation of LTMV, hours per day 
on LTMV, comorbidity and disease category (HR 0.98; 95% CI: 0.96-0.99) (Table 4, 
Paper Ⅲ). When analysing SRI subscales, adjusted associations with mortality were 
apparent in the case of the SRI ‘psychological well-being’ (HR 0.98; 95% CI: 0.97-
0.99), ‘physical functioning’ (HR 0.98; 95% CI: 0.97-0.99) and ‘social functioning’ 
(HR 0.98; 95% CI: 0.96-0.99) subscales (Table 4, Paper Ⅲ).  
Among NMD patients, the SRI scores for ‘psychological well-being’ (HR 0.97; 95% 
CI: 0.95-0.99), ‘physical functioning’ (HR 0.97; 95% CI: 0.94-1.00) and ‘social 
functioning’ (HR 0.97; 95% CI: 0.94-0.99) remained significantly associated with 
mortality after adjustment for age, comorbidity and hours per day on LTMV (Table 5, 






The overall aim of this thesis was to provide new knowledge about quality of life in 
patients receiving LTMV. Patients treated with LTMV have been involved in this 
project in the translation and cultural adaptation of the SRI questionnaire from German 
into Norwegian, by providing advice concerning aspects important in their daily lives 
and by filling out questionnaires. 
To the best of our knowledge, Paper Ⅱ is first worldwide study to examine the long-
term effect of LTMV using a specific and validated SRI questionnaire. Paper Ⅲ is the 
first study to examine the ability of a specific SRI questionnaire to predict mortality in 
people receiving LTMV in a follow-up period of more than three years.  
In the first part of this discussion, the main results will be discussed, while, in the 
second part, we will consider the strengths and limitations of the methodologies used 
in the studies.  
 
5.1 Discussion of the results 
Change in specific HRQoL  
We translated and validated the SRI questionnaire in order to examine HRQoL in 
patients receiving LTMV. The improvements in the SRI sum score and four of the 
seven SRI subscales after six years of patients receiving LTMV (Paper ⅠⅠ) represent 
important new knowledge in the discipline of LTMV. Previous research has shown 
consistent trends in the improvement of HRQoL as measured by SRI in patients with 
CHRF from before initiating LTMV to up to one year of receiving LTMV (10, 18, 19); 
however, no knowledge has been presented concerning how patients experienced 
HRQoL after one year. New knowledge is especially important because LTMV most 




Anxiety related to severe respiratory insufficiency 
A highly meaningful result for the patients receiving LTMV was that the SRI 
“anxiety” subscale improved after six years in all the four main disease groups. The 
findings imply that the patients after six years had fewer experiences of feeling 
anxious about suffering attacks of dyspnoea as well as breathlessness at night. The 
improvement in this subscale also reflects a lesser tendency among LTMV patients to 
avoid situations that are stressful due to breathing problems. Further, it indicates that 
patients receiving LTMV for a longer time period are less worried that their disease 
will get worse in the future. Another follow-up study found improvements in the SRI 
“anxiety” subscale in the same disease groups as our study, which covered the period 
from before initiating LTMV to one month and 12 months after starting LTMV (10).  
 
Psychological well-being related to severe respiratory insufficiency 
The improvement in the SRI “psychological well-being” subscale including nine items 
covering different aspects of life satisfaction and enjoyment of life is important for 
patients receiving LTMV. This indicates fewer feelings of sadness, nervousness and 
irritability because of reduced capacity and patients’ better ability to cope with 
respiratory insufficiency and LTMV treatment. Psychological well-being also 
improved from before to one year after starting LTMV in the German study (10).  
 
Social functioning related to severe respiratory insufficiency 
The improvement in the SRI “social functioning” subscale implies that the majority of 
the patients receiving LTMV most probably experienced an improvement in how their 
disease impacts on their marriage or partnerships. The improvement indicates better 
contact with people and ability to attend social events. The study by Windisch (2008) 





Social relationship related to severe respiratory insufficiency 
The highest improvement in this study was seen in the SRI “social relationship” 
subscale which was present in all the four patient groups. The results indicate that the 
LTMV patients have an improved experience of feeling comfortable in the company of 
other people as well as feeling less lonely and isolated. The results also indicate that 
the LTMV patients experienced less disease burden on family life. These results are 
different to the findings reported by Windisch (2008) who found no significant change 
in this subscale one month or one year after starting LTMV. The time perspective 
might be one reason for this difference. It might take some time to establish social 
relationships after the LTMV treatment has started.  
The lack of improvement in the SRI subscales, respiratory complaints, physical 
functioning, and attendant symptoms and sleep during six years of ongoing LTMV can 
be explained by the fact that HRQoL at baseline was measured during ongoing LTMV 
and therefore the physiological efficacy of LTMV was already, at least largely, 
achieved at the baseline in 2008.  
 
Factors predicting improvement in HRQoL 
Although several studies have described patient-reported side effects of LTMV (3, 4, 
9, 10, 17, 22), the association with HRQoL has, to the best of our knowledge, not been 
sufficiently studied. About half of the LTMV patients reported side effects at baseline 
in 2008. In addition, side effects were given as one of the reasons to terminate LTMV 
treatment. 
A significant improvement in the SRI sum score among LTMV patients reporting side 
effects was seen during the six-year follow-up. One possible explanation is due to the 
reduction in patient-reported side effects from 51% in 2008 to 44% in 2014. Air leaks 
between the mask and the face were reduced from 36% in 2008 to 23% in 2014. 
Further, facial soreness and skin lesions were reduced from 18% to 15% and 
condensation inside the mask was reduced from 9% to 5%.  
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Our findings highlight the importance of addressing relevant interventions to prevent 
side effects. Importantly, some side effects such as air leaks, the most commonly 
reported side effect in this study, are unavoidable. However, significant air leaks 
should be addressed immediately to prevent patient-ventilator asynchrony and 
worsened gas exchange, which would reduce the effectiveness of treatment (27). Very 
high leakage might lead to less ventilator treatment pressure, lowered tidal volumes 
and a less effective reduction of CO2. In addition, side effects might lead to less use of 
the ventilator and reduce the physiological effect of the treatment, in turn negatively 
influencing the prognosis. LTMV users from 11 European countries (Norway not 
included) reported that mask comfort was very important for 69% of the ventilator 
users (29). Interventions such as the choice of an appropriately sized mask, adjusting 
the straps, daily cleaning of the mask, and replacement masks every three to six 
months or sooner, if leakage or discomfort occurs, could help to prevent the major side 
effects.  
In general, the gains of all treatments have to be weighed against possible negative 
side effects on quality of life, especially when patients are seriously ill with incurable 
disease (13). On the other hand, studies have shown that patients accept severe side 
effects if there is the prospect of some benefit in terms of improved survival (13). 
Further, if patients perceive their conditions as chronic or terminal (170), this might 
also influence their perception of the side effects.  
 
The association between HRQoL and mortality 
Poor HRQoL measured by SRI was associated with higher mortality in LTMV patients 
before and after adjustment for covariates. These results are in accordance with 
findings from the two previous studies measuring the relationship between SRI score 
and mortality (121, 148).  
However, this study has a longer follow-up period and consequently a better 
foundation to examine the association between mortality and HRQoL as measured by 
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SRI. In addition, the analyses in the studies of Budweiser and colleagues (2007) and 
Oga and colleagues (2017) did not adjust for education level, LTMV hours per day, 
years on LTMV, main disease category, and comorbidity as in our study. However, 
Budweiser et al. (2007) included comorbidity in their univariate analyses; but, as they 
found no association with survival, they did not include comorbidity in their 
multivariate analyses. Meanwhile, two other studies (121, 148) adjusted for BMI, 
leukocytes, base excess, FEV1 and inspiratory vital capacity (121), and BMI, PaCO2 
and FVC (148). We also added baseline FEV1 and FVC to the multiple Cox regression 
analyses, but this did not alter the results by much. In Paper III, we have elaborated on 
the reasons for choosing the adjustment variables and consider them as important 
contributors to the validity of the results in this study. 
In the cumulative process of research, our study with longer follow-up time and other 
adjustment variables strengthened the main results from previous studies on the 
association between HRQoL as measured by SRI and mortality.  
We found a highly significant numeric difference in SRI subscales and the sum score 
between survivors and deceased. The differences in SRI scores – 17 on the “social 
functioning” subscale, 19 on the “physical functioning” subscale, 10 on the 
“respiratory complaints” subscale, and 12 on the “anxiety” subscale – between 
survivors and those who died need to be addressed in clinical practice.  
The SRI questionnaire is based on self-reported information on quality of life. 
Previous studies have examined how self-related measures were connected to 
mortality: in a review of 27 community studies, Idler (1997) found that self-rated 
health was an independent predictor of mortality. The same measure for self-rated 
health was applied in one previous study (171) and significant associations between 
this measure and risk factors for coronary diseases (such as smoking, serum 
cholesterol and blood pressure) were not found, indicating that low HRQoL relates 
directly to mortality, as opposed to through other known pathophysiological 
mechanisms of coronary diseases. Patients’ self-report on quality of life could differ 
from physician-rated data, as seen in one recent study, where a measure of HRQoL 
was better than physician-rated clinical data (such as the Karnofsky Performance Scale 
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and absence of bone metastases) in predicting survival in patients with lung cancer 
(172). The authors suggest that a self-reported measure could contain important 
information which is not detected by traditional clinical data. Data from the Health 
Survey in Northern Trøndelag (HUNT 1) also showed that mortality increased 
significantly with decreasing self-perceived health (173). According to Jylha (2009), it 
is not quite clear which self-rated health measures are most closely related to death and 
why these data have such a strong association with mortality. She states that this 
difficulty may not stem from a lack of empirical information, but rather from the poor 
integration of knowledge. She presents this integration in a model with information 
from different disciplines, both social and biological (174). This process of self-
reported health assessment contains contextual aspects based on cultural differences, 
in addition to the comparisons made of own health with reference groups such as age 
or gender (174). The individual aspects of this model contain a review of information 
such as medical diagnoses or symptoms, and an evaluation based on a comparison 
with different reference groups. This kind of information gathered on self-reported 
health may be transferred to self-reported data on quality of life.  
Some of the risk factors for death cannot be influenced directly by healthcare 
professionals, such as age, education level, ventilator dependency, and main disease 
category. Other factors might be difficult to influence such as lung function and 
comorbidity. Importantly, it is always necessary to individualize care for LTMV 
patients in relation to these factors.  
However, our findings showed that there is a significant potential for healthcare 
professionals to improve HRQoL by preventing the side effects of LTMV, and by 
effective training in the use of the ventilator and in the follow-up of patients receiving 
LTMV.  
Whether or not the relationship between mortality and HRQoL is causal cannot be 
concluded from this study, based on the study design (Paper Ⅲ). Improved survival 
without also maintaining or improving quality of life is not in accordance with ethics 
and the LTMV guidelines (4).  
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Importantly, improved HRQoL was found in the majority of patients receiving LTMV 
who were still alive after six years of treatment (Paper Ⅱ).  
 
5.2 Methodological considerations 
Study design 
In Paper I, we used a cross-sectional study design where data were collected at a fixed 
point in time (102). The cross-sectional design is appropriate for describing HRQoL 
and the relationship to other variables, such as socio-demographic and clinical 
measurements. However, the design cannot, in principle, demonstrate the direction or 
causation of associations. The lack of time perspective in this design can be reduced 
by obtaining information by asking questions about the past. However, recalling 
exposure data from the past may differ between comparison groups, a situation that 
could lead to a systematic error in estimates (175). On the other hand, data collection 
in cross-sectional design is simple, practical and cost-effective (102). This design is 
commonly used to test psychometric properties of HRQoL questionnaires, which was 
also the main purpose of Paper I. 
In Paper Ⅱ, we used a longitudinal design, in which data on HRQoL were measured 
twice, at baseline in 2008 and at follow-up in 2014. Longitudinal designs are 
appropriate for studying the dynamics of phenomena over time. A major advantage of 
longitudinal designs is that exposure is collected before the outcome under study. This 
might suggest both direction and causation of observed associations. One challenge 
with such designs is the loss of participants over time (102). In Paper II, 15 people still 
alive did not participate in the follow-up study. Of these, eight people had stopped 
LTMV treatment, three were unable to answer, three rejected participation, and one 
person did not respond. The loss of follow-up might have resulted in some bias 
because those who dropped out might differ systematically from those who continued 
to participate (102), a situation often referred to as selection bias (discussed below).  
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In Paper Ⅲ, we used a prospective cohort study design based on data from the SRI 
questionnaire, the Norwegian LTMV Register, the NPR and the Norwegian Cause of 
Death Register. In a prospective cohort study, subjects are classified according to their 
exposure status and then followed over time to ascertain incidence of a disease (175). 
The exposure in Paper III was HRQoL as measured by SRI in 2008, while the outcome 
under study was mortality status assessed in 2014. Similar to the longitudinal designs 
where the exposure is collected before the outcome under study, prospective cohort 
studies can suggest both direction and causation of associations.  
 
Psychometric properties of the SRI questionnaire 
Testing the psychometric properties of a questionnaire includes testing for sufficient 
reliability, validity and responsiveness (101).  
Reliability: The reliability examined by using Cronbach’s alpha considers a value 
above 0.70 to be sufficient (176). Internal consistency of the Norwegian version of the 
SRI questionnaire, measured by Cronbach’s alpha, was 0.94 for the SRI sum score and 
varied from 0.68 to 0.88 for the SRI subscales. This indicates an acceptable 
homogeneity for the Norwegian version of the SRI questionnaire, which is in line with 
other studies which tested the psychometric properties of the SRI questionnaire in 
different languages (14, 103-107). 
Validity: In general, there are three main aspects of validity related to the 
psychometric properties of an instrument measuring HRQoL. First, content validity 
concerns whether the items are sensitive and reflects the intended construct of interest. 
Face validity, which refers to an inspection of the questions without any formal 
statistical analyses of the validity of the questionnaire, is often seen as a part of content 
validity (13). Members of Respira and healthcare professionals with experience in and 
knowledge of the LTMV field contributed to the face validity for the Norwegian 
version of the SRI questionnaire.  
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Secondly, criterion validity refers to whether the instrument has empirical associations 
with external criteria, for example, with other instruments measuring HRQoL (13). 
The SF-36 was used as a validation tool for the Norwegian version of the SRI 
questionnaire. The correlation between subscales measuring similar aspects was 
sufficiently high, similar to other validation studies of the SRI questionnaire (14, 104-
107). The highest correlations were found between similar subscales such as SF-36 
‘physical function’ and “SRI ‘physical functioning’ (r=0.73), and between SF-36 
‘vitality’ and SRI ‘psychological well-being’ (r=0.72). 
Thirdly, construct validity is the most important aspect of the validity of an instrument. 
It refers to what extent the instrument measures the construct it was developed to 
measure (13). Construct validity of the Norwegian version of the SRI questionnaire 
was examined by mostly the same criteria as used in the validation study by Windisch 
and colleagues (14), including its ability to differentiate between a priori known 
aspects in patients receiving LTMV. Construct validity was confirmed by identifying 
that COPD patients had the poorest score on the SRI ’respiratory complaint’ subscale 
at 40.3 (18.7), compared with CWD patients who had the highest score at 65.0 (22.1).  
Furthermore, patients with COPD had the lowest HRQoL indicator related to ‘anxiety’ 
at 41.2 (26.3), compared to patients with NMD who had the highest score at 67.4 
(24.6). We also confirmed a trend that hours per day on a ventilator were associated 
with lower HRQoL by the negative correlation between the SRI sum score and hours 
per day receiving LTMV (r=-0.20) and in SRI ‘physical’ and ‘social function’ 
subscales.  
Responsiveness: The responsiveness of a questionnaire is of importance in 
longitudinal studies because it refers to the ability to detect improvement in or 
deterioration of HRQoL (13). In Paper Ⅱ, we examined whether HRQoL changed from 
baseline in 2008 to follow-up in 2014, and found that HRQoL did change in four of 
the SRI subscales related to ‘anxiety’, ‘social relations’, ‘social function’ and 
‘psychological well-being’. Changes in HRQoL measured by SRI have previously 
been examined in a one-year longitudinal study among a mixed LTMV population. 
The SRI questionnaire was better than the generic questionnaire SF-36 in terms of 
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detecting changes in HRQoL after commencement of non-invasive LTMV (10). In 
addition, changes in HRQoL were detected in patients with COPD who were receiving 
non-invasive LTMV (18, 20). 
 
Internal validity 
Internal validity refers to the degree to which extent scientific inference can be drawn 
for the population under study (175). In order to obtain high internal validity in 
observational research, case and comparison groups should be selected and compared 
in a manner that reduces both systematic and random errors (175). Below, we discuss 
the challenges of random error and three main sources of systematic errors: selection 
bias, information bias and confounding. 
Random error 
Random error has been explained as variability which is reduced to 0 if the numbers of 
measurements become endlessly large (175). A small sample size also increases the 
risk of a type Ⅱ error, which can cause the failure to detect statistically significant 
associations, even though there is an association between the variables from which the 
samples were drawn (102). Our study samples varied between 60 and 127 patients, 
numbers that might be considered as small, especially when performing subgroup 
analyses among disease groups.  However, our limited sample sizes in part reflect the 
fact that LTMV patients are not in large in numbers in the population.  
Systematic errors 
Selection bias 
Selection bias refers to the situation when the association between exposure and 
outcome among those included for analysis differs from the association among those 
who are eligible (177). Selection bias may occur due to the inappropriate selection of 
cases and controls in case-control studies, due to differential “loss to follow-up” of 
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comparison groups, or due to non-response to studies. Selection bias represents a 
major threat to internal validity in observational research.  
All subjects in our study were recruited from the Norwegian LTMV Register. In order 
to achieve a high response rate, we used pre-stamped and pre-addressed return 
envelopes. We also mailed out one reminder letter where we had not received any 
return envelopes from patients. Of the 193 invited patients, 66% responded, a response 
rate that we considered acceptable given the grave conditions of many LTMV users.  
In order to examine potential selection bias in our study, we compared the background 
characteristics of those who responded with those who did not respond. We found no 
significant differences in age, gender, diseases and treatment variables between 
responders and non-responders. However, LTMV patients who did not respond to the 
questionnaire had slightly lower FVC and FEV1, compared with the LTMV patients 
who responded (Paper Ⅰ). Given these small differences, we did not suspect that our 
three studies were subject to important selection bias. 
In Paper Ⅱ, 15 patients did not respond to the SRI questionnaire at follow-up in 2014. 
Consequently, there could be concern over selection bias because those who did not 
participate in the follow-up study could have had different associations with SRI than 
those participating.  However, out of these 15 people, as many as eight had stopped 
LTMV treatment and therefore did not meet the inclusion criteria for the follow-up 
study. After excluding these, we do not believe that the loss to follow-up of the 
remaining seven patients represents a major threat to the estimates in Paper Ⅱ.    
In Paper Ⅲ, data on SRI at baseline for all patients were linked to information on 
comorbidity from the NPR and to mortality from the Cause of Death Register for the 
period 2008-2014. Consequently, we had no loss to follow-up of patients. However, 
there could still be concern over selection bias because those who did not give consent 
to connect data to the NPR could have had different associations with SRI than those 




Information bias refers to a systematic error which results from incorrect measurement 
or classification of the exposure or outcome variable under study (175). Information 
bias is commonly grouped by differential and non-differential misclassification. 
Misclassification of exposure or outcome variables, which are not dependent on the 
value of the other, is called non-differential misclassification (175). If the exposure 
and outcome variables are dichotomous, non-differential misclassification often leads 
to attenuated association estimates (175). 
Misclassification of exposure or outcome variables, which depend on the value of the 
other, is referred to as differential misclassification and can either overestimate or 
underestimate association measures. Recall bias is a specific case of differential 
misclassification and refers to the situation where patients with a condition better 
recall risk factors preceding the condition than those who do not have a condition. 
Compared to prospective studies, differential misclassification is more common in 
case-control studies and cross-sectional studies in which risk factors are collected after 
patients have become ill.  
In Paper Ⅰ, 27% of the LTMV patients reported that they had received assistance to 
complete the questionnaires. In Paper Ⅱ, 22% of the patients reported that they had 
received this assistance at baseline, compared to 38% at the follow-up time in 2014. In 
Paper Ⅲ, 26% of the patients reported that they had received assistance to complete 
the questionnaire. Patients needing assistance could represent individuals with 
advanced disease and severe respiratory failure. Requiring assistance to complete 
questionnaires may have affected responses to the SRI questionnaire, e.g., patients 
wanting to appear more positive in front of others than they really were. However, we 
considered such information bias as less problematic. The alternative, not including 
people needing assistance to fill out the questionnaire, could lead to a lower response 
rate and thus to a more serious selection bias. 
We collected data at two time points. At follow-up in 2014, the patients completed the 
questionnaires when they had their regular outpatient contact in the hospital, while, at 
baseline in 2008, the questionnaires were filled in by the patients in their home and 
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returned by post. However, according to Lopez-Campos and colleagues (2007), the 
mode of administration does not influence the measures of the HRQoL level obtained 
from the SRI questionnaires (114).   
Confounding 
Confounding refers to the situation where a third variable (the confounding factor) 
explains all or part of the observed association between the exposure and the outcome 
under study (178). The confounding factors need to be controlled in case they are 
related to both the exposure and the outcome variables (102).   
In Papers Ⅱ and Ⅲ, we accounted for confounding factors using multiple regression 
analyses. The potential confounding factors were identified from the previous 
literature, i.e., we selected those studies that were either associated with the exposure 
or outcome of interest, or with both. Variables considered as confounding factors in 
Paper II were; age, sex, educational level and marital status, with main disease 
category and length of LTMV treatment time as background variables. In Paper III, we 
adjusted for age, educational level, main disease category, length of LTMV treatment 
time since initiation of LTMV, hours per day on LTMV, and comorbidity. We also 
evaluated FVC and FEV1 as confounding factors in the overall analyses. 
We reported unadjusted estimates and confounder-adjusted estimates, together with a 
description of the confounding factors and why they were adjusted for. Despite 
adjusting for educational levels, other social inequalities might influence mortality in 
the LTMV population, such as household income. Norwegian society is among the 
most equal worldwide. Nevertheless, it has been highlighted as a paradox that social 
differences in mortality are just as high in the Nordic countries as elsewhere in Europe 
(179).   
Importantly, the number of participants in this study limits the number of adjustment 
variables that can be adjusted for in regression analyses (rule of thumb: one variable 
per 10 events). To avoid potential overfitting, we therefore included only the most 
important adjustment variables in Papers II and III. Thus, our association measures 
might be subject to some unmeasured or residual confounding in these papers.  
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In Paper I, in which we did not adjust for variables, we performed psychometric 




External validity is the degree to which study results can be generalized to settings or 
samples other than the one studied (102). To achieve high external validity, our study 
needs to have high internal validity as well as to be representative of the larger 
population.  
We recruited patients from the Norwegian LTMV Register. At the time of requirement 
in 2008, we did not have exact information on the cover rate of the LTMV Register on 
a county basis. However, despite large regional variations in LTMV treatment in 
Norway, the estimated cover ratio was as follows: that 90% of patients treated with 
LTMV from 2002 to 31 December 2007 were registered on the Norwegian LTMV 
Register (36). This indicates a similar cover ratio to that in 2018, where 91% measured 
from hospitals could provide the basis for calculation (four out of 29 hospitals could 
not provide the basis for calculating the cover ratio) (39). We concider this cover ratio 
to be very high, as a cover ratio above 80% is at the highest requirement for the 
Norwegian medical quality registers (180). Our study included patients from 
Rogaland, Hordaland and Sogn og Fjordane, representing approximately 21% of the 
Norwegian population. As we believe that LTMV patients’ environment does not 
differ much between the Norwegian counties, we consider the three counties to be 
representative of Norwegian patients receiving LTMV. Given this, we propose that our 
results can be generalized to all patients receiving LTMV. 
A representative sample is essential when the research goal is to provide a description 
of the total population (175). However, it may not be that important when the goal is to 
report associations and risk estimates rather than prevalence estimates (175), such as 
the association between HRQoL measured by SRI and mortality (Paper Ⅲ). It has 
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been noted by several authors that a completely representative sample could even be 
more heterogeneous with respect to important confounders, in turn making it more 
difficult to control for confounding factors (175). One example is the cohort of 
associations between smoking habits and mortality among male British doctors. The 
study subjects were not representative of the general population; nevertheless, the 
results added important knowledge about the adverse effect of smoking habits on the 
general population (181).  
 
5.3 Ethical considerations 
The severity of patients’ condition and ventilator dependency might lead to vulnerable 
situations; thus, special awareness of their integrity is required. The need for assistance 
and follow-up from healthcare professionals might put people treated with LTMV in a 
situation where they feel an obligation to participate in studies. On the other hand, the 
LTMV user organization, Respira, has encouraged research on LTMV (51). In 
addition, the follow-up and close contact over several years between each LTMV 
individual and healthcare professionals might lead to a common responsibility towards 
solving the problems and challenges related to LTMV, and such relationships might 
influence treatment-related patient reported outcomes. However, this patient-carer 
relationship includes the patient as an equal partner in decisions concerning her/his 
treatment and follow-up and has the potential to empower those receiving LTMV.  
 
5.4 Implications and future research 
For the first time, we have a specific, validated HRQoL questionnaire for Norwegian 
LTMV users. The Norwegian version of the SRI questionnaire opens up avenues for 
research collaboration within this patient group. For that purpose, this Norwegian 
version and other versions of the questionnaire in the most spoken languages 
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worldwide (14, 103-107) are available on the website of the German Respiratory 
Society free of charge for non-profit research (159).  
We have shown that HRQoL has improved in the majority of patients receiving 
LTMV over a long period. Over time, patients receiving LTMV achieve enhanced 
overall satisfaction with life, reduced anxiety related to breathing and a better ability to 
cope with their condition. Their contact and relationship with other people also seem 
to be improved. The absence of deterioration in respiratory complaints, physical 
functioning, and attendant symptoms and sleep subscales during six years of ongoing 
LTMV also adds important knowledge both for healthcare professionals and for 
patients with CHRF concerning the preconditions for starting LTMV. Patient 
autonomy is fundamental in healthcare, and Norwegian health law emphasizes that 
patients have the right to receive information from competent healthcare personnel 
(182). However, there might be a risk that healthcare professionals and relatives judge 
patients’ health to be worse than patient’s own judgements (13). It has also been 
reported that healthcare professionals avoid informing patients about LTMV as a 
treatment option because they believe that the adverse effects of the treatment could 
outweigh the benefits (183). These concerns were related to invasive LTMV for 
diseases such as ALS. Importantly, none of the surviving patients in the six-year 
follow-up study had ALS. Nevertheless, our findings might add knowledge concerning 
long-term outcomes of HRQoL in patients receiving LTMV. This aspect is especially 
critical because LTMV is a life-supporting or a life-sustaining treatment (3, 4), with 
patients treated with LTMV having been described to be among the most vulnerable 
groups of patients (184).  
There are many factors influencing HRQoL in patients receiving LTMV which are 
difficult for healthcare professionals to change, such as the main disease, lung function 
and comorbidities. Nevertheless, this study suggests that interventions by healthcare 
professionals might improve HRQoL in LTMV patients by reducing side effects and 
improving training and follow-up. However, further intervention studies are needed to 
confirm this hypothesis. 
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Recently, the minimal clinically important difference (MCID) of the SRI questionnaire 
was identified in patients with COPD who were treated with non-invasive LTMV (94), 
which supports the clinical implications of our finding. However, research is needed to 
identify the MCID value for other groups of LTMV patients.  
We have shown that HRQoL measured by the SRI questionnaire is an independent 
predictor of survival and could therefore be used as an explanatory or outcome 
variable in further scientific studies, as well as a clinical follow-up instrument for this 
patient group. We cannot conclude with any causal relationship between improved 
HRQoL and survival in this study. However, the large differences in SRI subscales at 
the study baseline between LTMV patients surviving and dying during follow-up 
suggest that the early identification of subjects with a low SRI score and prompt 







With quality of life as a framework, this thesis has provided new knowledge about 
HRQoL in patients receiving LTMV.  
The Norwegian version of the SRI is a specific, valid and reliable questionnaire to 
measure HRQoL in people receiving LTMV both in research and in clinical practice. 
A six-year longitudinal study of patients treated with LTMV found improved HRQoL 
when measured by the SRI questionnaire. Patients reported satisfaction with training 
and follow-up from healthcare professionals and side effects were associated with 
changes in HRQoL.  
Finally, we found a strong independent association between HRQoL as measured by 
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INTRODUCTION
Long-term mechanical ventilation (LTMV) is a well-
established treatment for patients with hypercapnic
chronic respiratory failure (HCRF) caused by various
underlying disorders, such as chest wall deformities,
neuromuscular disorders and obesity hypoventilation syn-
drome (OHS).1–4 The total number of patients treated
with LTMV in Europe has increased and will rise further
with medical advances and the ageing of the population.5
The treatment prevalence in Norway at the end of 2010
was 26.5/100 000.6
Patient-reported health-related quality of life
(HRQOL) is an important instrument to understand and
improve overall quality of life in patients with chronic
diseases such as HCRF. During the last two decades,
several generic and disease-specific questionnaires have
been developed to assess HRQOL.7 Most generic ques-
tionnaires are not specific to any particular disease and
allow comparisons of HRQOL to be made between
patients with different diseases. One of the most com-
monly used and well validated is the 36-item Short Form
Health Survey (SF-36).8 Condition- or disease-specific
questionnaires measure how a specific disease affects
HRQOL. In the fields of respiratory care, the disease-
specific questionnaires ‘The Chronic Respiratory Ques-
tionnaire’ (CRQ) and ‘The St George’s Respiratory
Questionnaire’ (SGRQ) are both well validated for use in
patients with chronic obstructive pulmonary disease
(COPD).9,10 Patients with CRF caused by other diseases
might report some of the same respiratory complaints as
COPD patients. However, they might suffer from a
heavier burden of symptoms and other kinds of disease-
related problems, especially in the advanced stages of
disease. About one in five LTMV users in the Norwegian
population has a neuromuscular condition,6 and their spe-
cific problems and symptoms are poorly covered in ques-
tionnaires such as the SGRQ and CRQ. As a consequence,
two questionnaires were especially developed to measure
HRQOL in patients with CRF on LTMV treatment: the
Severe Respiratory Insufficiency (SRI) Questionnaire11 and
the Maugeri Foundation Respiratory Failure (MFR-28)
Questionnaire.12 The SRI, originally developed in Ger-
man, has proven more reliable and valid than the MFR-28
in this specific patient population,13 and the translation
processes, validations and clinical applications have been
published for the Dutch, English and Spanish versions.14,15
The SRI measures HRQOL in patients receiving
LTMV. A questionnaire developed and tested in one
country cannot merely be translated and used as a new
version in another country. QOL questionnaires measure
subjective and cultural relations, so it is necessary to test
a new version of the questionnaire psychometrically to the
specific country. The validation process consists of a
number of stages, in which the researcher looks for evi-
dence that the instrument produces useful measurements
that reflect the respondents’ QOL.7 Particularly, ‘con-
struct validity’ is the degree to which an instrument meas-
ures the construct it is supposed to measure. One of the
most common approaches is to relate a construct to prac-
tical criteria, to examine the scores on the instrument of
interest and then compare them with scores on a similar/
comparable instrument.16 In clinical research, the sensi-
tivity of a scale and its ability to detect individual
differences in clinical variables are also important.17
The aims of this study were to translate and
transculturally adapt the SRI Questionnaire into Norwe-
gian, and to test its reliability, internal consistency and
construct validity. The specific research questions were
threefold: (i) Is the SRI Questionnaire positively corre-
lated with the SF-36?; (ii) Does the SRI Questionnaire
discriminate between universally accepted clinical differ-
ences among categories of patients receiving LTMV?; (iii)
Do the most ventilator-dependent patients have a lower
HRQOL than patients requiring fewer hours on a venti-
lator? SRI data were collected from a cross-sectional




This cross-sectional study was performed in 2008 in the
western region of Norway. Informed consent was
obtained from each participant prior to the study, and the
study has been approved by the Regional Committee for
Medical Research Ethics and by the Norwegian Data
Inspectorate.
All patients older than 18 years in the Norwegian
National Registry of LTMV who were resident in three
counties were invited to participate in the study. Patients
treated with non-invasive and invasive LTMV who
showed mental clarity and were well oriented were
included. The LTMV had to be established for at least 3
months. The SRI and SF-36 Questionnaires, an informa-
tion letter, and a stamped return envelope were sent
by mail to the 211 LTMV users in the registry who met
the eligibility criteria. Returning the questionnaire was
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considered to constitute the patient’s consent to partici-
pate in the study. After 1 month, a reminder letter and
copies of the questionnaires were sent to the non-
responders. The register was cross-checked with the
National Inhabitant Registry before the questionnaires
were mailed to avoid sending them to individuals who had
recently passed away.
The SRI Questionnaire
The SRI Questionnaire was developed following an open
interview in which patients receiving LTMV had given
their important subjective impressions of their actual
quality of life. It contains 49 items based on social,
psychological and physical health domains, and is divided
into seven subscales. The SRI was validated in a
multicentre study that included 226 patients. All items are
rated on a five-point scale, from ‘strongly agree’ to
‘strongly disagree’. The summary scale (SS) is obtained as
summary of the seven subscales. High SS values (range
0–100) indicate a better HRQOL.11
Validation instrument
For validation purposes, the SF-36 was used as the objec-
tive gold standard for criterion validity, as in the original
validation study of the SRI.11 The SF-36 was originally
developed based on the Medical Outcome Study8 and has
been translated into and validated in several languages,
including Norwegian.18
Procedures for the translation and cultural adaptation
of the SRI into Norwegian were as follows. The author of
the SRI consented to the Norwegian translation. The
accepted procedures for the translation and adaptation of
QOL instruments were followed.19,20 A professional
translator and a physician specialist in pulmonary medi-
cine, whose first language was German, translated the SRI
into Norwegian. The translators worked separately and
did not cooperate in this phase. Two professional transla-
tors performed the back-translation to German. The
translation process revealed discrepancies in the transla-
tion of some of the items, and modifications to the
wording were made. In particular, translation of the word
‘Luftnot’ (English, shortness of breath) produced differ-
ent Norwegian words. Finally, the translators agreed on a
Norwegian version, ready for pretesting.
Measuring feasibility and face validity
A pilot test was performed to measure the face validity
and feasibility of the translated instrument. Members of
the Norwegian special interest organization for LTMV
users, ‘Respira’, were invited to act as the pilot test
group. All of the six individuals in question had been
receiving LTMV for at least 3 months. They were
requested to complete the questionnaire and were then
asked if the questionnaire was clear, easy to understand
and covered topics of interest, and whether any items had
been difficult to answer. They were also asked whether
the questionnaire was relevant to their lives as LTMV
users.
A group of health-care workers, physicians and nurses
experienced in LTMV were asked whether the items were
relevant for use in the LTMV population. The back-
translated version of the questionnaire was also sent to the
author of the original SRI, who commented on it in terms
of the equivalence between the original and the back-
translated versions.
Finally, a consensus group compared the translated
version and the original for equivalence, face validity and
feasibility. After its translation and pretesting in both the
consensus and user groups, the Norwegian version of SRI
was ready for psychometric testing.
Statistical analyses
Statistical analyses were performed by SPSS for windows
version 18.0 (SPSS Inc., Chicago, IL, USA).21 All statisti-
cal tests were two sided, and P-values below 0.05 were
considered statistically significant. Data were described as
percentages or means ± standard deviation. The chi-
squared test was used to test for difference in percentages,
whereas the two-sample t-test was used to test for
difference in means.
The items in the SRI were recoded according to the
guidelines for the original SRI Questionnaire. The total SS
of the SRI is calculated by summing the subscale scores
(SRI-RC, SRI-PF, SRI-AS, SRI-SR, SRI-AX, SRI-WB and
SRI-SF). Missing items in the SRI and SF-36 were treated
according to the accepted guidelines for these question-
naires, that is, the calculations were not performed if
results were missing for one of the scales.11 Internal con-
sistency for each domain, subdomain and the SS for the
SRI questionnaire was calculated using Cronbach’s α.
Forced vital capacity (FVC) and forced expiratory
volume in one second (FEV1) in per cent of the predicted
value (FVC% pred and FEV1% pred) was calculated
according to Langhammer et al.22 Daytime arterial blood
gas was taken prior to the initiation of mechanical venti-
lation and during spontaneous breathing in indoor air.
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All scores in the SRI Questionnaire were correlated
with all scores on the SF-36 using Spearman correlation
coefficient. Analysis of variance (ANOVA) was further
used to explore the differences in SRI scores between the
four main diagnostic groups (i.e. neuromuscular disease
(NMD), COPD, OHS, chest wall disease).
RESULTS
Initially, 211 subjects from the National Registry of
LTMV patients met the inclusion criteria for the study.
Four of the patients were excluded because of a primary
diagnosis of obstructive sleep apnoea and therefore did
not fulfil the inclusion criteria for the registry. Nine
patients returned the questionnaire unanswered because
they had stopped using the ventilator. One patient had
died during the week that the questionnaire was sent.
Two patients were unable to answer the questionnaire, as
judged by their relatives, and two patients were impos-
sible to locate. This reduced the number of potential
responders to 193. After a reminder letter had been sent,
127 patients finally completed and returned the question-
naire, giving a response rate of 65.8%.
Clinical characteristics of the
LTMV patients
The clinical and demographic characteristics of the LTMV
patients are shown in Table 1. The group of patients with
NMD was heterogeneous in terms of their diagnoses. It
consisted of patients with acquired conditions (post-polio
syndrome, n = 16; amyotrophic lateral sclerosis, n = 5;
cervical spinal cord lesion, n = 1; multiple sclerosis,
n = 1; brain damage, n = 3; central hypoventilation syn-
drome, n = 2; Cheyne-Stokes respiration, n = 3) and
congenital conditions (spinal muscle atrophy, n = 4;
Table 1 Clinical and demographic characteristics of the LTMV patients
Variable NMD COPD† OHS Chest wall disease‡
Subjects (n, %) 54 (42.5) 26 (20.5) 37 (29.9) 9 (7.1)
Males (n, %) 23 (18.1) 16 (12.6) 23 (18.1) 6 (4.7)
Age, years 57.2 ± 17.8 67.7 ± 9.2 65.9 ± 12.2 51.6 ± 18.3
Years of LTMV 5.7 ± 4.5 2.6 ± 1.9 4.9 ± 3.0 7.1 ± 6.7
FVC % predicted 66.1 ± 29.3 58.3 ± 19.1 70.1 ± 17.3 42.2 ± 22.2
FVC, litre 2.3 ± 1.1 2.2 ± 0.9 2.8 ± 1.0 1.7 ± 1.3
FEV1, litre 1.6 ± 0.9 1.1 ± 0.6 2.1 ± 1 1.2 ± 1.1
FEV1 % predicted 58.9 ± 26.9 36.2 ± 18.9 63.0 ± 23.9 37.3 ± 18.5
FEV1/FVC % predicted 93.7 ± 23.3 60.9 ± 18.8 88.7 ± 18.3 89.5 ± 23.6
PO2, kPa daytime 9.8 ± 1.9 7.0 ± 2.1 8.0 ± 1.9 10.1 ± 2.9
PCO2, kPa daytime 6.26 ± 1.4 7.73 ± 1.6 7.75 ± 3.0 7.80 ± 2.7
BMI, kg/m2 27.9 ± 10.0 29.6 ± 8.9 40.5 ± 7.6 25 ± 7.0
Tracheotomy, n 10 0 0 0
LTMV h/day (n, %)
5–8 29 (23.6) 8 (6.5) 17 (13.8) 4 (3.3)
8–12 15 (12.2) 13 (10.6) 14 (11.4) 4 (3.3)
12–24 8 (6.5) 5 (4) 5 (4) 1 (0.8)
Marital status (n, %)
Married or cohabiting 27 (21.3) 18 (14.2) 20 (15.7) 5 (3.9)
Single 19 (15) 3 (2.4) 9 (7.1) 4 (3.1)
Divorced 3 (2.4) 2 (1.6) 4 (3.1)
Widowed 6 (4.7) 3 (2.4) 4 (3.1)
Data are presented as means ± SD, unless otherwise stated. † One of the patients in this group had severe bronchiectasis disease. ‡ Three
of the patients in this group had other diseases. BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in one second; FVC, forced vital capacity; LTMV, long-term mechanical ventilation; NMD, neuromuscular disease; OHS,
obesity hypoventilation syndrome; PCO2, partial pressure of carbon dioxide; PO2, partial pressure of oxygen.
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Duchenne muscular dystrophy, n = 2; myotonic dystro-
phy, n = 2; other muscle atrophies, n = 7; limb-girdle
dystrophy and neuropathies, n = 2; cerebral disease,
n = 2; mitochondrial disease n = 1). The group of
patients with COPD included one patient with severe
bronchiectasis disease. The group of patients with chest
wall diseases included three patients with miscellaneous
diseases. All patients had severe hypercapnic CRF with
PCO2 > 6 kPa before the commencement of LTMV. The
patients with chest wall diseases had spent the longest
periods on LTMV (Table 1).
The demographic and clinical characteristics of the
LTMV patients who answered the questionnaire are com-
pared with those of the patients who did not return the
questionnaire in Table 2. A statistically significant differ-
ence was only seen for FEV1 and FVC.
Reliability
Cronbach’s α for each domain of the SRI varied
from 0.76 to 0.88 (Table 3). Because of the possible
misinterpretation of item 15, Cronbach’s α was measured
also for the SRI-SF domain excluding item 15. This
misinterpretation might be explained by a perceived dif-
ference in ‘feeling bonded to’ and ‘feeling connected to’
the patient’s home. The Cronbach’s α before and after
exclusion of item 15 was 0.84 and 0.80, respectively.
Validity
The correlation matrix for SRI and SF-36 for our study
population is shown in Table 4. Generally, the correla-
tions were high when the subscales of the SRI and SF-36
referred to comparable aspects of HRQOL, and were
lower when different topics were correlated. The highest
correlations were found between SRI-PF and SF-36-PF
(r = 0.729; P < 0.001) and between SRI-WB and SF-36
VT (r = 0.72; P < 0.001), and between SRI-WB and
SF-36 MHC (r = 0.714; P < 0.001). The lowest correla-
tion was between SRI-AS and SF-36-PF.
To examine whether SRI Questionnaire might dis-
criminate between clinical differences among categories
of patients receiving LTMV, we examined difference in
SRI scores between NMD, COPD, OHS and chest wall
diseases using ANOVA. A statistically significant overall
difference was found for all SRI subscales, except for
the domain of SRI-AS (Table 5).
DISCUSSION
The aim of this study was to translate a condition-specific
questionnaire that measures HRQOL in patients receiving
LTMV. The SRI Questionnaire was translated into Nor-
wegian, and the scale was tested for its reliability and
validity in a Norwegian patient population. In the process
Table 2 Differences in the demographic and clinical characteris-
tics of the LTMV patients who answered the questionnaire and
those who did not return the questionnaire
Participant Non-participant P-value
Subjects (n, %) 127 (100) 66 (100)
Males (n, %) 68 (53.5) 37 (56) 0.763
NMD (n, %) 54 (42.5) 26 (39.4) 0.759
COPD (n, %) 26 (20.5) 10 (15.2) 0.439
OHS (n, %) 38 (29.9) 22 (33.3) 0.627
Chest wall (n, %) 9 (7.1) 8 (12.1) 0.287
Age, years 61.5 ± 15.6 58 ± 21.27 0.250
Years of LTMV 4.92 ± 4.05 4.67 ± 3.26 0.674
BMI kg/m2 32.8 ± 10.5 32.2 ± 12.7 0.798
PO2, kPa daytime 8.6 ± 2.24 8.3 ± 2.29 0.52
PCO2, kPa daytime 7.16 ± 2.4 7.16 ± 2.0 0.993
FVC % predicted 64.6 ± 23.6 53.8 ± 23.2 0.052
FEV1 % predicted 54.3 ± 25.9 47.8 ± 22.9 0.275
FVC, litre 2.4 ± 1.0 1.8 ± 0.9 0.005
FEV1, litre 1.62 ± 0.96 1.32 ± 0.7 0.043
Data are presented as means ± SD unless otherwise stated. BMI,
body mass index; COPD, chronic obstructive pulmonary disease;
FEV1, forced expiratory volume in one second; FVC, forced vital
capacity; LTMV, long-term mechanical ventilation; NMD,
neuromuscular disease; OHS, obesity hypoventilation syndrome;
PCO2, partial pressure of carbon dioxide; PO2, partial pressure of
oxygen.





Respiratory complaints (RC) 8 0.81
Physical functioning (PF) 6 0.76
Attendant symptoms and sleep (AS) 7 0.68
Social relationships (SR) 6 0.82
Anxiety (AX) 5 0.81
Psychosocial well-being (WB) 9 0.88
Social functioning (SF) 8 0.79
Summary scale (SS) 49 0.94
SRI, Severe Respiratory Insufficiency.
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of translating the SRI into Norwegian, general guidelines
were followed7,19 and no major problems were encoun-
tered. Consistent with previous studies, there were some
items missing,7 which might be explained by several
factors, including the use of numerous items, the content
of some items and the ambiguity in the answer alterna-
tives.23 For example, we found that some missing items
were linked to a question about the influence on the
patient’s marriage, which lacked an alternative option for
single patients.
Internal consistency measures the homogeneity of the
items in a questionnaire. A Cronbach’s α value above
0.70 is regarded as acceptable, a value above 0.80 as good
and a value above 0.90 as excellent.7 In the original
Table 4 Correlation matrix for the SRI and the SF-36
SRI SF-36
PF RP BP GH VT SF RE MH PHC MHC
RC 0.378 0.520 0.362 0.633 0.521 0.515 0.400 0.286 0.527 0.396
PF 0.729 0.661 0.246 0.524 0.345 0.398 0.430 0.270 0.608 0.290
AS 0.172 0.206 0.494 0.359 0.436 0.330 0.252 0.323 0.339 0.272
SR 0.272 0.430 0.481 0.475 0.579 0.664 0.418 0.523 0.465 0.582
AX 0.297 0.408 0.449 0.499 0.436 0.582 0.439 0.494 0.421 0.548
WB 0.281 0.480 0.543 0.629 0.720 0.695 0.580 0.637 0.430 0.714
SF 0.417 0.613 0.449 0.589 0.518 0.656 0.446 0.373 0.587 0.489
SS 0.452 0.617 0.578 0.702 0.645 0.736 0.560 0.537 0.622 0.614
Significant correlations are shown in bold type; and summary scales for each questionnaire in grey. Notes: The SRI domains were respiratory
complaints (RC), physical functioning (PF), attendant symptoms and sleep (AS), social relationships (SR), anxiety (AX), psychosocial
well-being (WB), social functioning (SF), and summary scale (SS). The SF-36 domains were physical functioning (PF), role-physical (RP),
body pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional (RE), mental health (MH), physical health
component (PHC), and mental health component (MHC). SF-36, 36-item Short Form Health Survey; SRI, Severe Respiratory Insufficiency.












Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
SRI
SS 55.8 ± 18.4 61.0 ± 14.7 43.2 ± 19.0 58.4 ± 18.3 55.8 ± 18.4 0.001
PF 38.8 ± 24,7 35.5 ± 23.5 31.4 ± 23.2 47.6 ± 25.2 47.6 ± 25.2 0.048
RC 56.3 ± 22.1 60.3 ± 21.7 40.3 ± 18.7 61.4 ± 21.1 65.0 ± 22.1 0.001
AS 56.0 ± 20.2 60.5 ± 21.1 54.4 ± 21.1 52.8 ± 18.5 48.1 ± 16.7 0.169
SR 66.5 ± 24,0 72.7 ± 20.3 53.7 ± 27.2 67.8 ± 23.0 60.1 ± 26.7 0.009
AX 60.5 ± 27.5 67.4 ± 24.6 41.2 ± 26.3 66.4 ± 25.1 50.5 ± 31.7 0.001
WB 60.5 ± 23.3 68.1 ± 20.3 47.3 ± 24.5 59.1 ± 23.6 61.3 ± 20.9 0.003
SF 49.7 ± 23.4 55.1 ± 22.6 34.0 ± 22.0 53.6 ± 19.3 46.7 ± 23.4 0.001
† One of the patients in this group had severe bronchiectasis disease. ‡ Three of the patients in this group had other diseases. One-way
ANOVA. Significance level 0.05. Notes: The Severe Respiratory Insufficiency (SRI) domains were respiratory complaints (RC), physical
functioning (PF), attendant symptoms and sleep (AS), social relationships (SR), anxiety (AX), psychosocial well-being (WB), social
functioning (SF), and summary scale (SS). HRQOL, health-related quality of life; LTMV, long-term mechanical ventilation.
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German version of the SRI, Cronbach’s α ranged between
0.73 and 0.79 for three subscales, and between 0.80 and
0.89 for four subscales.11 This indicates that the reliability
of the present study was the same or even better than that
of the German version of the SRI and similar to that in
the English, Dutch and Spanish validation studies.14,15
Cronbach’s α increases as the number of items in the scale
increases, which might explain the high Cronbach’s α
values for the sum scores.7 For the remaining subscales of
the SRI, Cronbach’s α was good to excellent and consist-
ent with those of previous studies,14,15 indicating good
item homogeneity in the SRI. However, a very high
Cronbach’s α might also indicate that several items in the
questionnaire are approximately equivalent,7 but this is
not the occasion in this study.
Regarding our first research question, the correlation
matrix of the SRI and SF-36 confirmed the same pattern as
Windisch and colleagues,11 who established strong asso-
ciations between physical functions, well-being, vitality
and social functioning. As expected, the strongest corre-
lations were between subscales that focused on compa-
rable aspects of HRQOL in patients receiving LTMV, and
the weakest correlations were between the subscales that
focused on different aspects of life as an example between
respiratory complaints and mental health.
A correlation coefficient between 0.20 and 0.80 is
regarded as acceptable, but correlation coefficients higher
than 0.70 between the instruments might indicate that
they are measuring the same construct.7 In both the
present and previous studies, the correlation coefficient
was higher than 0.70 for the domain ‘physical functions
and vitality’, indicating that they were measuring the same
subdomain. Previous validation studies found the lowest
correlation between the subdomain ‘attendant symptoms
and sleep’ in the SRI and the domain ‘role-emotional’ in
the SF-36.11,14 This was expected because the SF-36 was
not designed to measure sleep disturbances or respiratory
complaints,24 which are frequently reported in patients
with CRF.
Construct validity is one of the most important char-
acteristics of a questionnaire and refers to the degree to
which it actually measures the construct it is meant to
measure. Construct validity can be established by several
methods. One approach is the ‘known group technique’,
which tests the discriminatory ability of an instrument by
administering the questionnaire to groups expected to
differ in some known characteristics.7 Concerning our
second research question, the results of the present study
confirm the findings of previous validation studies, indi-
cating that the SRI can discriminate between different
diagnostic groups of patients.11,14,15 Consistent with the
findings of previous studies, the COPD patients had the
lowest SRI-SS. They have more respiratory constraints
than the other groups of patients,3,11,14,15 and the associa-
tion between respiratory complaints and HRQOL was
highest in COPD patients, as shown in another study,25 on
both the physiological component scale and the mental
component scale. The higher levels of anxiety and depres-
sion in COPD patients compared with other patients are
also consistent with the results of other validation
studies,11,14,15 and the SRI total score was strongly associ-
ated with anxiety and depression, as assessed with the
Hospital Anxiety and Depression Scale.13 A review of
previous studies has shown contradictory results in
patients after they commenced LTMV.26 Some studies
have found significant improvements in HRQOL after the
initiation of LTMV.27–30 In two of these studies, the
improvement in HRQOL seemed more marked in
patients with higher body mass indices (BMIs), those with
no obstructive sleep apnoea syndrome or OHS and those
traditionally known as ‘blue bloaters’.29,30 The COPD
patients in the present study also had high BMIs which
might represent a subgroup of COPD patients with con-
comitant OHS or obstructive sleep apnoea syndrome
receiving LTMV. Until recently, randomized controlled
trials have demonstrated no significant improvements
in HRQOL in COPD after the commencement of
LTMV.4,31–36 However, these studies had two important
limitations. First, they did not use questionnaires specific
for patients receiving LTMV. Second, these studies
used low-pressure ventilator settings.4,31–36 A new high-
intensity pressure strategy for non-invasive ventilation,
aimed at maximal improvement of the blood gas values,
has been evaluated in some studies, and assessments with
the SRI have shown improvements in HRQOL.3,37,38
Concerning our third research question, we found that
the most ventilator-dependent patients had lower
HRQOLs than patients who spent fewer hours on venti-
lation. These results are consistent with the findings of
previous studies of patients receiving LTMV.11,14,15
A low response rate is common in survey studies and
might result in non-response bias.7 The response rate in
the present study was 65.8%, and the responders and
non-responders were similar with regard to their age, sex,
diagnosis and period of requiring LTMV, which might
indicate that ours was a representative sample.7,23
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However, those who did not return the questionnaire had
lower scores on the lung function test than those who
returned the questionnaire. A reasonable interpretation of
this difference is that the non-responders suffered more
severe disease than the responders did. Other studies have
confirmed the tendency for patients with more advanced
disease to fail to complete questionnaires.39 Mailing ques-
tionnaires might be a less than optimal way to administer
the questionnaires. However, the phenomenon of ‘social
desirability responding’, or the tendency to idealize one’s
life, could be less pronounced when the questionnaires
are mailed, thus circumventing meetings between the
researcher and the study participants.40
Implications for nursing practice
Nurses have a central role in the care and monitoring for
LTMV patients. The information in the SRI is crucial in
planning the structure, performance and evaluation of
patient care for LTMV patients. The use of SRI question-
naire will be an important tool in this effort and the
subscales give an understanding of what HRQoL repre-
sents for this group, in a way which no other questionnaire
does. The subscale, Respiratory Complaints (RC), includes;
dyspnoea with or without physical activity, during speak-
ing and meals. The RC subscale is crucial information for
nursing care and intervention. The scale Attendents Symp-
toms and Sleep (AS), addresses the quality of sleep. This is
measured by the patients reported waking up during the
night, problems with falling asleep, general interruptions
to the sleep cycle and also symptoms, such as daytime
tiredness, dizziness and headaches.
The Physical Function (PF) subscale gives information
which is important for the patient’s self-care or need for
support. Information regarding the patient’s ability to
execute daily activities such as getting clothed, doing
housework, shopping and leisure time, is significant for
the nursing care performance and follow-up.
The subscale Anxiety reflects the patient’s concerns and
fears of breathlessness. It also includes patient avoidance
of situations which could escalate or induce breathlessness
or embarrass the patient. Awareness of the patient’s
anxiety is required to perform the necessary interventions
in care. The Social function scale gives information about
the patient’s ability to take part in social activities. The
subscale includes factors such as patient capability of going
out for the evening, having visitors, and impact of the
disease on the patient’s friends and family.
The Well-Being scale in SRI consists of several global
questions of how the patients in general feel about life,
their expectations for the future and their reactions to the
limitations of their disease. Nurse staff has an impotent
role in improving the patient’s HRQoL, and the SRI ques-
tionnaire is an important instrument in the care of patients
receiving LTMV.
Conclusion and suggestions for
further research
Weighing the gains made in HRQoL by prolonging
treatment against the potential disadvantages of the same
treatment is challenging and complex. However, the
Norwegian version of the SRI qualifies for use as a valuable
research tool in assessing HRQOL in patients receiving
LTMV. Longitudinal and follow-up studies are recom-
mended to determine the responsiveness of the Norwe-
gian version of the SRI and to identify the changes in
HRQOL over time in different groups of patients with
different diagnoses receiving LTMV. It should also be
possible to examine how demographic and clinical
variables act as predictors of HRQOL.
Our study demonstrates that the Norwegian versions
of SRI shows good levels of internal consistency, and
face-, criterion- and construct validities. The translation
and cross-cultural adaptation of this instrument allow its
application to clinical practice and research within
Norway, and to comparative international studies that
assess HRQOL in patients receiving LTMV.
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Abstract
Aims: To examine changes and explanatory variables for changes in health-related
quality of life in patients treated with long-term mechanical ventilation over a 6-year
period.
Background: Long-term mechanical ventilation is a treatment for individuals with
chronic hypercapnic respiratory failure, primarily caused by neuromuscular diseases,
obesity hypoventilation syndrome, chronic obstructive pulmonary and restrictive
thoracic diseases. Studies on long-term outcome on health-related quality of life
and factors influencing it are lacking.
Design: Prospective cohort study.
Methods: Data were collected from the Norwegian Long-Term-Mechanical-Ventila-
tion Registry and from patient-reported questionnaire in 2008 and 2014. Health-
related quality of life was measured by the Severe Respiratory Insufficiency
questionnaire, containing 49 items and seven subdomains. Linear mixed effects
models were used to measure changes and identify factors for changes.
Results: After 6 years, 60 patients were still participating, out of 127 at baseline.
Health-related quality of life improved significantly in the total score and in four sub-
domains of the questionnaire. Satisfaction with training in long-term mechanical venti-
lation was an explanatory variable for improved ‘psychological well-being’ and follow-
up for improvement of ‘anxiety’. Side effects of the treatment like facial soreness were
associated with the total score. High age and high forced vital capacity were related
to lower ‘physical function’ and improved ‘social functioning’, respectively.
Conclusion: Long-term mechanical ventilation over 6 years improved health-related
quality of life in most patients. Patient training, follow-up and reduction of side
effects, largely delivered by trained nurses, contribute to achieve the main goal of
the treatment—improved health-related quality of life.
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1 | INTRODUCTION
Long-term mechanical ventilation (LTMV) is a treatment used for
individuals with chronic hypercapnic respiratory failure (CHRF) pri-
marily caused by neuromuscular diseases (NMD), obesity hypoventi-
lation syndrome (OHS), chronic obstructive pulmonary disease
(COPD) and restrictive thoracic disorders (RTD) (Windisch, 2008).
LTMV is defined as non-invasive ventilation using a mask or mouth-
piece, or invasive ventilation using a tracheostomy for a period of at
least 3 months on a daily basis and the treatment is carried out
mainly in the user’s home or at a long-term care facility (Lloyd-Owen
et al., 2005). The estimated prevalence of LTMV in Norway and Eur-
ope is 37 and 6.6 per 100,000 respectively (Norwegian LTMV Regis-
try 2016, Lloyd-Owen et al., 2005).
Most individuals treated with LTMV have incurable and often
chronically progressive diseases (Huttmann & Windisch, 2015; p.
277). Without LTMV, individuals with CHRF have severely impaired
health-related quality of life (HRQoL) (Dellborg et al., 2002), but
LTMV might have an impact on daily life (Brooks et al., 2004; Lin-
dahl, Sandmann, & Rasmussen, 2005) and lifelong follow-up from
the healthcare service is needed (Leasa & Elson, 2016). Improving or
maintaining HRQoL is one of the main goals both in invasively venti-
lated (AARC, 2007) and in non-invasively ventilated individuals
(McKim et al., 2011).
1.1 | Background
The knowledge about how LTMV has an impact on HRQoL, has
increased, but is still patchy (MacIntyre, Asadi, Mckim, & Bagshaw,
2016; Simonds, 2016). Certain aspects of HRQoL are well docu-
mented while others are poorly investigated. Knowledge from quali-
tative studies found that LTMV gave more energy to cope with daily
life (Ballangrud, Bogsti, & Johansson, 2009) and young men with
Duchenne muscular dystrophy (DMD) reported that acquiring a ven-
tilator enabled them to make a new positive start to life (Dreyer,
Steffensen, & Pedersen, 2010).
In a discussion paper on quality of life, Moons, Budts, and De
Geest (2006) found that quality of life was an umbrella term, cover-
ing different other concepts such as HRQoL, health status, symp-
toms and happiness (Moons et al., 2006). As a result, research under
the heading of quality of life may cover similar, but still different
concepts. In clinical research, the term HRQoL is widely used, but as
this term also is lacking in conceptual clarity, previous research is
based on many different measures. According to Windisch (2008),
the concept of HRQoL has many components and covers aspects of
self-reported physical health, psychological well-being, social rela-
tions and functional capacities. Following a comprehensive method-
ological process, including patients treated with LTMV, the Severe
Respiratory Insufficiency (SRI) questionnaire was developed, specific
for measuring HRQoL in LTMV patients (Windisch et al., 2003). Con-
dition-specific questionnaires are more tailored and responsive than
generic questionnaires towards problems of particular importance to
the target group of patients (Fayers & Machin, 2016, p. 118). The
Why is this research/review needed?
• The main goal with long-term mechanical ventilation is to
increase or maintain health-related quality of life. People
suffering from chronic hypercapnic respiratory failure not
treated with long-term mechanical ventilation have
severely impaired health-related quality of life.
• The knowledge of how long-term mechanical ventilation
has an impact on health-related quality of life is poor and
there are even fewer studies on which factors influence
changes in it over several years.
• Previous studies measuring health-related quality of life in
patient treated with long-term mechanical ventilation have
most often used questionnaires not specific for this group.
The validated Severe Respiratory Insufficiency question-
naire has been developed for and together with this group
of patients, but not yet used in a long-term follow-up study.
What are the key findings?
• Six-year follow-up study of patients treated with long-
term mechanical ventilation found improved health-
related quality of life measured by the specific and vali-
dated Severe Respiratory Insufficiency questionnaire.
• The improvements were in the total score of the question-
naire and in the domains reflecting anxiety related to
breathing, contact and relationships with other people and
the ability to cope with their condition and overall satisfac-
tion with life.
• Patient-reported satisfaction with training and follow-up
from healthcare professionals were factors that con-
tributed to improved health-related quality of life in this
group. Side effects from non-invasive ventilation inter-
acted with change in the total SRI score. High forced
vital capacity from lung function measurements was a
factor for improvements in the social functioning domain
and high age was an explanatory factor for reduced score
the physical function domain.
How should the findings be used to influence
policy/practice/research/education?
• The findings add valuable new knowledge in the field of
respiratory care and should be included in the current
curriculum for healthcare professionals. The study out-
comes are important to decision-making both at the indi-
vidual level concerning treatment options and in terms of
planning of healthcare services for patients treated with
long-term mechanical ventilation.
• Nurses interact with long-term mechanical ventilation
patients in the outpatient clinic, in hospital wards and
through home care and are in a unique position to offer sys-
tematic patient training, prevent or reduce side effects of
non-invasive ventilation and ensure that patients receive
realistic information about possible side effects.
• We recommend further prospective international multicen-
tre studies on the link between long-term mechanical venti-
lation and health-related quality of life aspects, including on
intervention models for training and follow-up in this group
of patients by including them as members of the multidisci-
plinary team and use of patient-reported and registry data
to improve care and health-related quality of life.
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scientific framework for the concept of HRQoL in the present study
was therefore based on research that used the SRI questionnaire in
patients treated with LTMV.
Applying the SRI questionnaire, a 1-year follow-up study found
significant improvements amongst patients with CHRF in a mixed
study population including NMD, OHS, RTD and COPD. HRQoL
improved after 1 month of LTMV and the results remained stable at
the elevated level during the following year (Windisch, 2008). Two
randomized controlled trials (RCT) reported significant improvements
in the SRI scores 1 year after initiating LTMV in patients with severe
COPD (K€ohnlein et al., 2014; Struik et al., 2014). Still, there is an
ongoing discussion regarding the indication and benefit of LTMV in
COPD patients (Simonds, 2016).
We have been unable to identify studies using a questionnaire
specific to patients treated with LTMV in a follow-up study over
more than 1 year, or studies focusing on the efficacy of ongoing
LTMV over several years. However, some sociodemographic and
clinical variables associated with HRQoL measured with the SRI
questionnaire have been identified. Men had poorer HRQoL scores
in the ‘respiratory complaints’ and ‘anxiety’ domains compared with
women (Lopez-Campos et al., 2008). The underlying disease was an
explanatory variable for change in the single domains of the SRI, as
significant improvements in ‘physical function’ were evident only in
patients with COPD and RTD. The largest improvements were
observed in NMD and OHS patients in the ‘attendant symptoms and
sleep’ domain (Windisch, 2008). Co-morbidity was more prevalent in
older patients with COPD, reducing their SRI score compared with
younger patients with NMD (Huttmann, Windisch, & Storre, 2015).
The physiological efficacy of the LTMV treatment is to decrease the
work of breathing and support gas exchange (Georgopoulo, 2013).
However, ventilation modes and additional long-term oxygen ther-
apy were not associated with HRQoL (Budweiser et al., 2007) and
ventilator settings in obese patients had no influence on change in
HRQoL assessed by the SRI questionnaire (Murphy et al., 2012;
Storre et al., 2006). Furthermore, the most common criteria generally
used to examine the severity of CHRF are the physiological mea-
surements, partial pressure of carbon dioxide (pCO2) and forced vital
capacity (FVC) (Simonds, 2016).
These physiological measurements do not reflect the perceptions
and subjective state of the patient, but correlations have been
reported between these physical measurements and the physical
aspects of HRQoL (Hahn et al., 2007). High ventilator pressure set-
tings, aiming to reduce levels of pCO2, were also proposed as the
explanation for improved SRI scores in individuals with COPD
(K€ohnlein et al., 2014).
Some aspects of HRQoL in LTMV are well documented. How-
ever, there are certain areas especially relevant for nurses that have
only been incompletely investigated. LTMV can be time-consuming
and costly and may contribute to significant side effects. If LTMV
increases the burden of disease without any positive effects on
HRQoL, it would raise ethical concerns (Windisch, 2010 p. 582). Fex,
Flensner, Ek, and S€oderhamn (2012) recommended supplementary
nursing support for people using advanced medical technology at
home. Good HRQoL in individuals receiving LTMV depends on good
care being provided by competent healthcare personnel (Brooks
et al., 2004; Lindahl et al., 2005). However, shortcomings in the
information and follow-up provided by healthcare staff have been
reported. Access to better trained personnel has been requested by
LTMV patients (Chang, Marsh, Smith, & Neill, 2010), who suffer from
severe conditions requiring information, support and long-term care
to enjoy the best quality of life available (Leasa & Elson, 2016).
There is limited knowledge of how indicators like side effects of the
treatment, satisfaction with LTMV training and follow-up might
influence changes in HRQoL.
2 | THE STUDY
2.1 | Aims
The objectives of the present study were as follows:
• to examine changes in HRQoL in patients treated with LTMV
from 2008-2014.
• To examine sociodemographic, clinical and patient-reported
explanatory variables associated with changes in HRQoL in this
group.
2.2 | Design
The research design was a prospective cohort study.
2.3 | Participants
In 2008, all patients aged ≥18 years in the Norwegian national
LTMV registry in Western Norway were invited to participate in the
study. The inclusion criteria were patients treated with non-invasive
or invasive LTMV for at least 3 months who were mentally able to
answer questions. Those who agreed to participate were followed
until 2014.
2.4 | Data collection
Data collection included clinical variables from the LTMV registry as
well as patient-reported clinical information from questionnaires at
the start of the study in 2008 and at its end in 2014. At the start,
an information letter, the baseline questionnaires and a stamped
return envelope were sent by mail. The follow-up (2014) question-
naires were completed when the patients attended their regular con-
sultation in the outpatient clinic at the two university hospitals in
Western Norway.
2.4.1 | Norwegian registry for LTMV
The LTMV registry was established in 2002 and formally approved
as a national medical quality registry 10 years later. The main pur-
pose of the registry is monitoring LTMV to promote geographic
equality, quality assurance, professional development, research and
resource planning. Patients permanently dependent on non-invasive
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or invasive LTMV during all or part of the day are included. There is
a written consent to participate in the registry and it is possible for
individuals to withdraw from the register. The national coverage
ratio in the registry was 72% in 2016 (Norwegian LTMV Registry
2016). Data collected to the present study from the LTMV registry
were sociodemographic data, the date and main diagnosis when
starting LTMV, the type of connection to the ventilator, blood gas
analyses and spirometry values.
2.4.2 | Explanatory variable for changes in HRQoL
Changes in HRQoL were examined according to baseline characteris-
tics measured in 2008. The background variables used were: sex;
age; education; marital status and disease. The potential explanatory
variable for changes in HRQoL included: number of years treated
with LTMV; pCO2 and FVC. Patient-reported explanatory variable
for changes in HRQoL included hours a day on LTMV, a yes/no
question regarding whether they experienced any side effects, with
further follow-up questions on which side effects, where they were
given the following options: air leakage from the mask; soreness
caused by mask pressure; condensation inside the mask; and an
option to describe other side effects in their own words. Depen-
dency on daily assistance with using the ventilator was measured by
one yes/no question. Patient satisfaction with the follow-up from
specialist healthcare professionals consisted of one statement
(“Received adequate follow-up”) as did patient satisfaction with
training in the use of LTMV (“Received adequate training in LTMV”),
both of which had five response categories ranging from “Strongly
disagree”—“Strongly agree”.
2.4.3 | Study setting: Clinical follow-up from
healthcare professionals
Clinical follow-up for LTMV patients is organized through a national
multi and interdisciplinary competence network. The network is
coordinated by a physician and includes specially trained nurses and
physiotherapists, specialists in neurology and general practitioners. It
also includes a liaison nurse who plays an important role when the
patient is transferred from hospital to their home with a ventilator,
both in terms of educating the caregiver team and promoting con-
tact with relatives and caregivers in the community. Follow-up visits
take place 1 to 4 times a year depending on individual circumstances
such as medical condition and psychosocial factors.
2.4.4 | Outcome variable of the study
The outcome variable in the present study was HRQoL, measured
by the SRI questionnaire at baseline (2008) and follow-up (2014).
This is a specific, multidimensional questionnaire covering physical,
psychological and social functioning and was originally developed for
and together with patients receiving LTMV to obtain subjective
descriptions of issues that were important in their daily lives. The
questionnaire contains 49 items and is divided into seven
subdomains. High summary scale values (range 0–100) indicate a
better HRQoL and the subscales are as follows:
SRI-Respiratory Complaints contains eight items relating to dysp-
noea at rest and during physical activity. It covers how often breath-
lessness occurs and the degree of waking up with breathlessness at
night. Breathlessness during speaking, eating and problems with
coughing or mucus in the airways are included in this subdomain.
SRI-Physical Function consists of six items and includes the
patient’s ability to execute everyday physical activities, such as get-
ting dressed, walking stairs and doing housework. Participation in
physical leisure activities and how breathing problems have an
impact on activities are covered by this subdomain.
SRI-Attendant Symptoms and Sleep contains seven items address-
ing the quality of sleep, measured by patient-reported waking up
during the night, problems with falling asleep and general interrup-
tions of sleep. Daytime tiredness, dizziness and headaches are also
covered by this subdomain.
SRI-Anxiety consists of five items including experiences of feeling
anxious about having attacks of dyspnoea and about suffering dysp-
noea at night. Avoiding situations that are stressful due to breathing
difficulties and being worried that the disease will get worse are also
included in this subdomain.
SRI-Social Relationships contains six items including having friends
and feeling comfortable in the company of other people or feeling
lonely and isolated. The disease burden on family life is also covered
in the subscore.
SRI-Social Functioning consists of eight items including the degree
of broken contact with friends and acquaintances. Limited leisure
opportunities, ability to attend social events and the impact of the
disease on marriage or relationships are covered by this subdomain.
SRI-Psychological Well-Being includes nine items covering the
patient’s ability to cope with the disease. The degree of sadness and
overall satisfaction with life are included. Each item belongs to only
one subscale and all items are rated on a five-point Likert scale from
“strongly agree” to “strongly disagree”.
Questions refer to the patient’s health status during the previous
week. The summary scale was obtained by calculating the mean of
the values of each scale (Windisch et al., 2003). However, the mini-
mal clinically important difference of the SRI questionnaire has not
been defined.
2.5 | Ethical considerations
The study was approved by the Norwegian Committee of Ethics in
Medicine, Region III and by the Norwegian Centre for Research Data
(project number 16001). In the Information letter, to the patients in
2008 it was informed that the data were stored for 10 years for a
possible follow-up study and returning the questionnaires by mail
were considered consent to participate in the study. One reminder
letter was sent (Markussen, Lehmann, Nilsen, & Natvig, 2015). Prior
to the follow-up study in 2014, the patients received a new informa-
tion letter about the follow-up study. There was a written consent
to participate in the follow-up study. It was possible for the patients
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to decline from participation in the study, but still be a part in the
register.
2.6 | Data analysis
All statistical analyses were carried out using SPSS version 20 (SPSS
Inc., Chicago, IL, USA) and Stata SE 14 (StataCorp LP, College Sta-
tion, TX, USA) for Windows. Descriptive statistics were used to
quantify sample characteristics. The items in the SRI were recoded
and summarized following the guidelines of the original SRI ques-
tionnaire (Windisch et al., 2003). All statistical tests were two-tailed
and p values lower than.05 were considered as statistically signifi-
cant.
To estimate changes in the seven SRI domains from the start of
the study in 2008 to its end in 2014, we used linear mixed effects
models. All models defined the time-period as a fixed effect,
whereas a random intercept for the individual was specified to
account for correlated observations of the same individual (an
exchangeable correlation structure was assumed). Further, to identify
explanatory variables associated with change in the seven SRI
domains from 2008 - 2014, we extended the abovementioned
models to include the relevant explanatory variables and the product
between the explanatory variable and time-period (i.e. an explana-
tory variable-by-time interaction) as model terms.
Estimated mean changes in the SRI domains from 2008 to 2014
in categories of explanatory variables were reported using regression
model coefficients (b) with 95% confidence intervals (CIs) and p val-
ues. To obtain p values for explanatory variables associated with SRI
change, we used the likelihood ratio test, i.e. comparing the log-like-
lihood between models with and without the explanatory variables -
by-time interaction term. Analyses were adjusted for the following
background variables: sex; age; education; marital status; years on
LTMV and disease.
2.7 | Validity, reliability and rigour
Validity and reliability in quality of life research has been discussed
(Macduff, 2000; Moons et al., 2006). Good validity and international
relevance of this study is provided by using the SRI questionnaire,
that has shown very good psychometric qualities and has been pro-
fessionally adapted and translated into several languages (Duiverman,
Wempe, Bladder, Kerstjens, & Wijkstra, 2008; Ghosh, Rzehak, Elliott,
2008: Potential patientsin the
Norwegian Registry of LTMV
(N = 211)
Excluded patients because 
they did not meet the 
inclusion criteria (N = 18)






Not able to 
contact (N = 1)
Died (N = 52)
Follow-up study-sample 
(N = 60)
2014: The six years follow-up
Not using 
LTMV (N = 8)
Non-responderes (N = 3)
Not able to respond
(N = 3)
Potential responders (N = 63)
F IGURE 1 Flow diagram of the long-
term mechanical ventilation (LTMV)
patients from 2008 to 2014
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& Windisch, 2012; Huttmann et al., 2015, p. 280; Lopez-Campos
et al., 2008; MacIntyre et al., 2016; Markussen et al., 2015; Oga
et al., 2017; Ribeiro, Ferreira, Conde, Oliveira, & Windisch, 2017;
Struik et al., 2013; Windisch, 2008; Windisch et al., 2003). Reliability
and rigour are provided through high-quality clinical data from the
LTMV registry.
3 | RESULTS
3.1 | Study population
Of 193 potential responders in the LTMV registry, 127 (65.8%)
patients agreed to participate and completed the SRI questionnaire
at baseline in 2008 (Figure 1). Of the 127 individuals eligible for fol-
low-up in 2014, 52 had died during the 6-year period. Additionally,
15 patients were excluded for the following reasons: dementia or
unable to answer the questionnaire (N = 3); stopped using LTMV
(N = 8); unable to make contact (N = 1); and did not want to partici-
pate in follow-up study (N = 3). These exclusions related to the dis-
ease groups NMD (N = 6), COPD (N = 2), OHS (N = 6) and RTD
(N = 1), leaving a final study sample of 60 (95%) patients (Figure 1),
ranged in age from 18 to 85 years at inclusion in 2008. The majority
of the patients lived in their own home, only five of the patients
lived in nursing homes.
3.2 | Clinical characteristics
Before LTMV treatment (at least 3 months before the start of the
study), the mean blood value of daytime carbon dioxide (PaCO2 kPa)
and oxygen (PaO2 kPa) was 6.7 (standard deviation [SD] 1.9) and 9.1
(SD 1.7), respectively. In 2008, the mean respirator inspiratory posi-
tive airway pressure (IPAP) was 15.5 cmH2O (SD 2.8) and the expira-
tory pressure (EPAP) was 6.9 cmH2O (SD 2.7) (N = 45). Non-invasive
ventilation (NIV) was the main ventilation mode, only 2 of the sur-
viving patients in 2014 had tracheostomy interface. No patients
used a mouthpiece or helmet as an interface for LTMV. Side effects
from the non-invasive LTMV were reported by 29 individuals
(Table 1). The most common side effects were air leakage between
the face and the mask (N = 21) and soreness caused by mask pres-
sure (N = 10). Other patient-reported side effects were condensation
inside the mask (N = 5), dry nose and mouth (N = 2), eye irritation,
ventilator noise and patient-ventilator synchronization problem
(N = 1). Three people reported three different kind of side effects,
five individuals reported two different side effects, while most indi-
viduals reported one single side effect (N = 21).
3.3 | Change in HRQoL from 2008 to 2014
There were statistically significant improvements in the total SRI
score at mean 4.74 (p = .005) and in four subdomains: SRI-Anxiety,
SRI-Social Functioning, SRI-Social Relationships and SRI-Psychologi-
cal Well-Being. The largest improvement was observed for the Social
Relationships domain, with an improvement of 8.47 (p = .001)
(Table 2) (Table S5). The improvements in the total score of SRI
were seen in all disease groups, except in patients with COPD
(Table 3), who also had a reduction in five of seven SRI subdomains
(Table 4) (Table S1–S4).
TABLE 1 Baseline characteristic of the surviving individuals
treated with LTMV in the longitudinal study
Characteristic N Baseline 2008
Background
Sex, male (n, %) 60 32 (53.3)
Age, years (M, SD) 60 58.0 (15.5)
Education (n, %)
Primary school 60 18 (30.0)
High school 60 23 (38.3)
College/University 60 19 (31.7)
Marital status (n, %)
Married/cohabiting 60 34 (56.7)
Single/divorced/widowed 60 26 (43.3)
Years of LTMV (M, SD) 60 5.23 (4.0)
Disease (n, %)
NMDa 60 26 (43.3)
COPD 60 6 (10.0)
OHS 60 22 (36.7)
RTD 60 6 (10.0)
Treatment
LTMV h/day (n, %)b
5–8 58 33 (56.9)
8–24 58 25 (43.1)
Dependency of daily assistance (n, %) 59 16 (27.1)
Side effects of non-invasive LTMV (n, %) 58 29 (50.9)
Satisfactions with LTMV training (n, %)c
Some satisfaction 59 9 (15.5)
Quite satisfied 59 18 (30.5)
Very satisfied 59 32 (54.2)
Satisfactions with follow-up (n, %)c
Some satisfaction 49 8 (16.3)
Quite satisfied 49 13 (26.5)
Very satisfied 49 28 (57.1)
Respiratory
FVC (litre) (M, SD) 47 2.09 (1.07)
PaCO2 kPa daytime (M, SD) 47 5.66 (0.86)
PaO2, kPa daytime (M, SD) 44 10.3 (1.63)
SD, standard deviation; LTMV, long-term mechanical ventilation; NMD,
neuro muscular disease; COPD, chronic obstructive pulmonary disease;
OHS, obesity hypoventilation syndrome; RTD, restrictive thoracic disor-
ders; FVC, forced vital capacity; PaCO2, partial pressure of carbon diox-
ide; PaO2, partial pressure of oxygen.
aNone with amyotrophic lateral sclerosis (ALS).
bBecause of low numbers, the 8–12 and 12–24 categories of this variable
were grouped together.
cBecause of low numbers, the three lowest categories of this variable
were grouped together.
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TABLE 2 Changes in HRQoL from 2008 to 2014 measured by The Severe Respiratory Insufficiency (SRI) questionnaire in the individuals





M (SD) Changea mean 95% CI p
Respiratory complaints 59 61.0 (22.4) 60 62.8 (20.8) 1.86 (3.19, 6.91) .46
Physical functioning 59 45.9 (23.0) 60 46.7 (23.4) 0.67 (4.07, 5.42) .78
Attendant symptoms and sleep 59 53.3 (20.1) 60 55.7 (21.6) 2.48 (2.14, 7.11) .29
Social relationships 59 70.7 (24.4) 60 79.1 (19.5) 8.47 (3.48, 13.5) .001
Anxieties 59 64.2 (27.5) 60 72.1 (22.9) 7.94 (2.42, 13.5) .006
Well-being 59 66.1 (22.0) 60 74.2 (17.0) 7.66 (3.28, 12.0) .001
Social functioning 59 56.5 (24.9) 60 62.4 (25.7) 5.89 (0.91, 10.9) .02
SUM score 59 60.0 (18.5) 60 64.8 (16.8) 4.74 (1.49, 8.00) .005
HRQoL, health-related quality of life; SD, standard deviation; CI, confidence interval.
aChange in SRI is estimated by linear mixed effects model with random intercept.







in meansa 95% CI p for change p for interaction
Background
Sex .88
Female 57.8 (16.1) 62.3 (15.0) 5.06 (0.30, 9.80) .04
Male 61.8 (20.0) 66.4 (18.0) 4.57 (0.21, 8.94) .04
Age .79
≤60 61.7 (16.2) 66.9(15.1) 5.25 (0.40, 10.1) .03
>60 58.7 (20.0) 62.7 (17.6) 4.37 (0.08, 8.66) .05
Education
Primary school 56.2 (20.8) 61.2 (19.1) 5.01 (0.74, 10.8) .09 .71
High school 56.0 (15.5) 61.7 (14.1) 6.16 (0.86, 11.4) .02
College/University 68.7 (16.8) 70.8 (15.9) 2.98 (2.76, 8.72) .30
Marital status .74
Married/cohabiting 59.9 (18.1) 64.9 (16.5) 5.25 (1.03, 9.48) .01
Single/divorced/widowed 60.2 (19.0) 64.0 (17.1) 4.17 (0.76, 9.11) .10
Years on LTMV .56
≤ 4 57.7(18.7) 63.0 (16.0) 5.65 (1.30, 9.99) .01
> 4 62.9 (17.8) 66.2 (17.5) 3.75 (1.00, 8.49) .12
Disease
NMD 62.8 (13.2) 65.2 (10.6) 3.2 (1.61, 8.00) .19 .14
COPD 51.1 (25.7) 48.5 (21.0) 2.6 (12.3, 7.06) .60
OHS 60.1 (20.2) 69.0 (18.5) 9.00 (3.85, 14.1) .001
RTD 57.8 (22.9) 61.6 (20.8) 3.83 (5.83, 13.5) .44
Treatment
LTMV h/dayb .88
5–8 61.0 (18.2 64.9(14.4) 4.51 (0.24, 8.77) .04
8–24 59.2 (19.6) 63.1(19.7) 4.02 (0.82, 8.88) .10
Dependency of daily assistance .76
No 60.9 (19.1) 65.4 (18.1) 4.56 (0.81, 8.31) .02
Yes 57.5 (16.2) 62.8 (12.4) 5.72 (0.54, 11.9) .07
Side effects of non-invasive LTMV .02
(Continues)
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3.4 | Explanatory variables associated with change
in HRQoL
Of 13 baseline characteristics evaluated as potential explanatory
variables for change in HRQoL from 2008 to 2014, five variables
were identified as significant factors for change in HRQoL. Side
effects of the non-invasive LTMV were significantly associated with
the total SRI score (Table 3) and SRI-Physical function (Table S1).
Satisfaction with LTMV training was associated with an improved
SRI-Psychological Well-Being score (Table 4). Satisfaction with fol-
low-up from healthcare professionals in the specialist health care
service was one explanatory variable for improvement in the SRI-
Anxiety score (Table 5). High age was one explanatory variable for a
lower SRI-Physical Function score (Table S1) and high FVC was cor-
related with improved HRQoL in the SRI- Social Functioning score
(Table S2).
4 | DISCUSSION
This study adds valuable new knowledge by being the first study to
examine the impact of 6 years of LTMV on HRQoL using the speci-
fic SRI questionnaire developed together with and for people treated
with LTMV. HRQoL improved both as measured by the total score
and by four of the seven SRI subdomains. The improvements
occurred in the clinically important domains ‘anxiety’, ‘social func-
tioning’, ‘social relationships’ and ‘psychological well-being’.
This study is also unique in that it identified explanatory vari-
ables possible for nurses to intervene on, aiming to achieve the main
goal of LTMV, which is to improve HRQoL. These results were
based on self-reported measures and as in most research on HRQoL,
the results may partly be explained by a better adaptation to living
with a chronic illness. However, a meta-analysis examining the clini-
cal significance of such an explanation, could not confirm this when
examining studies based on measures of response shift (Schwartz
et al., 2006).
4.1 | Patient evaluation of LTMV training and
follow-up as factors associated with changes in
HRQoL
The positive relationship between patient satisfaction with training
in the use of LTMV and improvement in the SRI-Psychological Well-
Being score is clinically important. It indicates that thorough basic
training in use of the ventilator and interfaces are vital success fac-








in meansa 95% CI p for change p for interaction
No 63.9 (20.1) 64.7 (18.8) 1.07 (3.38, 5.52) .64
Yes 56.2 (16.1) 65.1 (15.4) 8.89 (4.66, 13.1) <.001
Satisfactions with LTMV trainingc .09
Some satisfactionb 51.1 (15.2) 60.7 (16.2) 9.56 (1.69, 17.4) .02
Quite satisfied 55.2 (18.2) 62.7 (17.4) 8.06 (2.35, 13.8) .006
Very satisfied 65.1 (18.0) 67.0 (16.6) 1.80 (2.43, 6.03) .40
Satisfactions with follow-upc
Some satisfaction 57.0 (27.4) 63.8 (16.9 9.87 (0.13,19.6) .05 .24
Quite satisfied 53.1 (14.8) 60.0 (12.1) 6.90 (0.20, 13.6) .04
Very satisfied 66.4 (16.5) 68.5 (17.7) 2.01 (2.63, 6.65) .39
Respiratoryd
FVC (litre)
Per 1 unit increase 2.26 .17
PaCO2 kPa daytime
Per 1 unit increase 1.04 .62
PaO2, kPa daytime
Per 1 unit increase 1.67 .15
SRI-SS, severe respiratory insufficiency sum score; SD, standard deviation; CI, confidence interval; LTMV, long-term mechanical ventilation; NMD, neuro
muscular disease; COPD, chronic obstructive pulmonary disease; OHS, obesity hypoventilation syndrome; RTD, restrictive thoracic disorders; FVC,
forced vital capacity; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of oxygen.
aEstimated by mixed effects models, adjusted for background variables: sex, age, education, marital status, years on LTMV and disease.
bBecause of low numbers, the 8–12 and 12–24 categories of this variable were grouped together.
cBecause of low numbers, the three lowest categories of this variable were grouped together.
dFor continuous respiratory variables, data are presented as estimated change in SRI-SS for one unit increase (in the respiratory variables) and the corre-
sponding p for interaction.
8 | MARKUSSEN ET AL.












Female 65.8 (22.7) 73.4 (18.2) 7.91 (1.52, 14.3) .01
Male 66.6 (21.8) 74.5 (16.0) 7.44 (1.57, 13.3) .01
Age .96
≤60 66.8(21.7) 75.1(17.1) 7.73 (1.19, 14.2) .02
>60 65.8(22.6) 73.1 (17.0) 7.51 (1.74, 13.3) .01
Education .87
Primary school 60.3 (24.4) 69.4 (18.2) 9.18 (1.41, 16.9) .02
High school 62.9 (19.2) 70.4 (17.1) 7.49 (0.36, 14.6) .04
College/University 76.2 (20.2) 82.3 (12.6) 6.32 (1.42, 14.0) .11
Marital status .24
Married/cohabiting 65.1 (19.3) 75.1 (15.4) 9.85 (4.23, 15.5) .001
Single/divorce widowed 67.7 (25.4) 72.4 (19.0) 4.66 (1.90, 11.2) .16
Years on LTMV .43
≤4 63.4 (23.3) 73.2 (17,7) 9.21 (3.38, 15.0) .002
>4 69.7 (20.1) 74.9 (16.2) 5.72 (0.66, 12.1) .08
Disease .18
NMD 71.2 (16.6) 76.0 (13.0) 5.33 (1.18, 11.8) .12
COPD 62.0 (33.5) 60.6 (23.8) 1.39 (14.5, 11.7) .83
OHS 61.5 (23.7) 75.0 (18.8) 13.0 (6.07, 20.0) <.001
RTD 67.9 (23.0) 75.0 (16.1) 7.06 (6.03, 20.1) .29
Treatment
LTMV h/dayb .77
5–8 69.2 (21.8) 75.5 (15.9 6.65 (0.87, 12.4) .02
8–24 63.7 (22.7) 72.2 (18.8) 7.98 (1.39, 14.6) .02
Dependency of daily assistance .94
No 65.9, 22.3) 74.0 (18.4) 7.40 (1.02, 15.8) .08
Yes 67.2 (21.7) 73.6 (13.3) 7.76 (2.71, 12.8) .003
Side effects of non-invasive LTMV .15
No 67.2 (23.2) 72.1 (20.6) 11.2 (5.35, 17.1) <.001
Yes 64.6 (21.5) 75.9 (13.7) 4.87 (1.31, 11.0) .12
Satisfactions with LTMV trainingc .01
Some satisfaction 61.0 (16.0) 74.4 (11.8) 13.4 (3.13, 23.6) .01
Quite satisfied 58.5 (21.1) 72.5 (16.2) 14.8 (7.45, 22.2) <.001
Very satisfied 71.8 (22.8) 74.5 (19.1) 2.14 (3.35, 7.62) .45
Satisfactions with follow-upc .06
Some satisfaction 62.0 (27.2) 67.7 (14.3) 6.25 (6.23, 18.7) .32
Quite satisfied 60.0 (21.6) 74.6 (15.1) 14.5 (5.93, 23.1) .001
Very satisfied 74.2 (21.0) 76.7 (18.8) 1.78 (4.17, 7.74) .56
Respiratoryd
FVC (litre)
Per 1 unit increase 2.61 .27
PaCO2 kPa daytime
Per 1 unit increase 1.93 .52
(Continues)
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Patient satisfaction is related to the extent to which general
healthcare needs and condition-specific needs are met (Guldvog,
1999). The importance of giving proper training to a ventilator-
assisted individual is recognized as fundamental for good HRQoL.
However, it has not previously been well documented (Norregaard &
Escarrabill, 2010; p.172). According to Escarrabill (2015, p.282), the
competencies of the LTMV patient are directly related to the clinical
outcome. To our knowledge, no studies have focused on patient
training or education in patients receiving LTMV with HRQoL as a
primary outcome. A Cochrane review also concluded that there was
a small improvement in quality of life in COPD patients without
LTMV treatment who received a short patient training program com-
pared with those receiving usual care (Howcroft, Walters, Wood-
Baker, & Walters, 2016).
The SRI-Anxiety score was considerably improved both in the
overall analysis and in subanalysis of the different disease categories,
in line with the outcomes of other studies (K€ohnlein et al., 2014;
Struik et al., 2014; Windisch, 2008). The findings implicate that fol-
low-up from healthcare professionals might contribute to improve
the HRQoL of individuals receiving LTMV related to anxiety for
breathlessness. Furthermore, it might indicate that they feel safer
in situations where breathlessness may occur. According to Gibson,
Brooks, DeMatteo, and King (2009), it is especially important for
LTMV patients to have control over their day-to-day schedules, the
assistance provided and how it is carried out.
One of the challenges in clinical practice is to identify and target
the patients’ genuine needs (Leasa & Elson, 2016). There are differ-
ent approaches to follow-up. The setting for patient training and fol-
low-up in this study was a ‘real-world’ setting, including a multi and
interdisciplinary network model that shares and disseminates profes-
sional knowledge and skills in the field of LTMV. An evaluation of
management of DMD emphasizes the importance of multidisciplinary
care for these patients (Bushby et al., 2010). Escarbilrabill and Norre-
gaard (2010, p.179), also highlight the benefits of network models,
such as professional development and continuing education. An
important element of patient education and follow-up in ongoing
LTMV is the contact between patient and healthcare professionals
over several years, where patients and professionals identify and dis-
cuss problems caused by, or related to, the LTMV. The patient is
thus involved in the care process. This partnership might affect the
evaluation of and satisfaction with, the healthcare service. However,
the role of patient-reported outcomes measure (PROM) in facilitating
communication between healthcare professionals in the multidisci-
plinary team and the patient as a team member is yet to be explored
(Norekvaal, Faalun, & Fridlund, 2016).
4.2 | Patient-reported side effects as factors
associated with changes in HRQoL
Patient-reported side effects of non-invasive LTMV were signifi-
cantly associated with the total SRI score and the SRI-Physical func-
tion domain. To our knowledge, this study was the first to identify
side effects, such as soreness caused by mask pressure or air leakage
between the mask and face, were associated with a lower total SRI
score at baseline compared with those reporting no side effects.
According to Elliott (2004), some air leakage is an unavoidable con-
sequence of non-invasive LTMV. However, frequent side effects can
clearly worsen HRQoL or counteract the HRQoL benefits gained
from LTMV (Windisch, 2010, p. 585).
4.3 | Clinical data from the LTMV registry as
explanatory variables associated with changes in
HRQoL
High FVC was one explanatory variable for improved HRQoL in
terms of SRI-Social Functioning, a key domain because it indicates
improved leisure opportunities, including the ability to go out in the
evening and attend social events (Windisch et al., 2003). An explana-
tion of high FVC as clinically important factor might be that the
patients with higher FVC have more physical strength to carry out
the social functioning. Interaction between high FVC and improved
HRQoL are rarely reported. However, a weak but significant positive
association between pulmonary variables and HRQoL was also found
in patients with cystic fibrosis who were not treated with LTMV
(Hahn et al., 2007).
High age was an explanatory variable for a lower score for SRI-
Physical Function. This is in line with Huttmann et al. (2015), who
found reduced HRQoL in individuals receiving LTMV of higher age
and with chronic lung diseases, compared with younger patients with












Per 1 unit increase 2.93 .07
SRI-SS, severe respiratory insufficiency sum score; SD, standard deviation; CI, confidence interval; LTMV, long-term mechanical ventilation; NMD, neuro
muscular disease; COPD, chronic obstructive pulmonary disease; OHS, obesity hypoventilation syndrome; RTD, restrictive thoracic disorders; FVC,
forced vital capacity; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of oxygen.
aEstimated by mixed effects models, adjusted for background variables: sex, age, education, marital status, years on LTMV and disease.
bBecause of low numbers, the 8–12 and 12–24 categories of this variable were grouped together.
cBecause of low numbers, the three lowest categories of this variable were grouped together.
dFor continuous respiratory variables, data are presented as estimated change in SRI-SS for one unit increase (in the respiratory variables) and the corre-
sponding p for interaction.
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Female 63.9 (25.4) 73.6 (23.0) 9.9 (1.87, 17.9) .02
Male 64.4 (29.5) 70.7 (23.0) 6.3 (1.07, 13.7) .09
Age .96
≤60 63.9 (27.2) 71.7 (23.2) 7.79 (0.45, 16.0) .06
>60 64.4 (28.0) 72.3 (22.9) 8.05 (0.76, 15.3) .03
Education .22
Primary school 58.3 (27.0) 72.8 (24.6) 14.4 (4.70, 24.2) .004
High school 59.8 (27.3) 66.9 (23.7) 7.17 (1.61, 15.9) .11
College/University 74.9 (26.4) 77.6 (19.6) 2.76 (6.71, 12.2) .57
Marital status .53
Married/cohabiting 62.7 (29.1) 72.2 (21.9) 9.48 (2.31, 16.7) .01
Single/divorced/widowed 66.2 (25.5) 71.9 (24.5) 5.92 (2.42, 14.3) .16
Years on LTMV .59
≤4 60.7 (28.5) 70.0 (19.5) 9.28 (1.99, 16.6) .01
>4 68.6 (26.0) 74.6 (26.5) 6.26 (1.93, 14.4) .13
Disease .94
NMD 67.9 (24.0) 75.4 (16.0) 7.85 (0.63, 16.3) .07
COPD 48.3 (32.3) 52.5 (24.6) 4.17 (13.2, 21.5) .64
OHS 66.6 (27.4) 76.3 (25.8) 9.71 (0.63, 18.8) .04
RTD 55.8 (36.2) 61.7 (27.5) 5.83 (11.5, 23.2) .51
Treatment
LTMV h/dayb .40
5–8 64.5 (28.1) 73.5 (21.2) 9.28 (1.99, 16.6) .01
8–24 65.0 (27.8) 69.5 (25.5) 4.55 (1.93, 14.4) .27
Dependency of daily assistance .44
No 66.5 (26.7) 72.2 (24.2) 5.67 (0.19, 11.5) .06
Yes 61.4 (26.6) 71.2 (20.0) 10.2 (02.3, 20.1) .04
Side effects of non-invasive LTMV .15
No 69.8 28.1) 71.6 (25.1) 1.91 (5.07, 8.90) 1.92
Yes 62.3 (25.1) 71.4 (25.8) 9.09 (2.34, 15.8) .008
Satisfactions with LTMV trainingc .29
Some satisfaction 53.3 (26.2) 68.8 (23.4) 15.5 (2.83, 28.3) .02
Quite satisfied 61.8 (24.9) 68.9 (23.4) 7.35 (1.87, 16.6) .12
Very satisfied 70.3 (27.0) 74.5 (23.1) 4.18 (2.57, 10.9) .22
Satisfactions with follow-upc .009
Some satisfaction 49.5 (37.1) 75.0 (23.3) 26.9 (11.8, 41.9) <.001
Quite satisfied 53.1 (23.2) 66.5 (22.6) 13.5 (2.32, 24.6) .02
Very satisfied 73.6 (24.6) 75.3 (21.0) 1.69 (5.90, 9.29) .66
Respiratoryd
FVC (litre)
Per 1 unit increase 1.54 .60
PaCO2 kPa daytime
Per 1 unit increase 1.19 .75
(Continues)
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invasive LTMV >75 years had a significantly lower HRQoL measured
with SF-36 than patients <75 years.
Previous research has found improvements in the SRI scores
1 year after initiating LTMV in patients with severe COPD (K€ohn-
lein et al., 2014; Struik et al., 2014). One explanation of these dif-
ferences might be the progressive nature of some of the disease
categories might influence HRQoL more clearly in a 6-year study
than in a 1-year follow-up. The severity of COPD (GOLD 2017) is
also reflected in this study with a reduction in the total SRI score
and in five of seven SRI subdomains in the few surviving COPD
patients after 6 years in this study population. Huttmann et al.
(2015), also found reduced HRQoL in individuals receiving LTMV
with chronic lung diseases, compared with those with NMD. How-
ever, the ventilator pressure settings for these 60 patients were
lower compared with some of the other studies (Windisch, 2008;
K€ohnlein et al. (2014). Nevertheless, in this study we observed sig-
nificant reductions in carbon dioxide from before starting LTMV to
baseline in 2008, indicating good physiologic effect of the LTMV
treatment.
4.4 | Limitations of this study
The study has some limitations. Firstly, the study sample is relatively
small and heterogeneous in terms of the diagnoses leading to LTMV,
which means that the sample size is insufficient to perform subgroup
analyses, such as interaction studies between explanatory variables
and HRQoL for the specific subgroups, NMD, OHS, COPD or RTD.
Secondly, non-responders in 2008 had lower FVC than those who
attended, suggesting more severe disease and a lower HRQoL in the
non-participating group, which might influence the representative-
ness of the sample and generalizability of the result. However, infor-
mation about the physiological variables of non-participating LTMV
patients is a strength for the study. Recruiting patients from the
national registry also contributes to strengthen the representative-
ness of the sample and the generalizability of the result, even if the
coverage ratio in the registry was not 100%. Thirdly, there was no
control group in this study. Nonetheless, a RCT evaluation of HRQoL
in patients receiving LTMV vs. a non-ventilated control group of
patients would obviously be considered unethical. Despite the design
was unable to examine causal relationships, the study revealed clini-
cal important explanatory variables for improved HRQoL.
5 | CONCLUSION
This study adds important new knowledge by being the first study
to examine the impact of 6 years of ongoing LTMV on HRQoL using
the specific SRI questionnaire developed for and together with this
patient group. The total SRI score and the scores in four of the
seven subdomains improved in the majority of the patients treated
with LTMV. This study pointed out that patient training, follow-up
and reduction of side effects, a healthcare service largely delivered
by trained nurses, contribute to achieve the main goal of LTMV
treatment- improved HRQoL.
We recommend further prospective studies on HRQoL aspects
in LTMV, including standardized intervention models to minimize
side effects and to improve training, involvement and follow-up of
the patients. LTMV is an expensive treatment for few patients in the
community; to assure larger sample size we recommend international
cooperation and multicentre studies using the SRI questionnaire.
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Per 1 unit increase 2.18 .28
SRI-SS, severe respiratory insufficiency sum score; SD, standard deviation; CI, confidence interval; LTMV, long-term mechanical ventilation; NMD, neuro
muscular disease; COPD, chronic obstructive pulmonary disease; OHS, obesity hypoventilation syndrome; RTD, restrictive thoracic disorders; FVC,
forced vital capacity; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of oxygen.
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Health-related quality of life as predictor
for mortality in patients treated with long-
term mechanical ventilation
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Abstract
Background: The Severe Respiratory Insufficiency (SRI) questionnaire is a specific measure of health-related quality
of life (HRQoL) in patients treated with long-term mechanical ventilation (LTMV). The aim of the present study was
to examine whether SRI sum scores and related subscales are associated with mortality in LTMV patients.
Methods: The study included 112 LTMV patients (non-invasive and invasive) from the Norwegian LTMV registry in
Western Norway from 2008 with follow-up in August 2014. SRI data were obtained through a postal questionnaire,
whereas mortality data were obtained from the Norwegian Cause of Death Registry. The SRI questionnaire contains 49
items and seven subscales added into a summary score (range 0–100) with higher scores indicating a better HRQoL.
The association between the SRI score and mortality was estimated as hazard ratios (HRs) with 95% confidence
intervals (95% CI) using Cox regression models and HRs were estimated per one unit change in the SRI score.
Results: Of the 112 participating patients in 2008, 52 (46%) had died by August 2014. The mortality rate was the
highest in patients with chronic obstructive pulmonary disease (75%), followed by patients with neuromuscular disease
(46%), obesity hypoventilation syndrome (31%) and chest wall disease (25%) (p < 0.001). Higher SRI sum scores in 2008
were associated with a lower mortality risk after adjustment for age, education, hours a day on LTMV, time since
initiation of LTMV, disease category and comorbidity (HR 0.98, 95% CI: 0.96–0.99). In addition, SRI-Physical Functioning
(HR 0.98, 95% CI: 0.96–0.99), SRI-Psychological Well-Being (HR 0.98, 95% CI: 0.97–0.99), and SRI-Social Functioning (HR 0.
98, 95% CI: 0.97–0.99) remained significant risk factors for mortality after covariate adjustment. In the subgroup analyses
of patient with neuromuscular diseases we found significant inverse associations between some of the SRI subscales
and mortality.
Conclusions: SRI score is associated with mortality in LTMV-treated patients. We propose the use of SRI in the daily
clinic with repeated measurements as part of individual follow-up. Randomized clinical trials with interventions aimed
to improve HRQoL in LTMV patients should consider the SRI questionnaire as the standard HRQoL measurement.
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Background
Chronic hypercapnic respiratory failure (CHRF) is a
persistent state in which ventilation is insufficient to main-
tain a normal arterial pressure of carbon dioxide (PaCO2)
[1, 2]. Long-term mechanical ventilation (LTMV) is a
treatment for patients with CHRF due to different aetiol-
ogies and includes both non-invasive and invasive mech-
anical ventilation [2–4]. In adults, CHRF is mainly caused
by the following four disease categories: neuromuscular
diseases (NMD), chest wall diseases (CWD), obesity
hypoventilation syndrome (OHS), and chronic obstructive
pulmonary disease (COPD) [2–4]. The number of individ-
uals treated with LTMV is increasing, and the largest
growth has been observed in the use of a non-invasive
connection to the ventilator through a mask or a mouth-
piece [2, 3]. One of the main goals of LTMV is to improve
survival [2, 4]. Due to ethical reasons, few randomized
controlled trials (RCTs) comparing LTMV versus no
LTMV treatment have been carried out in these patients
[2, 3]. One of the exceptions is RCTs involving COPD pa-
tients with CHRF, where the benefit of LTMV on survival
has been and continues to be debated [3, 5, 6]. Two recent
RCTs found improved one-year mortality in COPD pa-
tients treated with non-invasive LTMV [7, 8]. In NMD pa-
tients LTMV has been well-established for several decades
[2–4]. One of the few RCTs in this heterogenic category
found improved mortality in patients with amyotrophic
lateral sclerosis (ALS) [9].
Additionally, several observational studies and
uncontrolled trials indicated that LTMV has a positive
effect on survival in patients with NMD [10–16],
OHS [10, 13, 17–20] and CWD [10–13, 21–23] rela-
tive to historical controls.
Self-reported health or health-related quality of life
(HRQoL) has been shown to provide prognostic infor-
mation for different groups [11, 24–27]. The Severe
Respiratory Insufficiency (SRI) questionnaire was devel-
oped to specifically measure patient-reported HRQoL in
patients receiving LTMV [28]. The role of SRI in pre-
dicting mortality in patients with CHRF has been exam-
ined during two three-year follow-up studies [29, 30]. In
the first study, the clinical variables body mass index
(BMI), leukocytes, base excess, forced expiratory volume
in one second (FEV1), and inspiratory vital capacity were
included in the multivariate analysis [29]. The SRI score
was associated with mortality in all patients except for
those with COPD [29]. The second study found signifi-
cant relationships between the SRI score and three-year
mortality in LTMV patients with COPD and pulmonary
tuberculosis sequelae after adjustment for BMI, PaCO2
and forced vital capacity (FVC), but without subgroup
analyses for the different diagnosis group [30]. Other
measures of HRQoL, such as St. George’s Respiratory
Questionnaire (SGRQ) and the Maugeri Respiratory
Failure Questionnaire (MRF-28), were associated with
mortality in LTMV-treated COPD patients from 21
study centres during 3 years of follow-up [26]. The SRI
score’s ability to predict mortality in patients treated
with LTMV has been poorly investigated. Furthermore,
findings are inconclusive [29, 30] and the associations
have been investigated for only a limited time period (up
to three years). Longer follow-up time might capture a
more robust association due to higher mortality rates
over time.
Methods
The main objective of the current study was to examine
the association between HRQoL measured by the SRI
questionnaire and all-cause mortality in LTMV patients
over 80 months follow-up.
Study population
This study drew on resources from the Norwegian
Registry for LTMV [31], the Norwegian Patient Registry
[32], and the Norwegian Cause of Death Registry [33].
The registry data were linked by the personal identity
number provided to all Norwegian citizens. The study
was approved by the Regional Committee for Medical
and Health Research Ethics number (273.06, 2012/
1090–11) and the Norwegian Centre for Research Data
(project number 16001). A written consent was a pre-
requisite from the Regional Committee for Medical and
Health Research Ethics and the NPR to allow linking
data between the registries. For cohort patients who
died, exemption from the consent requirement for regis-
ter connection to the Norwegian Patient Registry and
Cause of Death Register was given.
The Norwegian Registry for LTMV was established in
2002 at Haukeland University Hospital, Bergen. The
registry includes all patients in Norway who are treated
with LTMV on a daily basis. The registry contains
detailed information on patient characteristics, medical
diagnosis, LTMV treatment and lung function. The
registry has been described in detail previously [34, 35].
During the period of March to June 2008, patients in
the Norwegian LTMV registry in Western Norway were
invited to participate in the current study. The inclusion
criteria were patients treated with non-invasive or inva-
sive LTMV, over 18 years old and mentally able to an-
swer additional study questions. Well-adapted LTMV
treatment for at least 3 months was required for all par-
ticipants. The invitation letter also included the SRI
questionnaire, a form with questions on socioeconomic
demographic conditions, and questions whether the pa-
tient had received help with completing the information.
Of 211 potential patients in the LTMV registry, 18
patients did not meet the inclusion criteria (Fig. 1). The
remaining 193 eligible patients were invited to participate
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in the study by postal mail, and 65% (n = 127) consented
to participate [34]. Of the 127 patients eligible for
follow-up, written consent to connect comorbidity data
from the NPR were not available from 15 of the patients.
The reason for this were dementia or unable to answer
the question (n = 3), had stopped using LTMV (n = 8),
unable to make contact (n = 1) or did not want to respond
(n = 3). The disease category for these patients were NMD
(n = 6), COPD (n = 2), OHS (n = 6) and CWD (n = 1),
leaving a final study sample of 112 LTMV patients.
The severe respiratory insufficiency (SRI) questionnaire
Study participants were asked to complete the SRI ques-
tionnaire, which is a multidimensional questionnaire
covering physical, psychological and social functioning.
It was developed with a comprehensive methodology by
physicians specialized in pulmonology and psychologists
specialized in HRQoL and by open interviews with pa-
tients with CHRF treated with LTMV. The SRI question-
naire contains 49 items, and each item is categorized in
one of the following seven subscales: SRI-Respiratory
Complaints, SRI-Physical Functioning, SRI-Attendant
Symptoms and sleep, SRI-Anxiety, SRI-Social Relation-
ships, SRI-Social Functioning, or SRI-Psychological
Well-Being. The subscales were added into a summary
scale in which high values (range 0–100) indicate a bet-
ter HRQoL [28]. The SRI questionnaire demonstrates
very good psychometric qualities and has been validated
and translated into several languages [2, 34–40]. The
SRI and MRF-28 questionnaires were recommended for
research on HRQoL in patients treated with LTMV [41].
However, the reliability and validity in were better in the
SRI compared to MRF-28 Questionnaire, Clinical COPD
Questionnaire and Chronic Respiratory Questionnaire in
patients with severe COPD treated with non-invasive
LTMV [42]. The responsiveness of the SRI to changes in
HRQoL after initiating non-invasive LTMV was superior
to the generic questionnaire Short form-36 [43] and the
SRI had the best ability to predict mortality compared to
other HRQoL questionnaires [30]. The English valid-
ation study of the SRI included both non-invasive and
invasive (tracheostomy) ventilated LTMV patients [37].
All-cause mortality
Information on the date of death was obtained from the
Norwegian Cause of Death Registry in October 2014.
The Cause of Death Registry covers all deaths in Norway
and the deaths of Norwegian citizens who die abroad
[33]. All deaths (approximately 40,000 each year) are
reported by doctors, who are required to complete a
standardized death certificate for each death [33].
Other variables
Based on previous research we also obtained data on
educational level [44] and marital status [45]. Educational
level was categorized as primary school, high school or
college/university, and marital status was classified as mar-
ried/cohabiting or single/divorced/widowed. Ventilator
Fig. 1 Flow diagram of patients treated with long-term mechanical ventilation in the prospective cohort study from 2008 to 2014. Follow-up time
was 80months
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dependency was reported by the patients in hours a day
they used the ventilator, the answer options were catego-
rized as follow; less than 8 h, 8–12, 12–24 h a day.
From the LTMV registry, we collected data on patient
age, sex, treatment time since initiation of LTMV, FVC,
FEV1, PaCO2, partial pressure of arterial oxygen (PaO2)
and main medical diagnosis, which was further catego-
rized into NMD, COPD, OHS, and CWD. Studies have
shown that comorbidity is a major prognostic factor in
LTMV patients with NMD [13], COPD [46], OHS [18]
and CWD [22]. Data concerning comorbidity were not
available in the LTMV registry and were therefore col-
lected from the Norwegian Patient Registry (NPR) [33],
In this study, comorbidity was assessed similar to an-
other study [47], as the number of somatic ICD-10 diag-
nosis codes at hospital discharge or an outpatient
control for each patient during the recruitment period
from March to June 2008.
Statistical analysis
Patient characteristics were quantified using descrip-
tive statistics. The description was performed ac-
cording to mean SRI sum score and to mortality
status. We used the Kaplan-Meier survivor function
with the log-rank test to describe the percentage of
survivors according to disease groups (NMD, COPD,
OHS and CWD).
The association between SRI and mortality was esti-
mated as hazard ratios (HRs) with 95% confidence inter-
vals (95% CIs) using Cox regression models and HRs
were estimated per one unit change in the SRI score.
The time in months from study inclusion in 2008 (when
baseline SRI was measured) until death was used as a
measure of event-free time. All patients were followed
up to 80months until censoring, with August 30, 2014,
as the final day of follow-up. We verified that the pro-
portional hazards assumption was fulfilled for SRI, both
in overall analyses and in subgroup analyses of NMD,
COPD and OHS, by visual inspection of log-log plots.
Subgroup analyses of CWD were not performed due to
the small sample size.
The HRs with 95% CIs were estimated both by crude
and adjusted Cox regression models to control for vari-
ables that may potentially confound the true association
between SRI and mortality. The adjustment variables
included age, education, hours a day on LTMV, treat-
ment time since initiation of LTMV, main disease
category and comorbidity. We also evaluated FEV1 and
FVC as confounding factors in the overall analyses of
SRI. To avoid model overfitting in subgroup analysis of
disease categories, only the most important covariates
were included in the regression models (for NMD: age,
hours a day on LTMV, and comorbidity; for COPD: age
and comorbidity; for OHS: comorbidity only).
All statistical analyses were carried out using SPSS
version 20 (SPSS Inc., Chicago, IL, USA) and Stata
SE 14 (StataCorp LP, College Station, TX, USA) for
Windows. All statistical tests were two-sided, and p




The study sample comprised 112 LTMV-treated pa-
tients. Of these patients, 48 (43%) were diagnosed with
NMD, 24 (21%) with COPD, 32 (29%) with OHS, and 8
(7%) with CWD. At baseline, 103 (92%) patients received
non-invasive LTMV, whereas 9 (8%) patients, with
NMD, were ventilated invasively via tracheostomy. The
mean BMI (n = 71) was 27.1 (9.5) in NMD patients, 29.2
(9.1) in COPD patients, 40.6 (7.7) in OHS patients, and
22.5 (5.1) kg/m2 in CWD patients.
The baseline mean SRI sum score varied considerably
by sex, age group, education level, LTMV hours a day,
years on LTMV, disease category and comorbidity
(Table 1). The SRI sum score in invasively (n = 10) and
non-invasively (n = 117) ventilated patients was 57.0 (16.2)
and 58.0 (18.8), respectively. Assistance to complete the
SRI questionnaire was reported by 26% of the study
participants.
Among the respiratory variables, baseline FEV1 and
FVC correlated significantly with all SRI subscales ex-
cept for SRI-Attendant symptoms and sleep scale and
SRI-Social Functioning (Additional file 1: Table S1).
Baseline PaO2 correlated significantly with SRI-Physical
Functioning only. All participants were receiving ventila-
tion treatment at study start, and PaCO2 levels were
therefore normalized at baseline. An inverse correlation
between baseline PaCO2 and SRI-Social Relationships
was present, but no other associations were found for
the SRI sum score or for any of the six remaining SRI
subscales (Additional file 1: Table S1).
During the 80 months of follow-up, 52 (46%) patients
died (Fig. 1). By Kaplan-Meier survival analyses (Fig. 2),
we found that patients with COPD had the highest over-
all mortality rate (75%), followed by patients with NMD
(46%), OHS (31%) and CWD (25%) (p < 0.001) (Fig. 2).
The mortality rates differed between age groups, educa-
tion levels, LTMV hours a day, years on LTMV, disease
categories and burden of comorbidity (Table 2), but not
between men and women (p = 0.88), and between mar-
ried /cohabiting and single/divorced/widowed (p = 0.91).
We found significant differences between survivors and
deceased patients in baseline mean FEV1 and FVC (both
p < 0.001), and a minor difference in PaO2 that was not
statistically significant (Table 2). There was no signifi-
cant difference in PaCO2 between the survivors and
deceased patients (Table 2).
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SRI sum and subscales in relation to mortality
Crude analyses of baseline SRI showed significantly higher
mean values among the survivors compared to the de-
ceased for the SRI sum score and SRI subscales except in
the SRI-Attendant symptoms and sleep scale (Table 3).
The association between the SRI sum score and mor-
tality remained significant after adjustment for age, edu-
cation level, hours a day on LTMV, treatment time since
initiation of LTMV, disease category and comorbidity
(HR 0.98, 95% CI: 0.96–0.99). In addition, SRI-Physical
Functioning (HR 0.98, 95% CI: 0.96–0.99),
SRI-Psychological Well-Being (HR 0.98, 95% CI: 0.97–
0.99), and SRI-Social Functioning (HR 0.98, 95% CI:
0.97–0.99) remained significant risk factors for mortality
after covariate adjustment (Table 4). Additional adjust-
ment for baseline FVC and FEV1 did not alter the results
much for SRI sum score (adjustment for FVC: HR 0.97,
95% CI: 0.94, 0.99); adjustment for FEV1: HR 0.97, 95%
CI 0.94, 0.99).
Among NMD patients, SRI-Physical Functioning (HR
0.97, 95% CI: 0.94–1.00), SRI-Psychological Well-Being
(HR 0.97, 95% CI: 0.95–0.99) and SRI-Social Functioning
(HR 0.97, 95% CI: 0.94–0.99) remained significant
factors for mortality after adjustment for age, hours a
day on LTMV and comorbidity (Table 5).
In COPD patients, SRI-Attendant Symptoms and Sleep
(HR 0.97, 95% CI: 0.94–1.00) and SRI-Psychological
Well-Being (HR 0.98, 95% CI: 0.96–1.00) remained associ-
ated with mortality after adjustment for age and comor-
bidity (Table 6). The SRI sum score or subscales were not
associated with mortality among patients with OHS (Add-
itional file 1: Table S2).
Discussion
We found that HRQoL, as measured by the SRI question-
naire, was inversely associated with mortality in LTMV
patients before and after adjustment for covariates. In the
total group of LTMV patients, the adjusted analyses showed
significant inverse associations between mortality and the
SRI sum score and the SRI subscales, ‘physical functioning’,
‘social functioning’ and ‘psychological well-being’. Further-
more, mortality varied considerably between the disease
groups during the six-year period. The highest mortality
was among COPD patients with established CHRF receiv-
ing LTMV. The majority of mortality in COPD is related to
cardiac disease and the requirement of LTMV in COPD
might be understood as a marker of overall frailty and
multi-system disease severity. The lowest mortality was in
the CWD group, reflecting the non-progressive nature of
the disease in these patients.
As shown in previous studies [3, 10–13, 23], mortality
in patients treated with LTMV is associated with under-
lying disease categories. Previous studies have shown large
variations in the attending patient categories, severity of
disease, and follow-up times. Thus, a direct comparison of
mortality between studies on patients with LTMV is
challenging and might lead to an oversimplification.
HRQoL as a prognostic factor
The association between poor HRQoL and increased
mortality in the total group of LTMV patients is consist-
ent with the main findings of other similar studies on
Table 1 Baseline sum score of the Severe Respiratory Insufficiency
questionnaire by background characteristics in 112 patients treated







Female 48 51.4 (16.7)
Male 57 57.7 (19.5)
Age
≤ 60 37 59.0 (16.7)
> 60 68 52.5 (19.2)
Education
Primary school 31 50.0 (20.5)
High school 41 52.2 (16.0)
College/university 33 62.5 (17.6)
Marital status
Married /cohabiting 60 54.7 (19.1)
Single/divorced/widowed 45 54.9 (18.0)
LTMV h/day
5–8 45 57.9 (18.3)
8–12 42 55.2 (18.8)
12–24 16 44.9 (17.1)
Years on LTMV
≤ 4 60 51.9 (18.2)
> 4 45 58.6 (18.4)
Disease
NMD 43 60.0 (14.8)
COPD 23 41.1 (18.3)
OHS 31 58.0 (18.5)
CWD 8 54.3 (21.1)
Co-morbidity
No additionally diagnosis 41 60.2 (17.6)
1 additionally diagnosis 28 55.7 (17.9)
≥ 2 additionally diagnosis 36 48.0 (18.3)
Abbreviations: SRI-SS, Severe Respiratory Insufficiency sum score; SD, standard
deviation; CI, confidence interval; LTMV, long-term mechanical ventilation;
NMD, neuro muscular disease; COPD, chronic obstructive pulmonary disease;
OHS, obesity hypoventilation syndrome; CWD, chest wall diseasese
a Numbers do not add to 112 due to missing in the Severe Respiratory
Insufficiency questionnaire, as well as missing in education level, marital status
and daily hours on LTMV responses
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LTMV patients [30, 31]. In line with Budweiser (2007a),
crude analyses of SRI were significantly associated with
mortality in all SRI subscales, with the exception of the
‘attendant symptoms and sleep’ scale.
The adjusted analyses among NMD patients showed
that SRI ‘physical functioning’, ‘psychological well-being’
and ‘social functioning’ continued to be significant factors
for mortality, which was consistent with the study by
Budweiser [30], but with different adjustment variables
than those in our study. We also found associations
between SRI and mortality among COPD patients in the
adjusted analyses in the ‘attendant symptoms and sleep’
and ‘psychological well-being’ SRI subscales.
The initial choice of the adjustment variables in the
present study was based on previous work that evaluated
age [10, 15, 26, 45], sex [18, 48], education level [44], mari-
tal status [45], disease categories (NMD, COPD, OHS and
CWD) [2, 3, 10–13, 23] and comorbidity [13, 18, 22, 46].
The variables ventilator dependency and time since LTMV
was initiated were chosen a priori. Marital status was not
associated with neither mortality nor the SRI sum score
and was therefore excluded as adjustment variable.
There were no sex differences between survivors and
those who deceased, thus sex also was excluded as an
adjustment variable.
However, we have considered the possibility that
HRQoL could be influenced by other confounding
covariates that might also pose a risk of death, such as
PaCO2. Reduced PaCO2 levels have been related to
lower one-year mortality and improved SRI scores in
COPD patients treated with LTMV [7, 8]. On the other
hand, exploratory analyses did not identify any signifi-
cant correlations between changes in hypercapnia status
or baseline hypercapnia status and mortality in this group
[5]. However, in the present study, PaCO2 values were
normalized at baseline as a result of ongoing LTMV and
were therefore not included in the analyses. The results
from studies on lung function and survival in LTMV pa-
tients are not conclusive. Some studies [19, 23, 30] re-
ported associations between low FEV1 and FVC and
mortality, whereas another study [11] found no differences
in baseline lung function between the survivors and de-
ceased patients. When FVC and FEV1 were added to the
Cox regression analysis in the current study, the result
was altered only slightly; however, this result might also be
influenced by missing lung function data (FVC baseline
numbers did not sum to 112 due to 23 missing data
points, FEV1 baseline numbers did not sum to 112 due to
22 missing data points), some of the missing data might
be explained due to patients having difficulties performing
the spirometry test.
We also considered to include ventilation mode as a
covariate as longer survival were reported in patients
with DMD using non-invasive LTMV compared to those
receiving LTMV via a tracheostomy [14, 49]. However,
another study concluded that the risk of death was not
associated with use of invasive versus non-invasive
LTMV in patients with DMD [16], No significant differ-
ence in one year mortality was found between patients
receiving LTMV via a tracheostomy and those weaned
after discharged from the Intensive Care Unit (ICU) and
no significant difference in HRQoL measured by SRI at
Fig. 2 Kaplan-Meier survival estimates in patients treated with long-term mechanical ventilation between 2008 and 2014. Follow-up time was 80
months. Abbreviations: NMD, neuro muscular disease; COPD, chronic obstructive pulmonary disease; OHS, obesity hypoventilation syndrome;
CWD, chest wall diseasese
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discharge from ICU were found between the two groups
[50]. However, HRQoL tended to be lower, in the SRI
‘physical functioning’, while scores for ‘anxieties’ tended to
be better in patients receiving LTMV via tracheostomy
compared to those treated with non-invasive LTMV [51].
Although the analyses in the present study were ad-
justed for education level, other economic confounding
variables, such as income, might also have an impact on
HRQoL and mortality. On the other hand, Norwegian
society and health care services probably represent one
of the most equitable systems worldwide, where all
citizens have equal access to health care services. Never-
theless, the number of covariates that could be included
in the analyses in this study was limited by the sample
size at baseline, and we can never exhaustively cover all
variables of minor importance among LTMV patients.
Table 2 Background variables at baseline in the survivors and deceased individuals treated with LTMV between 2008 and 2014
Characteristic All participants, n (n = 112) Survivors, n (%) (n = 60) Deceased, n (%) (n = 52)
Sex
Female 53 28 (53) 25 (47)
Male 59 32 (54) 27 (46)
Age
≤ 60 38 26 (68) 12 (32)
> 60 74 34 (46) 40 (54)
Education
Primary school 33 18 (55) 15 (45)
High school 44 23 (52) 21 (48)
College/university 35 19 (54) 16 (46)
Marital status
Married /cohabiting 64 34 (53) 30 (47)
Single/divorced/widowed 48 26 (54) 22 (46)
LTMV h/daya
5–8 50 33 (66) 17 (34)
8–12 42 23 (55) 19 (45)
12–24 17 2 (12) 15 (88)
Years on LTMV
≤ 4 65 33 (51) 32 (49)
> 4 47 27 (57) 20 (43)
Disease
NMD 48 26 (54) 22 (46)
COPD 24 6 (25) 18 (75)
OHS 32 22 (69) 10 (31)
CWD 8 6 (75) 2 (25)
Co-morbidity
No additionally diagnosis 44 32 (73) 12 (27)
1 additionally diagnosis 29 18 (62) 11 (38)
≥ 2 additionally diagnosis 39 10 (26) 29 (74)
Respiratorya
FVC (litre) (mean, SD) 89 2.64 (1.15) 1.89 (0.93)
FEV1(litre) (mean, SD) 90 1.88 (1.04) 1.16 (0.70)
PaCO2 kPa daytime (mean, SD) 84 5.61 (0.76) 6.01 (1.06)
PaO2 kPa daytime (mean, SD) 69 10.1 (1.78) 9.14 (1.92)
Abbreviations: LTMV, long-term mechanical ventilation; NMD, neuro muscular disease; COPD, chronic obstructive pulmonary disease; OHS, obesity hypoventilation
syndrome; CWD, chest wall disorders; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; PaCO2, partial pressure of arterial carbon dioxide;
PaO2, partial pressure of arterial oxygen
a Numbers do not add to 112 due to missing in daily hours on LTMV and respiratory variables
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Why and how SRI predicts mortality
Previous studies using patient-reported measures other
than SRI have also reported an association between
self-reported health and mortality in patients treated
with LTMV [11, 26]. However, these studies did not
adjust for the same covariates as the present study, and
they lacked important variables, such as comorbidity
and education level. There is a large body of evidence on
the association between self-reported health measures
and mortality in other settings and disorders, such as in
communities [24], in patients with cancer [25] and idio-
pathic pulmonary fibrosis [27]. Explanations of these
consistent findings are complex and imply that survey
respondents’ perceptions of health status are holistic;
they include information on medical status but that
information might be evaluated differently by men and
women in different social positions, with different refer-
ence groups providing different social comparisons [24].
Further, the accuracy of self-reported health as a pre-
dictor of mortality depends on the comprehensiveness
and accuracy of the information that the person incor-
porates into the self-rating [52]. This hypothesis corre-
sponds with SRI as a multidimensional comprehensive
questionnaire that captures the symptoms of CHRF and
covers essential aspects of LTMV patients’ daily life [28].
Clinical implication of the associations between SRI and
mortality
Individuals suffering from CHRF treated with LTMV often
have an incurable disease [2–4]. Health care professionals
and relatives tend to behave differently depending on
whether the disease is perceived as a chronic or terminal
condition. However, the distinction between the patient’s
condition as chronic or terminal might become vague and
can sometimes be ambiguous and difficult to interpret
[53]. Prognostic information from the SRI questionnaire
might provide valuable knowledge on how to cope with
these situations, improving treatment plans and commu-
nication between involved professionals, family members,
and the LTMV patient. Our study demonstrates that the
Table 3 Mean baseline scores (both sum score and subscales) of the Severe Respiratory Insufficiency questionnaire in patients
treated with long-term mechanical ventilation between 2008 and 2014
SRI Survivors (n = 60) Deceased (n = 52) P
valuebna mean (SD) na mean (SD)
SRI- Sum Score (SS) 58 60.0 (18.3) 47 48.4 (16.8) 0.001
SRI- Physical Functioning (PF) 59 45.9 (23.0) 50 26.9 (21.3) < 0.001
SRI- Respiratory Complaints (RC) 59 61.0 (22.4) 50 51.1 (22.6) 0.02
SRI- Attendant Symptoms and Sleep (AS) 59 53.3 (20.1) 50 55.8 (20.2) 0.53
SRI- Social Relationships (SR) 59 70.7 (24.4) 49 59.0 (21.8) 0.01
SRI- Anxiety (AX) 59 64.2 (27.5) 49 52.9 (27.2) 0.03
SRI- Psychological Well-Being (WB) 58 66.2 (22.0) 47 52.3 (22.9) 0.002
SRI- Social Functioning (SF) 59 56.5 (24.6) 49 39.1 (18.7) < 0.001
Abbreviations: SRI, Severe Respiratory Insufficiency; SD, standard deviation
a Numbers do not add to 60 and 52 due to missing in the Severe Respiratory Insufficiency questionnaire
b By two-sample t-test
Table 4 Hazard ratios for mortality by baseline scores (both sum score and subscales) of the Severe Respiratory Insufficiency
questionnaire in all patients (n = 112) treated with long-term mechanical ventilation between 2008 and 2014
SRI Crude Adjusteda
N b HR 95% CI P value HR 95% CI P value
SRI- Sum Score (SS) 103 0.97 (0.95, 0.98) 0.001 0.98 (0.96, 0.99) 0.04
SRI- Physical Functioning (PF) 107 0.97 (0.95, 0.98) < 0.001 0.98 (0.96, 0.99) 0.007
SRI- Respiratory Complaints (RC) 107 0.98 (0.97, 0.99) 0.01 0.99 (0.98, 1.01) 0.28
SRI- Attendant Symptoms and Sleep (AS) 107 1.00 (0.99, 1.02) 0.50 0.99 (0.98, 1.01) 0.64
SRI- Social Relationships (SR) 106 0.98 (0.97, 0.99) 0.009 0.99 (0.98, 1.00) 0.14
SRI- Anxiety (AX) 106 0.99 (0.99, 1.00) 0.03 0.99 (0.98, 1.00) 0.25
SRI- Psychological Well-Being (WB) 103 0.98 (0.97, 0.99) 0.001 0.98 (0.97, 0.99) 0.009
SRI- Social Functioning (SF) 106 0.97 (0.96, 0.99) < 0.001 0.98 (0.97, 0.99) 0.02
Abbreviations: SRI Severe Respiratory Insufficiency, HR hazard ratio, CI confidence interval
a Adjusted for age, education level, daily hours on LTMV, treatment time since initiation of LTMV, disease category and comorbidity
b Numbers do not add to 112 due to missing in the Severe Respiratory Insufficiency questionnaire
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risk of death decreases by each unit increase in the SRI
score. This result suggests that LTMV patients with low
SRI should be identified, initiating thorough consider-
ations on how to improve HRQoL. However, whether the
relationship between mortality and quality of life is causal
and changes in HRQoL status in some way influences
mortality cannot be confirmed in this study design.
The minimal clinically important difference of the SRI
questionnaire has not been defined [41]. However, the
great numerical difference in SRI score at baseline
between the surviving LTMV patients and those who
died during the follow-up, support the clinical relevance
of the study.
Strengths and limitations
As far as we are aware, this study is among the very first
to examine SRI scores as a predictor for mortality in
LTMV patients with a follow-up time as long as 80
months. The strengths of the study include the use of
standardized data collection [32–34], including relevant
confounders, such as comorbidity, which is often lacking
in study of this type, and the prospective study design.
Another strength is the use of the specific and validated
SRI questionnaire, which can capture HRQoL related to
symptoms and the experience of having CHRF and
LTMV [2, 28–30, 34–43].
The study has some limitations. First, its small sample
size may decrease the statistical power to detect clinic-
ally relevant associations in multivariate Cox analyses.
Second, comorbidity modeled simply as the number of
somatic diagnoses. Charlson Comorbidity Index [54] is a
common index to measure comorbidity using ICD-10
codes. However, as complete ICD-10 codes were not
available in our data, we chose to measure comorbidity
as the number of somatic diagnoses. Thirdly, some of
the LTMV patients answered that they received help to
complete the questionnaire, which might introduce
some information bias in SRI scores. However, it is of
Table 5 Hazard ratios for mortality by baseline scores (both sum score and sub-scales) of the Severe Respiratory Insufficiency
questionnaire in neuromuscular patients (n = 48) treated with long-term mechanical ventilation between 2008 and 2014
SRI Crude Adjusteda
Nb HR 95% CI P value HR 95% CI P value
SRI- Sum Score (SS) 43 0.97 (0.94, 1.00) 0.09 0.97 (0.93, 1.01) 0.16
SRI- Physical Functioning (PF) 46 0.97 (0.94, 0.99) 0.008 0.97 (0.95, 1.00) 0.05
SRI- Respiratory Complaints (RC) 45 1.00 (0.98, 1.02) 0.88 0.99 (0.97, 1.02) 0.67
SRI- Attendant Symptoms and Sleep (AS) 45 1.01 (0.99, 1.03) 0.20 1.00 (0.98, 1.03) 0.43
SRI- Social Relationships (SR) 45 0.98 (0.96, 1.00) 0.14 0.99 (0.96, 1.01) 0.30
SRI- Anxiety (AX) 45 0.99 (0.98, 1.01) 0.46 0.99 (0.97, 1.01) 0.32
SRI- Psychological Well-Being (WB) 43 0.98 (0.96, 1.00) 0.08 0.97 (0.95, 0.99) 0.03
SRI- Social Functioning (SF) 44 0.96 (0.94, 0.99) 0.002 0.97 (0.94, 0.99) 0.02
Abbreviations: SRI Severe Respiratory Insufficiency, HR hazard ratio, CI confidence interval
a Adjusted for age, daily hours on LTMV and comorbidity
b Numbers do not add to 48 due to missing in the Severe Respiratory Insufficiency questionnaire
Table 6 Hazard ratios for mortality by baseline scores (both sum score and sub-scales) of the Severe Respiratory Insufficiency
questionnaire in chronic obstructive pulmonary disease patients (n = 24) treated with long-term mechanical ventilation between
2008 and 2014
SRI Crude Adjusteda
Nb HR 95% CI P value HR 95% CI P value
SRI- Sum Score (SS) 23 0.98 (0.95, 1.01) 0.14 0.97 (0.95, 1.01) 0.19
SRI- Physical Functioning (PF) 23 0.98 (0.95, 1.01) 0.16 0.97 (0.93, 1.01) 0.13
SRI- Respiratory Complaints (RC) 23 0.98 (0.95, 1.01) 0.33 0.98 (0.95, 1.01) 0.26
SRI- Attendant Symptoms and Sleep (AS) 23 0.98 (0.96, 1.01) 0.15 0.97 (0.95, 1.00) 0.10
SRI- Social Relationships (SR) 23 0.99 (0.97, 1.01) 0.08 0.98 (0.99, 1.01) 0.37
SRI- Anxiety (AX) 23 0.99 (0.97, 1.01) 0.32 0.99 (0.97 1.01) 0.34
SRI- Psychological Well-Being (WB) 23 0.98 (0.96, 1.00) 0.07 0.98 (0.96, 1.00) 0.13
SRI- Social Functioning (SF) 23 0.99 (0.97, 1.01) 0.50 0.99 (0.97, 1.01) 0.64
Abbreviations: SRI Severe Respiratory Insufficiency, HR hazard ratio, CI confidence interval
a Adjusted for age and comorbidity
b Numbers do not add to 24 due to missing in the Severe Respiratory Insufficiency questionnaire
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great importance to include the SRI scores from patients
who needed help to fill out the questionnaire.
In addition, because of the observational study design,
we cannot exclude the possibility of residual or unknown
confounding. Whether HRQoL score reflects a percep-
tion by the LTMV patient of progression of her or his
condition or whether change in HRQoL status in some
way also influences the course of the condition is an in-
teresting question. However, the research design cannot
confirm causality between improvement in HRQoL and
survival in this study. To address this question a ran-
domized interventional study aiming to improve HRQoL
with a control group receiving standard treatment would
be more suitable.
Conclusion
This study suggests that SRI is an important factor in prog-
nostic mortality models in LTMV-treated patients. The de-
sign and data do not allow us to imply any causal
relationships between a change in HRQoL and a change in
mortality. We propose an active use of the SRI question-
naire in the daily clinic with repeated measurements as part
of individual follow-up. Future studies on this topic should
be larger and preferably organized as multicentre long-term
RCTs, including specific interventions aimed at improving
HRQoL in LTMV patients, compared to standard care.
Even if there is no comparison in this paper made between
SRI and other quality of life measures, we suggest SRI to be
used as the quality of life measure in the studies to come.
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Forespørsel om å delta i oppfølgingsundersøkelse om hvordan det er å leve 
med hjemmerespirator eller annet hjelpemiddel til pustestøtte 
Helse Bergen HF 
Haukeland universitetssjukehus, Jonas Liesvei 65, 5021 Bergen | Tlf 05300  
Org. nr: 983 974 724 postmottak@helse-bergen.no 
Tusen takk for at du i 2008 svarte på spørreskjema om hvordan det er å leve med hjemmerespirator 
eller annet hjelpemiddel til pustestøtte. Undersøkelsen bidro blant annet til testing og norsk 
godkjenning av et internasjonalt spørreskjema om livskvalitet til denne gruppe pasienter. Du kontaktes 
nå med spørsmål om å delta i en oppfølgingsundersøkelse. Vi håper at du vil fylle ut tilsvarende 
spørreskjema som du gjorde i 2008. Vi vil også spørre om din tillatelse til å sammenstille data fra 
denne undersøkelsen med opplysninger fra Norsk Pasient register.  
 
Studiens hensikt: 
Helsevesenet i Norge har mangelfulle opplysninger og kunnskap om hvordan det er å leve med 
hjemmerespirator eller annet hjelpemiddel til pustestøtte. Informasjon fra deg er viktig for å gi best 
mulig behandlingstilbud til personer som bruker eller er avhengig av denne type behandling.   
 
Gjennomføring av undersøkelsen og hva dette innebærer for deg: 
Neste gang du har time i Poliklinikken vil jeg kontakte deg for utfylling av spørreskjema. Det tar ca. 
30 minutter å fylle ut spørreskjemaene.  
 
Taushetsplikt 
Alle medarbeidere i prosjektet har taushetsplikt og datamateriale behandles konfidensielt. 
Opplysningene avidentifiseres ved registrering. Datamateriale som inngår i undersøkelsen blir 
oppbevart og lagret etter gjeldende retningslinjer og vil bli oppbevart i 10 år for evt. en 
oppfølgingsundersøkelse. Data fra Nasjonalt register for langtids mekanisk ventilasjon vil bli innhentet 
for å få utvidet kunnskap om behandlingen.  Prosjektet er tilrådd av Personvernombudet for forskning, 
Norsk samfunnsvitenskapelig datatjeneste. Studien er godkjent av Regional komite for medisinsk 
forskningsetikk, Vest Norge. 
 
Frivillig deltakelse: 
Deltakelse er frivillig. Det vil ikke få noen betydning for ditt forhold til behandlere eller helsetjenesten 
dersom du ikke ønsker å svare på spørreskjemaene.  
 
Prosjektgruppe: 
Studien er et samarbeidsprosjekt mellom Lungeavdelingen, Nasjonal Kompetansetjeneste for 
hjemmerespiratorbehandling, Haukeland Universitetssykehus og Institutt for global helse og 
samfunnsmedisin ved Universitetet i Bergen. Professor Gerd Karin Natvig er hovedveileder i 
prosjektet, og seksjonsoverlege /førsteamanuensis, Sverre Lehmann er biveileder.   
 
Har du spørsmål, ta gjerne kontakt. Jeg kan treffes på telefon 55 97 35 49/ mobil 97499915 eller  




Heidi Øksnes Markussen 
Master i helsefag/ Intensivsykepleier 
Lungeavdelingen/ Nasjonal Kompetansetjeneste for hjemmerespiratorbehandling  
Haukeland Universitetssjukehus 









Erklæring om samtykke  
 
 
Jeg er gjennom vedlagt informasjonsskriv gjort kjent med at det skal gjennomføres en 
oppfølgingsundersøkelse om hvordan det er å leve med hjemmerespirator eller annet 
hjelpemiddel til pustestøtte. Jeg er også gjort kjent med studiens formål og hvordan 
opplysninger skal innhentes og registreres.  
 
Jeg samtykker herved på å delta i studien samt at data fra studien kan kobles sammen med 























9. Dersom du er tilkoblet pustestøtte via maske, hvilken maske bruker du? (sett ett eller flere kryss) 
Nesemaske    Maske som dekker både munn og nese    Munnstykke    Munnmaske   
 
 
10. Har du problemer med bruk av masken? (sett ett kryss) 
Ja   Nei   
 
 
11. Hvis JA, hvilke problemer har du? (sett ett eller flere kryss) 
Lekkasje   Trykksår   Kondens   
Annet  
…………………………………………………………………………………………………………… 
   
 
12. Hvor fikk du opplæring i bruk av din hjemmerespirator eller din BIPAP? (sett ett eller flere kryss) 
Sykehus poliklinikk   Sykehus sengepost   Seksjon for behandlingshjelpemidler   





Kan du krysse av på følgende utsagn: 
 Stemmer  



















13. Jeg fikk tilstrekkelig opplæring i 
bruk av min hjemmerespirator 
eller min BIPAP  
  




14. Trenger du hjelp til daglig til bruk av din hjemmerespirator eller din BIPAP? (sett ett kryss) 
Ja   Nei   
 
 
15. Hvis Ja, hvem er det som hjelper deg ? (sett ett eller flere kryss) 
Personlig assistent   Ektefelle/samboer   Barn   Hjemmesykepleien   







Dersom du har behov for personlig assistent eller hjelp fra hjemmesykepleien kan du krysse av på 
følgende utsagn: 
 Stemmer  



















16. Mine hjelpere har fått 
tilstrekkelig opplæring 
 
     
17. Jeg får tilstrekkelig hjelp    
 
     
 
 
18. Har du hatt hjemmebesøk av helsepersonell fra spesialist helsetjenesten (personell fra sykehuset)? 
(sett ett kryss)     
Ja   Nei   
 
 
19. Dersom ja, hvor ofte? 
Ca. 1 gang pr. halvår   Ca.1 gang pr.år   Sjeldnere enn 1 gang pr. år   
Annet   
…………………………………………………………………………………………………... 
 
Vedr. oppfølging fra spesialisthelsetjenesten /sykehuset kan du krysse av på følgende utsagn: 
 Stemmer  



















20. Jeg opplever å få tilstrekkelig 
oppfølging 
 
     
 
 
Hvordan vil du beskrive din livssituasjon: 
 Stemmer  



















21. Jeg føler meg trygg i min 
hjemmesituasjon 
 




22. Har du hatt hjelp til å fylle ut spørreskjemaet? (sett et kryss) 





Vennligst se etter at du har svart på alle spørsmål. 
 
Takk for hjelpen! 
  ID  
The Severe Respiratory Insufficiency Questionnaire (SRI) ble utviklet i 2003 av W. Windisch, Universitätsklinik Freiburg.  
Oversatt til norsk og validert av H. Markussen ved Nasjonal kompetansetjeneste for hjemmerespiratorbehandling,  
Haukeland Universitetssjukehus 
            
Spørreskjema til deg som bruker maskinell pustestøtte  
hele eller deler av døgnet 
 
Følgende spørsmål berører den generelle helsetilstanden din.  
Utsagnene nedenfor tar for seg forskjellige aspekter ved det daglige liv. 
Hvordan har du hatt det i løpet av den siste uken?  
Vennligst sett et kryss ved svaret som passer best med HVERT enkelt utsagn. 
 
 Stemmer  

















1. Det er vanskelig å gå i trapper. 
 
     
2. Jeg har tung pust under måltider. 
 
     
3. Jeg kan gå ut om kvelden. 
 
     
4. Jeg føler meg ofte dårlig. 
 
     
5. Selv uten fysiske anstrengelser har 
jeg pustevansker. 
 
     
6. Jeg har ofte hodepine. 
 
     
7. Jeg har mange venner og bekjente. 
 
     
8. Jeg er bekymret for at sykdommen 
min skal bli verre. 
 
     
9. Jeg har ingen problemer med å sovne.  
 
     
10. Jeg kan godt omgås andre mennesker. 
 
     
11. Jeg er av og til svimmel. 
 
     
12. Jeg våkner med tung pust om natten. 
 
     
13. Jeg er redd for å få pustevansker om 
natten. 
 
     
14. Jeg har ofte vondt i nakken. 
 
     
15. Jeg er sterkt bundet til hjemmet mitt.  
 
     
16. Husarbeid er vanskelig for meg.  
 







  ID  
The Severe Respiratory Insufficiency Questionnaire (SRI) ble utviklet i 2003 av W. Windisch, Universitätsklinik Freiburg.  
Oversatt til norsk og validert av H. Markussen ved Nasjonal kompetansetjeneste for hjemmerespiratorbehandling,  
Haukeland Universitetssjukehus 
 
Hvordan har du hatt det i løpet av den siste uken?  
Vennligst sett et kryss ved svaret som passer best med HVERT enkelt utsagn. 
 
 Stemmer  


















17. Jeg våkner ofte om natten. 
 
     
18. Jeg sover godt hele natten. 
 
     
19. Jeg er ofte kortpustet. 
 
     
20. Jeg ser positivt på framtiden. 
 
     
21. Jeg har følelsen av å være ensom. 
 
     
22. Jeg er tungpusten når jeg snakker. 
 
     
23. Det anstrenger meg veldig å få besøk. 
 
     
24. Jeg hoster mye. 
 
     
25. Jeg har ofte slim i luftveiene. 
 
     
26. Jeg unngår situasjoner der mine 
pustevansker kan gjøre det pinlig for 
meg. 
     
27. Jeg føler meg vel sammen med venner 
og bekjente. 
 
     
28. Jeg er redd for å få anfall med 
tungpust. 
 
     
29. Jeg er tungpusten ved fysisk 
anstrengelse. 
 
     
30. Jeg er irritert over innskrenkningene 
som min sykdom medfører. 
 
     
31. Mitt ekteskap /parforhold lider under 
sykdommen min. 
 
     
32. Jeg kan gå og handle. 
 
     
33. Jeg kan utøve alle fritidsaktiviteter 
som interesserer meg. 
 
     
 
 
  ID  
The Severe Respiratory Insufficiency Questionnaire (SRI) ble utviklet i 2003 av W. Windisch, Universitätsklinik Freiburg.  
Oversatt til norsk og validert av H. Markussen ved Nasjonal kompetansetjeneste for hjemmerespiratorbehandling,  
Haukeland Universitetssjukehus 
 
Hvordan har du hatt det i løpet av den siste uken?  
Vennligst sett et kryss ved svaret som passer best med HVERT enkelt utsagn. 
 
 Stemmer  




















34. Jeg føler meg ofte irritabel. 
 
     
35. På grunn av sykdommen min er 
kontakten med venner/bekjente 
innskrenket. 
 
     
36. Jeg gleder meg over livet mitt. 
 
     
37. Jeg kan delta på sosiale 
sammenkomster. 
 
     
38. Jeg er ofte trist. 
 
     
39. Pustevanskene mine plager meg 
       når jeg er ute blant folk. 
 
     
40. Jeg er ofte nervøs. 
 
     
41. Jeg kan kle på meg selv. 
 
     
42. Jeg er trett på dagtid. 
 
     
43. Jeg føler meg isolert. 
 
     
44. Jeg klarer meg fint når det gjelder 
sykdommen min. 
 
     
45. Mine pusteplager hemmer meg i 
dagligdagse aktiviteter. 
 
     
46. Sykdommen belaster familielivet mitt. 
 
     
47. På grunn av mine pusteplager har jeg 
brutt kontakten med andre mennesker. 
 
     
48. Mine fritidsmuligheter er innskrenket. 
 
     
49. Generelt er jeg fornøyd med livet mitt. 
 
     
 
Tusen takk for utfylling av spørreskjemaet! 
 
 
                                                               © W. Windisch, Universitätsklinik Freiburg 
                                                                            Oversatt til norsk og validert, H. Markussen,  
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For å gjøre verdiene sammenlignbare oppgis svaralternativene i tall fra 1 til 5: 
Stemmer ikke                  =>   1 
Stemmer nesten ikke     =>   2 
Stemmer delvis         =>   3 
Stemmer ganske bra       =>   4 
Stemmer helt       =>   5 
 
Deretter blir sifrene rekodet slik at de høyere sifrene skal samsvare med sin: 
 
Råverdi               Rekodet verdi 
1   →  5 
2   →   4 
3   →   3 
4   →   2 
5   →   1 
 
I neste omgang blir skalaene beregnet. Middelverdiene utregnes dersom minst   
halvparten av punktene er besvart. Ved hjelp av formlene nedenfor blir råverdiene 
omgjort til skalaverdier mellom 0 og 100. 
 
Punkter som skal rekodes : 
1, 2, 4, 5, 6, 8, 11, 12, 13, 14, 
15, 16, 17, 19, 21, 22, 23, 24, 
25, 26, 28, 29, 30, 31, 34, 35, 
38, 39, 40, 42, 43, 45, 46, 47, 
48;   
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1]45,41,33,32,16,1[ •−=− MeanPFSRI  
 
Attendant Symptoms and Sleep 
100
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1]48,47,37,35,31,23,15,3[ •−=− MeanSFSRI  
 
Totalsummen (SRI-SS = sumskala) regnes ut etter skalaverdienes middelverdi (SRI-
RC, SRI-PF, SRI-AS, SRI-SR, SRI-AX, SRI-WB, SRI-SF). Dersom verdiene i en  
skala mangler, skal beregningen utelates. I vurderingen tilsvarer høye verdier høy 
livskvalitet , mens lave verdier står for lav livskvalitet. 
INTRODUKSJON: Dette spørreskjemaet handler om hvordan du ser på din egen helse. Disse
opplysningene vil hjelpe oss til å få vite hvordan du har det og hvordan du er i stand til å utføre dine
daglige gjøremål.
Hvert spørsmål skal besvares ved å sette et kryss (X)  i den boksen som passer best for deg. Hvis du er
usikker på hva du vil svare, vennligst svar så godt du kan.
1. Stort sett, vil du si at din helse er
2. Sammenlignet med for ett år siden, hvordan vil du si at din helse stort sett er nå ?
3. De neste spørsmålene handler om aktiviteter som du kanskje utfører i løpet av en vanlig dag. Er din helse slik
at den begrenser deg i utførelsen av disse aktivitetene nå? Hvis ja, hvor mye?
a. Anstrengende aktiviteter som å løpe, løfte tunge gjenstander,






meg ikke i det
hele tatt
b. Moderate aktiviteter som å flytte et bord, støvsuge, gå en
tur eller drive med hagearbeid
c. Løfte eller bære en handlekurv
d. Gå opp trappen flere etasjer
e. Gå opp trappen en etasje
f. Bøye deg eller sitte på huk
g. Gå mer enn to kilometer
h. Gå noen hundre meter
i. Gå hundre meter
j. Vaske eller kle på deg
1
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Utmerket Meget god God Nokså god Dårlig
Mye bedre nå enn
for ett år siden
Litt bedre nå enn
for ett år siden
Omtrent den samme
som for ett år siden
Litt dårligere nå enn
for ett år siden
Mye dårligere nå
enn for ett år siden
Draft
4. I løpet av de siste 4 ukene, hvor ofte har du hatt noen av de følgende problemer i ditt arbeid eller i andre av
dine daglige gjøremål på grunn av din fysiske helse?
a. Du har måttet redusere tiden du har brukt på arbeid eller
på andre gjøremål
b. Du har utrettet mindre enn du hadde ønsket
c. Du har vært hindret i å utføre visse typer arbeid eller gjøremål
d. Du har hatt problemer med å gjennomføre arbeidet eller
andre gjøremål (for eksempel fordi det krevde ekstra
anstrengelser)
5. I løpet av de 4 siste ukene, hvor ofte har du hatt noen av de følgende problemer i ditt arbeid eller andre av dine
daglige gjøremål på grunn av følelsesmessige problemer (som for eksempel å være deprimert eller engstelig) l?
a. Du har måttet redusere tiden du har brukt på arbeid eller
på andre gjøremål
b. Du har utrettet mindre enn du hadde ønsket
c. Du har utført arbeidet eller andre gjøremål mindre
grundig  enn vanlig
6. I løpet av de siste 4 ukene, i hvilken grad har din fysiske helse eller følelsesmessige problemer hatt innvirkning på
din vanlige sosiale omgang med familie, venner, naboer eller foreninger?
7. Hvor sterke kroppslige smerter har du hatt i løpet av de siste 4 ukene?
8. I løpet av de siste 4 ukene, hvor mye har smerter påvirket ditt vanlige arbeid












Ikke i det hele tatt Litt En del Mye Svært mye
Ikke i det hele tatt Litt En del Mye Svært mye












9. De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt det de siste 4 ukene. 
For hvert spørsmål, vennligst velg det svaralternativet som best beskriver hvordan du har hatt det.
Hvor ofte i løpet av de siste 4 ukene har du:
a. Følt deg full av liv?
b. Følt deg veldig nervøs?
c. Vært så langt nede at ingenting 
har kunnet muntre deg opp?
d. Følt deg rolig og harmonisk?
e. Hatt mye overskudd?
f. Følt deg nedfor og deprimert?
g. Følt deg sliten?
h. Følt deg glad?











10. I løpet av de siste 4 ukene, hvor mye av tiden har din  fysiske helse eller følesesmessige problemer påvirket din 
sosiale omgang (som det å besøke venner, slektninger osv.) ?
11. Hvor RIKTIG eller GAL er hver av de følgende påstander for deg ?
a. Det virker som om jeg blir syk litt lettere enn andre
b. Jeg er like frisk som de fleste jeg kjenner
c. Jeg tror at helsen min vil forverres











Vennligst kontroller at du har besvart alle spørsmålene
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